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General introduction 
Treatment aims in RA   
Rheumatoid arthritis (RA) is an inflammatory auto-immune disease of unknown aetiology, 
characterized by symmetric synovitis of synovial joints and, in some cases, extra-articular 
involvement (1;2). In the western world, the prevalence of RA is estimated as 1% (1). Predominant 
symptoms are joint pain and swelling, morning stiffness, fatigue, and disability. In most patients, 
progressive synovitis leads to erosion of cartilage and underlying bone, leading to impairment and 
functional disability (3). 
There is no definite cure for RA. Therefore, the treatment aim of RA is to control disease activity, 
limit disability, slow the rate of radiographic joint damage and, ideally, induce complete remission 
(4-7). Clinical trials have shown that the remission aim is achievable, however, the number of 
patients who achieve remission in daily practice is still small and only a minority of these patients 
reach sustained remission (8;9). Though remission is difficult to reach and even to sustain, current 
treatment approaches make the remission aim more achievable. It is clear that early diagnosis and to 
start treatment as soon as possible after diagnosis, has contributed to better suppression of disease 
activity, normalization of disability and limitation of joint damage (10-13). Results from clinical 
trials affirmed the benefit of early over delayed introduction of disease-modifying anti-rheumatic 
drugs (DMARDs) in RA (10;11;14-16). Moreover, studies have shown that an initial good response to 
treatment, and thus remission, is associated with sustainability of remission (17;18). This underlines 
the concept of the existence of a window of opportunity: successful disease course modification by 
intensive treatment early in the disease course of RA (19-21). 
Since several therapeutic options in the treatment of RA have shown to be efficacious, different 
treatment strategies could be recommended. Aiming for remission is achievable with traditional 
DMARDs, either given as monotherapy or as combination therapy and the more recent biological 
response modifiers (BRMs), the anti-tumour necrosis factor agents (anti-TNF) agents, in particular 
(22-25). The traditional DMARD methotrexate (MTX) is regarded as the anchor drug in RA treatment 
(26). Early treatment with MTX has been shown to be very successful in aiming for remission; 30 to 
40% of early RA patients will experience a sustained good response to MTX only (23;24). Besides MTX, 
sulfasalazine (SSZ) and leflunomide (LEF) are other traditional DMARDs with comparable efficacy as 
MTX (27;28) and commonly used as first-choice treatment. In case of failure to MTX or SSZ, either 
a switch to monotherapy or a combination of DMARDs can be given to increase clinical efficacy. 
Besides, the relatively new anti-TNF agents have shown to be highly effective, in particular after 
failure of DMARD therapy (29). In order to suppress disease activity rapidly and prevent radiographic 
damage, it has been suggested to start with combination therapy of DMARDs or even an anti-TNF 
agent, instead of DMARD monotherapy.
Additionally to these intensive treatment options, tailored treatment on the basis of disease 
activity (tight control) has shown to be highly effective in RA and increase the ability to incuse 
remission in early RA (30;31).
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Figure 1. Remission as treatment goal in RA.
Copyricht by Breedveld et al. Ann Rheum Dis. 2004;63:627-33.
Thus, in the treatment of RA it is aimed for early and sustained remission. Though, the question 
remains how should this be reached? The aim of this thesis is to elucidate the most optimal treatment 
strategy in patients with early RA. The research questions are the following: 
•	 What is in patients with early RA the relation between achieving early remission and the 
ability to maintain remission?
•	 Should early treatment be started with either MTX or SSZ monotherapy or a combination of 
MTX and SSZ? 
•	 Which strategy should be followed in case of SSZ failure: switching to MTX monotherapy or 
should the combination of MTX and SSZ be given?  
•	 Is there a difference in the costs and effectiveness between a strategy of anti-TNF after failure 
of two DMARDs, a strategy of anti-TNF given after one DMARD and a strategy of initial anti-
TNF treatment?  
•	 How should treatment be adapted on the basis of disease activity in order to achieve 
remission; with or without protocolised treatment adjustments?
•	 Further, is a strategy of treatment adjustments based on disease activity (tight control) 
feasible in patients with early RA as treated in daily clinical practice?
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Diagnosis of early RA
In RA, the range of presentation is broad and several months can go by before a firm diagnosis 
can be settled. Though there is a set of classification criteria for RA (32), this set was based on 
patients with established RA, and, therefore, not applicable for patients with early signs and 
symptoms (33;34). However, new diagnostic criteria for RA have recently been developed, which 
can be used to diagnose RA at early stages if the ‘old’ criteria are not yet fulfilled (35;36). There is also 
a prediction formula available that can be used in patients with undifferentiated arthritis to predict 
the development of persistent and/or erosive arthritis (37;38). Such prediction could be helpful in 
making choices of treatment and treatment strategies.
Treatment in early RA
Early diagnosis of RA should be followed by an early start of treatment. This is in line with the 
concept of a window of opportunity. Early treatment has a beneficial effect on the suppression of 
the disease activity and joint damage and is, therefore, supposed to have great impact on the long-
term outcome as well (15;39-41). In clinical practice, methotrexate (MTX) is the current DMARD of 
first choice (6;26). Other traditional DMARDs, like sulfasalazine (SSZ), hydroxychloroquine (HCQ) and 
leflunomide (LEF), are good alternatives in case of not tolerating MTX or failure of MTX (27;28;42-
45). Glucocorticoids are often supplemented to initial DMARD therapy until full efficacy of a DMARD 
develops. The relatively new anti-TNF agents have shown to be highly effective, in particular after 
failure of DMARD therapy (29). Overall, treatment of RA is often supported by the use of nonsteroidal 
anti-inflammatory drugs (NSAIDs), which alleviate pain and morning stiffness.
With the increase in DMARDs and BRMs, even more combinations and treatment strategies are 
conceivable. In general, the treatment strategies are: sequential monotherapy, add-on strategy and 
step-down strategy. The sequential strategy involves starting with DMARD monotherapy and in 
case of treatment failure, a switch to another DMARD monotherapy is made. In daily clinical practice, 
rheumatologists usually use the add-on strategy. Within this strategy they start with MTX as initial 
monotherapy and start with anti-TNF when at least two DMARDs have failed as monotherapy (26). 
However, the step down strategy which involves initial combination therapy may provide a better 
outcome than MTX monotherapy in patients with early RA. In addition to this strategy, combination 
therapy including DMARDs as MTX, SSZ with or without glucocorticosteroids may be more 
effective, without additional toxicity than starting with monotherapy. This strategy may contribute 
to an improved long-term radiologic outcome as well (10;12;16;23;46-49). In case of remission, 
one of DMARDs could be tapered and ultimately a state of drug-free remission can be obtained. 
Unfortunately, there is still little evidence about the sustained effect of tapering of DMARDs in case 
of remission and drug-free remission hardly occurs.
The question remains whether combination therapy is indeed more effective than starting 
monotherapy both on the short-term and long-term. So the issue is: should be started with DMARD 
monotherapy and add a second DMARD or anti-TNF in case of suboptimal efficacy (add-on strategy) 
or should be started with intensive combination therapy (DMARDs or anti-TNF) and taper in case of 
remission has been achieved (step-down strategy)?  The next paragraphs will give an introduction 
to the conventional DMARDs and subsequently the new anti-TNF treatment, both applied in early 
RA. 
1
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DMARDs in early RA
First choices in the conventional DMARD therapy are both MTX and SSZ (6;50-52). Reasons 
are that their efficacy has been proved in clinical trials, there is wide experience with these drugs, 
and their toxicity is relatively low. Furthermore, MTX and SSZ have low costs and are easy to use 
(27;28;42-45). Several therapeutic strategies are feasible to apply these conventional DMARDs: 
starting monotherapy of either MTX or SSZ and switch to or add the other in case of inadequate 
response or initially starting with a combination of MTX and SSZ (53). Despite their widespread use, 
only four trials investigated the efficacy of MTX-SSZ combination therapy versus either monotherapy 
(54-57). The efficacy of this combination has never been established in daily practice. Moreover, it 
is not clear in case of treatment failure of SSZ whether MTX monotherapy is effective (switching) or 
the combination of MTX and SSZ should be used for the most optimal treatment effect (addition) 
(54). Only one clinical trial showed that after MTX failure (24;58), addition of SSZ to MTX (thus 
combination therapy) was not superior to a switch to SSZ alone (monotherapy). By comparing 
efficacies of monotherapy and combination therapy in DMARD-naive patients, more details will be 
revealed on which initial treatment is preferred: MTX or SSZ monotherapy or combination therapy 
of both DMARDs. Also, what should be done thereafter, in case of MTX or SSZ failure: ‘switching to 
another DMARD or adding a second DMARD to the current DMARD therapy?’. 
Anti-TNF in early RA  
In daily clinical practice, the relatively new and more expensive anti-TNF are only reserved for 
patients who fail to achieve an adequate response to traditional DMARD therapy (at least MTX and 
another DMARD) (22;59-61). Clinical trials have shown that for these patients the addition of an 
anti-TNF agent to MTX is more effective than switching to anti-TNF monotherapy. Moreover, the 
combination of anti-TNF and MTX have shown to be highly effective, well-tolerated and demonstrated 
less radiographic progression of joint damage in patients who previously failed traditional DMARD 
therapy (MTX) (62-68). The question still standing is: ‘what is the effect of initial anti-TNF in patients 
with early RA who have not been treated with prior MTX?’. It has been suggested that the use of a 
anti-TNF as first-line therapy will show more clinical and radiological effects compared to traditional 
DMARDs, MTX monotherapy (24;69). Several RCTs showed that in early RA patients, treatment 
with an anti-TNF agent in combination with MTX was more effective than either anti-TNF or MTX, 
both given as monotherapy (25;64;70;71). In other words, it could be proposed that an effective 
treatment with anti-TNF is delayed when this treatment is given only to patients who first fail to 
traditional DMARDs. On the other hand, a large proportion of patients (about 40%) will have good 
clinical responses to MTX only (67;72). Thus, a considerable number of patients would then be over 
treated in case of initial anti-TNF. There is one clinical trial that compared a strategy of initial MTX and 
addition of anti-TNF in case of DMARD failure with a strategy of initial anti-TNF (24). Though clinical 
effects were comparable after one year, more radiological progression was shown in initial MTX 
strategy. Since the results are based on only one clinical trial, it remains to be clarified whether initial 
anti-TNF is indeed more effective than a strategy of initial DMARDs and anti-TNF in case of treatment 
failure, ‘delayed’ anti-TNF.
13
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Cost-effectiveness in RA
A few trials have tested the efficacy of anti-TNF versus MTX in patients with early RA. The clinical 
efficacy results have shown that there is only small difference between these two treatments in 
favour of early anti-TNF treatment. Also, anti-TNF appear to inhibit radiological damage more than 
MTX. Therefore, it is suggested that despite the initial high costs of anti-TNF (about €14.000 in the 
first year (73;74)), these agents are highly effective and may, therefore, have beneficial effects on the 
long-term and leading to cost savings as well. In addition, less hospital visits or surgical admissions 
and preventing early job loss (due to less joint damage). The question remains whether anti-TNF 
lead to more cost reduction than starting DMARDs both on the short-term and long-term outcome 
of RA. 
Several studies have performed cost-effectiveness analyses (CEAs) that compared DMARDs 
strategies with that of anti-TNF agents. In general, the results of these studies vary: some studies 
suggest that the use of anti-TNF agents fall within acceptable cost-effectiveness ranges (<€80,000), 
whereas others report very high ICERs (above $100,000) (75-78). However, these results were all 
based on studies that evaluated RA patients who failed at least one DMARD and concluded that the 
additional benefit of anti-TNF agents may be worth the additional costs compared with DMARDs 
continuation after failing DMARDs (79). CEAs of initially use of anti-TNF has not yet been performed. 
Therefore, it is important to compare both effects and costs of treatment strategies starting with 
anti-TNF with that of initial DMARDs and thus ‘delayed’ treatment of anti-TNF (initial DMARDs and 
anti-TNF in case of failure). These results will favour decision making in early RA and could give an 
answer to the following clinical question: ‘Should all early patients receive initially anti-TNF or should 
these agents be given only to RA patients not responding to DMARDs and thus start with DMARD 
monotherapy or combination therapy?’. By cost-effectiveness analyses, it could be established 
whether the additional costs of a new treatment (initial anti-TNF) are justified given the additional 
effects as compared to the conventional treatment (initial DMARDs and ‘delayed’ anti-TNF). 
Tight-controlled treatment    
Maintaining remission is as important as achieving remission, and it is obvious that disease 
activity should be closely monitored in order to change DMARD therapy if necessary; tight control 
(5;30;49;80;81). Tight control is a treatment strategy tailored to the individual RA patient, which 
aims to achieve a predefined level of low disease activity or clinical remission (82). Tight control 
comprises regular assessments (i.e. monthly) of disease activity (i.e. valid DAS28), a treatment goal 
(i.e. remission), and performs treatment adjustments with or without using a treatment protocol 
(26;31). Such protocol determines whether treatment is escalated or reduced based on disease 
activity. Accordingly, if remission is not achieved the therapeutic strategy must be intensified by 
employing other DMARDs until the aim of treatment is achieved (83-85). 
Several trials have shown that frequent evaluations of disease activity, using validated tools 
combined with therapy adjustments aiming at low disease activity or even remission, result in better 
disease outcomes (less disability and less progression of joint damage) than routine care (30;80;81). 
Some trials performed tight control in combination with protocolised treatment adjustments, 
whereas others gave rheumatologists an advice to change treatment in case of no remission. The 
question remains whether protocolised tight control is better than non-protocolised tight control. 
1
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Moreover, tight control aiming for remission seems also a promising and feasible option in treating 
early RA in daily practice (83;86). Though clinical trails have proven the beneficial effects of tight 
control, no comparison has yet been made in daily practice. In addition, is tight control indeed 
feasible and more effective than usual care in case both are applied in daily practice? 
Outline of this thesis  
The general aim of this thesis is to elucidate the most optimal treatment strategy in patients with 
early RA in order to aim for early and sustained remission.
Aiming for remission
In the treatment of RA, it is hypothesized that early remission is associated with sustained 
remission in line with the concept of window of opportunity. However, there are no current studies 
that investigated the relationship between time to achieve first remission and sustainability of 
remission in early RA. Therefore, the objective of chapter two was to study the association between 
time to achieve first remission and sustainability of remission in an early RA cohort with patients 
treated according to daily practice care during three years follow-up.
Treatment strategies with MTX and SSZ in RA 
To recommend an optimal treatment strategy, data from clinical trials are required. In chapter 
three, a meta-analysis is performed on the effects of monotherapy and the combination of MTX and 
SSZ in naive patients and patients with an insufficient response to either DMARD. 
There still is some doubt on the benefit of the combination of MTX and SSZ if one of the drugs 
previously failed. Since other clinical trials on this item are not being performed, we analysed the 
data from a large Dutch observational inception cohort in chapter four. It was studied whether the 
addition of MTX to SSZ in patients who failed SSZ therapy is beneficial compared to a switch to MTX 
monotherapy in daily clinical practice. 
Cost-effectiveness analysis of anti-TNF in early RA 
The aim of chapter five was to determine whether there was a difference in early RA patients 
in the cost and effectiveness between delayed and immediate anti-TNF. Three strategies were 
compared: 1) starting with MTX followed by addition of LEF then followed by MTX plus anti-TNF in 
case of inadequate response; 2) starting MTX-LEF combination therapy followed by MTX and anti-
TNF or 3) starting MTX plus anti-TNF. A CEA model was used to compare both costs and effects of 
these three treatment strategies. The results were given as incremental cost-effectiveness ratios in 
order to establish whether the additional costs of an early anti-TNF treatment is justified given the 
additional effects as compared to a delayed anti-TNF treatment.
Applying tight control 
It has been shown that frequent assessments of disease activity and an intensive escalation 
treatment protocol improve the effects of RA compared with routine care. However, the additional 
value of protocolised treatment adjustments in performing tight control has not yet been 
established. Therefore, the objective of chapter six was to compare the effects of tight control with 
15
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and without protocolised treatment adjustments by means of a meta-analysis.
Further, the question remains in how far the promising results of protocol-driven tight control 
from clinical trials can be transferred into daily practice. The aim of chapter seven was, therefore, 
to investigate whether a protocol-driven tight control strategy was more effective than treatment 
according to daily practice (usual care) in reaching remission in early RA patients. For this aim, two 
strategies derived from two different early RA cohorts were compared.
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Abstract
Objectives. Though remission currently is a treatment goal in patients with rheumatoid arthritis 
(RA), the number of patients who achieve and sustain remission in daily practice is still small. It is 
suggested that early remission will be associated with sustainability of remission. Therefore, the aim 
was to study the association between time-to-remission and sustainability of remission in a cohort 
of early RA patients treated according to daily practice.
Methods. For this study, three-year follow-up data were used from the Nijmegen RA Inception 
Cohort of patients included between 1985 and 2005 (N=753). Patients were included upon diagnosis 
(ACR criteria), were systematically evaluated at three-monthly visits and treated according to daily 
practice. Remission was defined according to the Disease Activity Score (DAS) <1.6 and the ACR 
remission criteria. Remission of at least 6 months duration was regarded as sustained remission. 
Predictors for time-to-remission were identified by Cox-regression analyses. The relation between 
time-to-remission and sustained remission was analyzed using longitudinal binary regression.
Results. N=398 (52%) patients achieved remission with a median time-to-remission of 12 months. 
Male gender, younger age and low DAS at baseline were predictive to reach remission rapidly. There 
were n=142 (36%) patients experiencing sustained remission, which was determined by a shorter 
time-to-remission only. The relationship between time-to-remission and sustained remission was 
described by a significant odds ratio (1.11) (1.10-1.12-95% CI) that was constant over the whole 
period 1985 to 2005. Results obtained with the ACR remission criteria were similar.
Conclusions. A shorter time-to-remission is related to sustainability of remission, supporting 
striving for early remission in patients with RA.
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Introduction  
Expectations considering the treatment effect of rheumatoid arthritis (RA) have changed and 
aiming for clinical remission is currently regarded as an appropriate treatment goal in patients with 
early RA (1). However, the number of patients who achieve remission in routine care is small and 
only a minority of these patients reach sustained remission (2, 3). Rather than complete remission, 
it is a near-remission disease state that currently is an achievable treatment goal in daily practice. 
Forthcoming treatment approaches will make the remission aim more realistic.
Starting treatment as early as possible after the diagnosis of RA is essential to provide the best 
clinical outcome (4). Moreover, starting methotrexate (MTX) in combination with corticosteroids 
has been shown to be very successful in aiming for remission; 30 to 40% of early RA patients will 
experience a sustained good clinical response to MTX monotherapy (5, 6). In case MTX therapy fails, 
biological therapy should be added to disease-modifying anti-rheumatic drug (DMARD) therapy 
(5-8). Additionally to this add-on strategy, applying tight control increases the ability to induce 
remission in early RA (9). Tight control includes regular adaptations of treatment guided by the level 
of disease activity, i.e. remission (10). Application of tight control may even be more important than 
the initial treatment given (5, 9).
Following the concept of ‘a window of opportunity’ - successful disease course modification Is 
determined by aggressive treatment early in the disease course of RA - it can be hypothesized that 
early remission will be associated with sustainability of remission. There currently are no studies that 
investigated the relationship between time-to-remission and sustainability of remission. However, 
there are sufficient indications that in RA indeed early response is predictive for later results (11-
13). Insight into the factors that determine sustained remission early in the disease course of RA is 
important to provide a better long-term outcome of patients with RA.
The main objective of this study was to study the association between time-to-remission and 
sustainability of remission during the first three years of follow-up in a cohort of patients with 
early RA, who were treated according to daily practice. A second aim was to identify independent 
predictors of time-to-remission and sustainability or remission.
 
Methods  
Selection of patients   
Eligible patients for this study were obtained from the Nijmegen early RA inception cohort (14). 
In this cohort patients were included who were at least 18 years of age, meeting the 1987 revised 
American College of Rheumatology (ACR) classification criteria for RA, who had a disease duration 
less than one year and did not use DMARDs before (15). Patients were visiting the outpatient clinic 
of the rheumatology departments of the Radboud University Nijmegen or the Maartenskliniek 
in Nijmegen, The Netherlands. In The Netherlands, nearly all patients with RA are treated by 
rheumatologists working in hospitals.
All patients were regularly assessed in three-monthly visits, but treatment decisions could be 
made at any time according to the discretion of the treating rheumatologist. Patients were treated 
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with conventional DMARDs and/or biologicals and also glucocorticoids and non-steroidal anti-
inflammatory drugs (NSAIDs) could be used. All clinical data on patient characteristics, medication 
use, clinical and laboratory measures were prospectively stored in an electronic database. All 
patients gave their informed consent before inclusion in the inception cohort, and the responsible 
local medical ethics committee had approved the study protocol. Inclusion and data collection for 
this cohort are still ongoing. 
Since we were interested in remission during three years follow-up, all patients that were enrolled 
in the inception cohort between 1 July 1986 and 31 December 2005 were selected for this study. 
Clinical assessments  
The following baseline patient variables were retrieved from the database: age, gender, duration 
of RA, rheumatoid factor positivity, disease activity (disease activity score (DAS)) and physical 
function (Health Assessment Questionnaire, HAQ). Disease activity was assessed at baseline and 
every three months thereafter by trained research nurses, using tender and swollen joint counts, 
erythrocyte sedimentation rate (ESR; mm/h) and patient ratings. The DAS was calculated using a 
44 joint count for swelling (swollen joint count, SJC), a 53 joint count graded for tenderness (tender 
joint count, TJC), counted in 26 joint units (Ritchie Articular Index, RAI), general health on a Visual 
Analogue Scale (VAS) of 100 mm, and the value for ESR measured by the Westergren method (16). 
The DAS has not the same cut points as the DAS28. A DAS ≤2.4 is regarded as low disease activity, 
and a DAS >3.7 is regarded as high disease activity (17). 
Other clinical variables assessed were: duration of morning stiffness expressed in minutes, patient 
rating for pain, patient’s global assessment of disease activity and physician’s global assessment 
of disease activity all on a VAS from 0-100, and C-reactive protein (CRP; mg/L). Use of DMARDs, 
biologicals, and concomitant glucocorticoids or NSAIDs was recorded during follow-up.  
Remission definitions
Remission was defined according to a DAS < 1.6 (DAS remission) and to modified ACR remission 
criteria (mACR remission) (18). Fulfillment of the mACR remission criteria required four of the 
following five criteria to be met: 1) morning stiffness ≤ 15 minutes, 2) VAS pain ≤ 10 mm, 3) no tender 
joints (out of 53 joints), 4) no swollen joints (out of 44 joints), and 5) ESR < 30 mm/h (female) or < 20 
mm/h (male) (18). In comparison with the original ACR remission criteria (19), fatigue was omitted 
since this item was not assessed in the cohort. Since there were three-monthly visits in our inception 
cohort, duration of mACR remission had to be at least three months, which differs from the duration 
of two months as defined in the original ACR remission criteria (19).
Patients were regarded to be in sustained remission when they maintained remission for six 
consecutive months, which is three consecutive visits for DAS remission and two consecutive visits 
for mACR remission.  
Statistical analysis      
Time-to-remission was described using a Kaplan-Meier curve. A Cox proportional hazard model 
with time-to-remission as the dependent variable was used to calculate the hazard for achieving 
remission within three years for baseline variables. Variables univariately showing a significance level 
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of p<0.05 were included into a multivariate Cox model. The full multivariate model was reduced by 
stepwise removal of baseline variables with a significance level of p<0.05. 
For predicting sustained remission, a logistic regression model with achieving sustained 
remission as dependent variable was used to identify baseline predictors. The same variable 
selection procedure was followed as described above.
The relationship between time-to-remission and sustainability of remission was analyzed 
using longitudinal binary regression (mixed models), correcting for repeated measurements 
(autoregressive covariance structure) and using a logit link function for binary data. Remission 
during three years was the dependent variable with time-to-remission as the main covariate. The 
value of the DAS in the previous visit was included in the model. Other covariates were added to 
the model as confounders only if their addition leaded to a change of 10% or more in the effect. 
In addition, the following interaction terms were tested: gender with age, and calendar time with 
time-to-remission. Besides the interaction term with calendar time, also four sub-cohorts (inclusion 
between 1985-1990, 1991-1995, 1996-2000, 2001-2005) were defined, to analyze whether the 
relation between time-to-remission and sustained remission changed over calendar time. 
For the relation between time-to-remission and sustained remission, medical treatment was 
regarded as an intermediate variable rather than a confounder.  Treatment was not considered 
as a confounder because both time-to-remission and sustained remission are treatment effects. 
Treatment obviously is in the causal pathway and, therefore, it should not be treated as a confounder. 
Instead, it was analyzed whether the relation between time-to-remission and sustainability was 
different (effect modification) for patients treated using DMARDs in sequential monotherapy or as 
add-on therapy and also for patients using MTX or SSZ as first DMARD. For descriptive purposes, 
treatment with DMARDs and glucocorticoids was studied at baseline and during three years for all 
sub-cohorts.
Regarding the three-year follow-up and definition of sustained remission (six months or more) 
there might have been patients who were not able to sustain their remission since they attained 
remission after two and half year. Therefore, a sensitivity analysis was performed with only patients 
who achieved first remission before two and half year and compared to using all patient.
In case of missing DAS values, the mean of the previous and following scores was used (linear 
intrapolation) for imputation. By means of sensitivity analysis, results of the analysis using the 
dataset after imputation were compared with the results using the dataset with missing values. 
All analyses were performed separately for both DAS and mACR remission as outcome. Statistical 
analyses were carried out using SPSS version 16.0, statistical software package (Chicago,IL,USA) and 
using PROC GENMOD of SAS version 8.2 software (SAS Institute,Cary,NC). 
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Results 
Baseline characteristics  
Complete datasets with assessments of disease activity scores from baseline and a minimal 
follow-up of 140 weeks were available in 753 (86%) of the 873 included early RA patients. Patients, 
who were not included in this study, did not differ significantly or remarkably from patients who 
were included with respect to age, gender, rheumatoid factor positivity, disease duration, DAS, HAQ, 
medication use and change in DAS between baseline and six months (not shown). 
Table 1 shows the baseline demographic and clinical variables of all patients included. Nearly 
all patients were included at moment of diagnosis as can be seen in the low disease duration. The 
patients had on average a high level of disease activity as shown by the mean DAS and the joint 
counts, and a moderate level of disability a shown by the HAQ. 
Table 1. Demographic and baseline disease characteristics of patients (n = 753) 
Age, mean ± s.d., years  54 ± 14
Women, n (%)  477 (63)
Rheumatoid factor positive, n (%)  578 (77)
Disease duration, median (IQR), weeks  0 (0, 4)
Disease activity score, mean ± s.d.  3.98 ± 1.28
Disease activity score-28, mean ± s.d.  5.07 ± 1.32
HAQ score, median (IQR)  0.63 (0.25, 1.19)
ESR, median (IQR), mm/h  29 (16, 48)
CRP, median (IQR), mg/L  12 (1.7, 37)
44 swollen joint count, median (IQR)  13 (8, 18)
53 tender joint count, median (IQR)   10 (5, 17)
VAS pain 0-100, mean ± s.d., mm  44 ± 23
Patient’s global assessment 0-100, mean ± s.d., mm   46 ± 24
VAS GH 0-100, mean ± s.d., mm  44 ± 22
Physicians global assessment 0-100, mean ± s.d., mm  34 ± 18
Morning stiffness, median (IQR), min  30 (0, 90)
Disease activity score (DAS) was based on 53 tender joint counts (Ritchie Articular Index) and 44 swollen 
joint counts, Disease activity score-28 (DAS28) was based on 28 tender and swollen joint counts, HAQ: health 
assessment questionnaire, ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, VAS: visual analogue 
scale, IQR: interquartile range (P25-P75), s.d.: standard deviation.
Predictors for time-to-remission  
From all n=753 patients, n=398 patients (53%) achieved at least one visit in remission during the 
three years of follow-up. The median time-to-remission was 33 months. Figure 1 shows a Kaplan-
Meier time-to-event curve of the time-to-remission for the four sub-cohorts of calendar time. 
The curves indicate that the earliest sub-cohort had median time-to-remission of 35 months, the 
following two sub-cohorts had a median time of 36 and 28 months respectively, and the last sub-
cohort had a median time of 26 months to attain remission. Comparison of the early and late sub-
cohorts revealed a significantly difference in this time-to-remission (P<0.01 by overall log rank test). 
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Analyzing time-to-remission of only patients who attained remission within three years, resulted 
into a median time-to-remission of 14 months in the earliest cohort and 10 months in the latter 
cohort.
In Table 2 it is shown which baseline variables are univariately and multivariately predictive for 
time-to-remission. Univariate Cox-regression analyses showed a significant difference between 
the sexes: male patients reached remission sooner than female patients (18 and 36 months, 
respectively) (P<0.0001). Baseline DAS was strongly predictive for time-to-remission: patients with 
a lower DAS at baseline achieved remission more rapidly than those with a higher DAS at baseline 
(P<0.0001). A higher HAQ and higher age at disease onset were also found to prolong the time-to-
remission (P<0.01). Further, all individual components of DAS at baseline were predictive for time-
to-remission (P<0.05). The interaction between age and gender was not significant. In multivariate 
Cox-regression, only gender, age, and DAS were independently predictive for time-to-remission. 
Figure 1. Time to achieve DAS-remission within 3 years of follow-up in a cohort of early RA patients derived 
from the Nijmegen inception cohort. Remission was defined according to the disease activity score (DAS) 
based on 53 tender joint counts and 44 swollen joint counts.
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Table 2. Baseline predictors for time-to-DAS remission 
  Univariatea     Multivariateb
Variable   Beta (β) P- value HR (95%CI)  Beta (β) P- value HR (95%CI)
RF positive 0.114 0.328 1.121 (0.892-1.408)   
Male gender -0.641 0.000 0.527 (0.433-0.641)  -0.511 0.000 0.600 (0.469-0.767)
Age  -0.009 0.008 0.991 (0.984-0.998)  -0.007 0.047 0.993 (0.986-0.999)
Baseline DAS -0.364 0.000 0.695 (0.635-0.760)  -0.693 0.000 0.500 (0.434-0.576)
Baseline HAQ   -0.436 0.000 0.647 (0.529-0.791)   
Dis duration -0.005 0.217 0.995 (0.987-1.003)   
44 SJC  -0.018 0.007 0.982 (0.969-0.995)   
53 TJC  -0.057 0.000 0.945 (0.932-0.958)   
ESR   -0.004 0.048 0.996 (0.992-0.999)   
VAS GH  -0.017 0.000 0.983 (0.978-0.987)   
RF: rheumatoid factor, DAS: disease activity score based on 53 tender joint counts (TJC) and 44 swollen joint 
counts (SJC), HAQ: health assessment questionnaire, Dis: disease, ESR: erythrocyte sedimentation rate, VAS: 
visual analogue scale, GH: general health. Age was measured in years and disease duration in weeks. aResults of 
univariate Cox proportional hazard models with baseline predictors for time-to-DAS remission (disease activity 
score, DAS<1.6) up to three years of follow-up, given with hazard ratios (HR) and 95% confidence intervals 
(95%CI). bResults of the final multivariate Cox proportional hazard prediction model with independent baseline 
predictors for the time-to-remission (disease activity score, DAS<1.6) up to three years of follow-up, given with 
hazard ratios (HR) and 95% confidence intervals (95% CI).   
Predictors for sustained remission      
Of the 398 patients who ever attained remission, 142 (36%) patients had sustained remission 
with a median time of being in remission of 19 months. Table 3 shows the univariate and multivariate 
logistic regression analyses to determine baseline predictors for reaching sustained remission. 
Univariately, sustained remission was predicted by a shorter time-to-remission, and lower DAS and 
HAQ at baseline. Also, the tender joint count at baseline was predictive for sustained remission. 
In multivariate regression, none of the baseline variables were independently associated with 
sustained remission, except for time-to-remission. No significant interaction terms were detected. 
Thus, time-to-remission emerged as an important predictor of sustained remission. 
Table 3. Baseline predictors of sustained DAS remission 
  Univariatea  Multivariateb
Variable   Beta (β) P- value OR (95%CI) Beta (β) P- value OR (95%CI)
Time-to-remis  -0.091 0.000 0.913 (0.889-0.939) -0.094 0.000 0.910 (0.878-0.944)
RF positive  0.447 0.058 1.563 (0.985-2.481)   
Male gender  -0.379 0.067 0.685 (0.457-1.026)   
Age  0.007 0.302 1.007 (0.993-1.022)   
Baseline DAS  -0.302 0.001 0.740 (0.620-0.882)   
Baseline HAQ    -0.567 0.011 0.567 (0.367-0.878)   
Dis duration  -0.003 0.745 0.997 (0.982-1.013)   
44 SJC  -0.012 0.384 0.988 (0.963-1.015)   
53 TJC  -0.070 0.000 0.932 (0.903-0.962)   
ESR   -0.004 0.349 0.996 (0.988-1.004)   
VAS GH  -0.009 0.075 0.991 (0.980-1.001)  
Remis: remission, RF: rheumatoid factor, DAS: disease activity score based on 53 tender joint counts (TJC) and 44 
swollen joint counts (SJC), HAQ: health assessment questionnaire, Dis: disease, ESR: erythrocyte sedimentation 
rate, VAS: visual analogue scale, GH: general health. Time-to-remission was measured in months, age was 
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measured in years and disease duration was measured in weeks. aResults of the univariate logistic regression 
model for sustaining remission (DAS<1.6 for at least 6 months or more) during 3 years of follow-up and baseline 
variables, given with odds ratios (OR) and 95% confidence intervals (95%CI). bResults of the final multivariate 
logistic regression model for sustaining remission (DAS<1.6 for at least 6 months or more) during 3 years of 
follow-up and baseline variables, given with odds ratios (OR) and 95% confidence intervals (95% CI). 
Relationship between time-to-remission and sustained remission 
Table 4 shows the descriptives of time-to-remission and sustained remission and the relation 
between time-to-remission and sustained remission.
Table 4. Relationship between time-to-remission and sustained remission 
 All patients  1985-1990 1991-1995 1996-2000 2001-2005
 (n = 753) (n = 147) (n = 158) (n = 219) (n = 229)
DAS remission     
Achieving remission, n (%)a 398 (53)  77 (52)  68 (43) 124 (57) 129 (56)
Time-to-remission, median 33 35 36 28 26
 (IQR), months  (11, 36) (14, 36) (12, 36) (9, 36) (9, 36)
Sustained remission, n (%)b 142 (36) 22 (29) 25 (37) 46 (37) 49 (38)
Time in sustained remission,  19 9 22 18 22
median (IQR), months (10, 28) (6, 22) (14, 29) (10, 26) (13, 29)
Relationship between time to  1.11 1.09 1.15 1.09 1.13
achieve and sustained remission,  (1.10, 1.12) (1.07, 1.11) (1.12, 1.17) (1.08, 1.11) (1.11, 1.15)
OR (95%CI)c
mACR remission     
Achieving remission, n (%)d 226 (30) 48 (33) 45  (29) 62 (28) 71 (31)
Time-to-remission, median 13 15 13 15 10
 (IQR), months (8, 24) (10, 28) (7, 24) (9, 23) (7, 19)
Sustained remission, n (%)e 58 (26) 8 (17) 18 (33) 13 (21) 19 (27)
Time in sustained remission,  10 7 11 7 13
median (IQR), months (6, 16) (6, 8) (7, 16) (6, 16) (7, 24)
Relationship between time to  1.15  1.13 1.12 1.08 1.12
achieve and sustained remission,  (1.14, 1.16) (1.09, 1.16) (1.07, 1.18) (0.96, 1.22) (0.93, 1.16)
OR (95%CI)c
 
IQR: interquartile range (P25-P75), CI: confidence interval. aNumber of patients achieving at least one period of 
remission (disease activity score, DAS<1.6) during 3 years follow-up. bNumber of patients who had sustained 
DAS remission (6 months or more) during 3 years follow-up. cOdds ratios (ORs) of remission during 3 years 
follow-up analyzed by longitudinal binary regression with remission status over time as dependent variable, 
time-to-remission (months) and DAS value of the previous visit as main covariates. dNumber of patients 
achieving at least one period of remission (modified American College of Rheumatology, mACR) during 3 years 
follow-up. Fulfillment of the mACR remission criteria was based on 4 of the following 5 criteria to be met: 1) 
morning stiffness ≤ 15 minutes, 2) VAS pain ≤ 10 mm, 3) no tender joints (out of 53 joints), 4) no swollen joints 
(out of 44 joints), and 5) ESR < 30 mm/h (female) or < 20 mm/h (male). eNumber of patients who had sustained 
mACR remission (6 months or more) during 3 years follow-up. 
 
The median time needed to reach remission was 12 months. The median time that remission 
sustained was 19 months. The odds ratio (OR) (95% CI) of the relation between time-to-remission 
and having sustained remission was 1.11 (1.10-1.12) (P<0.0001). As time-to-remission was calculated 
in months, this means that patients who achieved first remission one month earlier, had a higher 
chance on sustained remission, an OR of 1.11 than patients who achieved first remission one month 
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later. Achieving remission three months earlier resulted in an OR of 1.37 to remain in remission. 
In case of one year earlier remission, this OR even increased to 3.5 to keep sustained remission. 
Accordingly, the chance on sustained remission increases with every month time-to-remission 
is shorter. Illustratively, the median time-to-remission in patients with sustained remission was 
9 months (interquartile range, IQR 4-13 months) while time-to-remission in patients with non-
sustained remission was 13 months (IQR 7-24 months) (P<0.0001). There were no baseline variables 
(such as age and gender) that acted as confounders, only the DAS value of the previous visit was 
included as covariate in the model.
Sensitivity analyses with only patients who attained remission before two and half year, resulted 
in an OR of 1.1. Also, using the dataset with missing values did not alter the above OR.
Sustained remission during calendar time
The cohort was divided into four sub-cohorts according to calendar time (Table 4). The number of 
patients who achieved remission was comparable between the first and the latter cohort. Sustained 
remission, on the other hand, occurred more frequently in the latter cohort. Time-to-remission was 
longer in the beginning of the cohort (1985-1990) and also time in remission was less in the early 
years of the cohort (Table 4). Despite these differences, the relationship between time-to-remission 
and sustained remission remained constant over calendar time as can be seen by the OR of each 
sub-cohort that varied from 1.09 to 1.15 with great overlap of the four confidence intervals. 
mACR remission  
Figure 2. Time to achieve mACR-remission within 3 years of follow-up in a cohort of early RA patients derived 
from the Nijmegen inception cohort. Remission was defined according to the modified American College of 
Rheumatology (mACR) criteria based on fulfilment of 4 of the 5 criteria: 1) morning stiffness ≤15 minutes, 2) VAS 
pain ≤10 mm, 3) no tender joints (out of 53 joints), 4) no swollen joints (out of 44 joints), and 5) ESR <30 mm/h 
(female) or <20 mm/h (male).
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Overall, mACR remission occurred less frequently than DAS remission (Table 4). The independent 
predictors for time-to-mACR remission were comparable with those found for achieving DAS 
remission. Time-to-remission for the four sub-cohorts is shown in Figure 2. Again, the earlier sub-
cohorts had a longer median time-to-remission than the last sub-cohort (P<0.01). To sustain mACR 
remission was also more difficult than DAS remission. Time-to-remission was the strongest and 
single predictor of sustained mACR remission. The relationship between time-to-remission and 
sustained remission was again significant (OR=1.15) and remained constant over calendar time. 
Medication use  
Among the 753 patients included, 720 patients started monotherapy (14% methotrexate (MTX), 
67% sulfasalazine (SSZ), 15% hydroxychloroquine and 4% other DMARDs) and 33 patients received 
DMARDs combination therapy at baseline, mainly MTX combined with SSZ. During three years, 29% 
patient received a combination of DMARDs (mostly MTX plus SSZ) as an add-on strategy applied 
and 71% of the patients received a sequential strategy of DMARDs. In the beginning of the cohort, 
5% of the patients were given combination therapy, which increased to 39% in the last sub-cohort. 
Further, in earlier cohorts SSZ was in 54% the starting drug compared to 24% in the latter cohorts. 
The use of MTX increased from 1% to 16%. Biologicals were given to 17% of the patients. Overall, 
19% of the patients used prednisone and 49% received at least one intra-muscular/intra-articular 
injection of prednisolone with a median of number of two (IQR 1-4). 
With respect to patients who sustained their remission (n=142), nearly all (96%) patients started 
with monotherapy and SSZ was described as first DMARD in 69%. A higher proportion of patients 
received DMARDs in sequential monotherapy until their first remission (87%) compared to the 
whole patient group (71%) and a DMARD add-on strategy was less commonly applied (13% versus 
29%). Also, the percentage of anti-TNF users before first remission was actually low (3%). Further, 
11% of the patients received prednisone and 35% at leas one intra-muscular/intra-articular injection 
of prednisolone (median number of 1).  
Remission and medication use
Since more patients started with SSZ as first-line DMARD, we investigated remission in both 
SSZ and MTX first-line patients. Whether treatment was started with MTX or with SSZ did not 
predict time-to-remission (p=0.412), sustainability of remission (p=0.091), nor did it modify the 
relationship between time-to-remission and sustainability of remission (p=0.153). Further, patients 
in sustained remission received more often DMARDs in sequential monotherapy. Therefore, patients 
were stratified according to treatment strategy: DMARD sequential monotherapy (70%) or add-on 
therapy (30%). The relation between time-to-remission and sustainability was not different between 
both treatment groups (p=0.609).
 
Discussion  
This study was conducted to identify predictors for achieving and sustaining remission and to 
investigate the relationship between time-to-remission and sustained remission according to two 
different remission criteria in a cohort of early RA patients treated in daily practice between 1985 
and 2005. According to the results of this study, the number of patients achieving remission was 
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comparable during the whole time frame of the cohort. Predictors to achieve more rapidly DAS 
remission were male gender, younger age and a low DAS or HAQ at baseline. Sustained remission 
was only and mainly determined by time-to-remission; the chance of sustained remission increased 
significantly with decreasing time-to-remission. Over time, reflecting more intensive treatment, the 
time-to-remission tended to shorten, the occurrence of sustained remission tended to increase, but 
the relation between time-to-remission and sustainability remained fairly constant. This indicates 
that the relation between time-to-remission and sustainability does not heavily depend on the type 
or strategy of DMARDs given. Results obtained with the mACR remission criteria were similar.
This study is the first daily care study showing the influence of time-to-remission at sustained 
remission. In earlier studies on evaluation of remission in daily practice, comparable predictors have 
been identified for achieving remission in patients with early RA (20, 21). Rheumatoid factor (11, 20) 
and anti-cyclic citrullinated peptide (anti-CCP) antibody status (22), level of CRP (23) and presence 
of erosions at baseline (20) have also shown to be predictive for not achieving remission rapidly. 
Further, the early start of DMARDs combination therapy (24) or anti-TNF agents plus MTX (5, 7, 8) in 
RA patients emerged to be predictive for sustained remission. 
Since treatment in patients with RA has shifted towards a more early and aggressive treatment 
strategy, higher remission rates and more sustainability of remission are expected these days. 
Remarkably in this study, the association between time-to-remission and sustained remission was 
present in all cohort patients, irrespective of date of inclusion. Therefore, early remission seems to 
be essential for sustained remission, and thus the further course of RA. Earlier studies have already 
confirmed this implication. In addition, the frequency of remission after one year was significantly 
higher among responders than among the non-responders (11, 25) and achieving low disease 
activity within three months of treatment was associated with low disease activity or remission at 
one year (12).   
Several criteria of (sustained) clinical remission are available and remission results of studies 
may for this reason depend on the remission criterion used (3, 26). This study applied both DAS 
and mACR as remission criteria, which resulted in similar predictors for attaining and sustaining 
remission. Moreover, the relationship between time-to-remission and sustained remission 
remained significant. Reaching and sustaining mACR remission was only more difficult than DAS 
remission. Additionally, a great proportion of patients (23%) who attained DAS remission did not 
fulfill mACR remission. Since mACR remission criteria include absence of both tender and swollen 
joints, remission according to mACR is regarded as very strict (27). 
For the aim of this study, we used cohort data from the Nijmegen inception cohort. Cohort 
data have the advantage to be closely related to daily practice care (28) and, therefore, the patients 
included in this study are supposed to be representative of the general RA population attending 
outpatient clinics. Moreover, the inception cohort from this study is regarded as a very valuable and 
complete cohort since this cohort includes a long time span, started from 1985 and still ongoing, 
and clinical variables are systematically collected every three months. 
However, a limitation of using data from daily practice is that medication use differs for each 
patient and changes over time. For that reason, medication use cannot be analyzed as would it be an 
effect-modifier and studying medical treatment may be complicated using cohort data. Therefore, 
medication use in this study was regarded as an intermediate variable and was described for each 
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sub-cohort to get more insight into time-trends of medication. Further, we have demonstrated 
that despite medication adjustments at the discretion of rheumatologists, the treatment strategy 
applied was mostly a sequential or step-up strategy (with or without glucocorticoids), starting with 
either MTX or SSZ and the prescription of anti-TNF agents was low.
The number of anti-TNF users in this study was low. On the one hand the study includes the 
period 1990-2000 when anti-TNF was not available, on the other hand because in the Netherlands, 
anti-TNF is used after failure on at least two DMARDs. The results of this study, therefore, do not 
automatically generalize to patients treated with anti-TNF. Leaving out the patients treated with 
anti-TNF from the analysis did not change the results (not shown). Further research should be 
necessary to investigate, and even generalize, the relationship between time-to-remission and 
sustained remission in patients using (their first) anti-TNF treatment.
In some patients, joint damage may proceed despite clinical remission (29, 30), However, low 
levels of inflammation and specifically remission are associated with less (further) progression of 
joint damage (31, 32). Clinical remission and ultimately the halt of progression of joint damage is 
regarded as the current treatment goal in RA (1). In clinical trials, remission has already shown to 
be attainable (7, 33, 34) and striving for a sustained state of (drug-free) remission has become the 
ultimate aim in RA (35). However, the rate of achieving and sustaining (mACR) remission in daily 
practice is still very low. The results of this study have shown that within three years, 53% and 30% 
of the patients achieved at least one visit in DAS or mACR remission, which are comparable (or even 
higher) to those found in other daily care studies (2, 5, 9, 11, 18, 36).  A state of sustained clinical 
remission was in this study difficult to reach (23-36%), which was also demonstrated in previous 
studies (11, 37). 
Despite the relatively low percentage of sustained remission, there are arguments to believe that 
substantial increases in sustained remission rates are these days expected. Additionally, treatment 
strategies with conventional DMARDs can be improved considerably by applying tight control of 
disease activity, including a medication protocol with regular assessments of disease activity and a 
threshold (remission) to determine whether treatment has to be changed (9, 34, 38, 39). Moreover, in 
clinical trials the early introduction of DMARDs in combination with prednisone or anti-TNF, applied 
as a ‘step-down’ strategy (5, 6), has shown to be very effective. However, in daily practice this is not a 
common treatment strategy. Therefore, starting anti-TNF therapy more rapidly, in DMARDs failures 
and patients with poor prognosis at baseline in particular, may be necessary for achieving higher 
remission rates. 
In conclusion, the results of this study show that attaining first remission sooner, chance of 
sustained remission is becoming significantly higher. This relationship between time-to-remission 
and sustained remission remained constant over the whole cohort period from 1985 to 2005. The 
fact that time-to-remission is the strongest predictor for sustained remission supports the fact that 
aiming for remission as soon as possible is the treatment goal in patients with early RA. Aiming for 
remission will be better achievable with treatment strategies applied as tight control. By measuring 
disease activity and targeting a low value in the measure (remission) we use, remission is achievable 
and even sustained remission. Tight control may be applied with any DMARD and all DMARDs 
may be needed to get remission, For many patients with RA, MTX alone, or in combination with 
corticosteroids, will give the desired state of sustained remission.  
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Abstract
Objectives. For pharmacological reasons, the effect of the combination of MTX and SSZ may 
be different in RA patients who are naïve to these drugs compared to patients with an insufficient 
response to one of them. Therefore, we compared the results of randomized controlled trials (RCTs) 
on the combination of MTX and SSZ in naïve patients and in patients with an insufficient response 
to SSZ. 
Methods. A systematic literature search was performed to identify RCTs that compared the 
MTX–SSZ combination to either drug alone. The databases MEDLINE and the Cochrane Clinical Trials 
registry were searched from 1966 up to April 2007. The efficacy of the single therapeutic agents or 
their combination was assessed using the mean change in the disease activity score (DAS) and the 
ACR improvement criteria. 
Results. Four RCTs were identified to compare the efficacy of the combination MTX–SSZ to the 
efficacy of either drug alone. Two parallel trials were performed with patients naïve to both drugs 
and two add-on trials were performed in SSZ failures. In the trials with naïve patients, the mean 
DAS changes for the combination MTX and SSZ pointed to a sub-additive efficacy. In the trials with 
patients who previously failed to SSZ, the mean DAS changes for the combination MTX and SSZ 
indicated additive efficacy. 
Conclusions. In RA, addition of MTX to SSZ is a therapeutic option in SSZ failures, whereas 
combination of MTX and SSZ in DMARD-naïve patients has no added value. 
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Introduction 
Methotrexate (MTX) and sulfasalazine (SSZ) are frequently used disease modifying anti-rheumatic 
drugs (DMARDs) in the treatment of rheumatoid arthritis (RA), especially early in the disease course. 
Both drugs are effective, have an acceptable toxicity and their cost price is low. MTX and SSZ are 
used as monotherapy and in combination. Combination therapy can be started simultaneously in 
patients naïve to both drugs, or in an add-on fashion if one of the agents does not have the desired 
effect. However, for pharmacological reasons, the effect of the combination of MTX and SSZ may 
be different between patients who are naïve to these DMARDs and those who have an insufficient 
response to one of them. 
Figure 1. Possible effects of combination therapy.
In general, a combination of two drugs may result in effects that are: multiplicative if one drug 
promotes the action of the other, additive if both effects add to each other, or sub-additive if the two 
drugs act in competition. The effects of drugs in combination are best studied using randomized 
clinical trials (RCTs) with three parallel arms consisting of drugs A, B and the combination A + B, 
with all randomized patients being naïve to A and B (Figure 1). Other settings consist of RCTs with 
an add-on fashion. In the latter, patients with an insufficient response to drug A are randomized to 
continuation of drug A, switch to drug B or addition of drug B. The effect of the combination is more 
likely to be different in parallel trials (naïve patients) than in add-on trials (drug failure) since the 
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latter encompass a subpopulation of patients with partial or no response to one of the drugs. In an 
add-on trial with patients with an insufficient response to one of the study drugs, a multiplicative 
effect (in naïve patients) may look like addition (in drug failures), an additive effect may look like sub-
additivity (competition) and a sub-additive effect may look even more like competition (1). 
These theoretical interactions are often not well studied when using combinations of DMARDs 
in real daily practice. Since the combination of MTX and SSZ is frequently used in the therapy for RA 
and has been tested in several clinical trials, we chose these drugs for the present study. 
The objective of this study was to review the effects of the combination of MTX and SSZ in naïve 
patients and patients with an insufficient response, using the results of published parallel and add-
on clinical trials in RA. 
 
Methods 
Search strategy
To identify clinical trials for our study, a search of the electronic databases MEDLINE (OVID 1966 
to April 2007), and the Cochrane Clinical Trials registry (Issue 2, 2007) was performed using the 
following MeSH headings (including all subheadings): ‘arthritis, rheumatoid’; and ‘methotrexate’; 
and ‘sulfasalazine’, combined by the operator AND. The search was limited by English as language of 
publication and RCT as type of study. The specific search strategy was: 
 i. ‘rheumatoid arthritis’/ 
 ii. ‘methotrexate’/ 
 iii. ‘sulfasalazine’/ 
 iv. randomized controlled trial 
 v. and/(i)—(iv) 
 vi. limit (v) to English. 
Study selection
The following selection criteria were used to consider studies for our analysis: the study had to 
be a RCT of at least 12 weeks duration with a parallel or an add-on design, in which combination 
therapy with MTX and SSZ was compared with MTX and/or SSZ monotherapy, in RA patients 
fulfilling the American College of Rheumatology (ACR) 1987 revised criteria (2). Included patients 
could either be naïve to MTX and SSZ (parallel trials) or had failed to one of them (add-on trials). The 
outcome measures of the study had to be the Disease Activity Score (DAS) and/or the ACR response 
criteria. The DAS is a composite index consisting of the Ritchie articular index or joint pain count, the 
joint swelling count and the Elevated Sedimentation Rate (ESR) (3). The ACR responses are defined 
by at least 20, 50 and 70% improvement in joint swelling and joint tenderness counts, and three of 
five other variables, i.e. ESR, Health Assessment Questionnaire (HAQ), pain score and assessors’ and 
patients’ global assessments (4). Open extensions of an RCT or retrospective studies were excluded 
from our analysis. 
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Data selection
Data extracted from the studies included study characteristics (number of patients and their 
rate of withdrawal and follow-up duration), baseline patient characteristics (age, sex, duration of RA, 
proportion rheumatoid factor (RF) positive and baseline DAS), intervention (treatment drug, dose at 
baseline and during follow-up, concomitant treatment including folic or folinic acid, Non-steroidal 
anti-inflammatory drugs (NSAIDs) and glucocorticoids), outcome measures and adverse events. 
All data were extracted by one reviewer (L.G.S.). The mean change in the DAS (end value minus 
baseline value) for each treatment drug at the end of the study was chosen as primary outcome 
measure since the DAS was reported in all included studies. The proportion of patients fulfilling ACR 
improvement criteria at the end of the study was used as secondary outcome measure. 
Data analysis
The theoretical efficacy of the MTX–SSZ combination was calculated by adding up the observed 
efficacies of the mean DAS changes of the single agents (MTX alone and SSZ alone) and this was 
then compared with the actual mean DAS change of the MTX–SSZ combination observed in the 
RCTs. A similar calculation was performed using the ACR responses. Furthermore, the effect sizes for 
MTX–SSZ combination vs monotherapy (MTX or SSZ) for change of DAS were calculated based on 
Cohen’s D formulation of effect size. The DAS and ACR outcome measures were evaluated according 
to an intention to treat analysis using last observation carried forward. Data were obtained from trial 
results as published (5–8). In one study which only reported DAS values (8) individual patient data 
were available to calculate ACR responses. 
 
Results 
Search results
The current search strategy yielded a total of 44 RCTs. By screening titles and abstracts, nine 
articles were retrieved and selected for detailed review. After application of the inclusion criteria, 
five studies which described MTX and SSZ as combination therapy were excluded. The first was not 
an RCT but a review of another selected trial (9). The second was an extended follow-up of another 
selected article and lacked data on the effects of the single DMARD therapies (10). The third study 
was excluded because it was retrospective (11). The fourth and fifth study did not match with the 
pre-defined study intervention, because HCQ was used as a third study medication (12–13). The 
remaining four studies were included in our analysis (5–8). 
Study description
Three of the studies included were placebo-controlled, double-blind RCTs and compared the 
efficacy of combined MTX and SSZ to each individual agent (5, 6, 8). The fourth was a randomized, 
open study comparing the combination of MTX and SSZ with MTX alone (7). Furthermore, two of 
the trials were performed with patients naïve to either DMARD (6, 8) (parallel trial design) and two 
trials assessed the efficacy of the combination therapy in patients with a suboptimal response to 
SSZ (5, 7) (add-on design). All trials evaluated outcome measures according to an intention to treat 
analysis using last observation carried forward. The proportion of patients who withdrew during 
3
46
Chapter 3
follow-up varied in three studies from 19 to 28%. In the study of Haagsma et al. (7) the rate of 
withdrawal was low (5%). As shown in Table 1 the dosages of MTX and SSZ at baseline and at the 
end of the study were comparable. None of the trials allowed concomitant glucocorticoids and only 
one trial regarded consistent folic acid as supplementation (5). All studies allowed a stable dose of 
concomitant NSAIDs. 
Table 1. Main study, treatment and patient characteristics 
 Haagsma et al. (8) Dougados et al. (6) Haagsma et al. (7) Capell et al. (5) 
Study design Double-blind  Double-blind Single-blind Double-blind
 randomized randomized randomized randomized
Treatment comparison MTX + SSZ  MTX + SSZ MTX + SSZ MTX + SSZ 
 vs MTX  vs SSZ vs MTX vs SSZ vs MTX  vs MTX vs SSZ 
Type of patients Naïve to Naïve to SSZ failures  SSZ failures
 MTX or SSZ  MTX or SSZ  
Length of follow-up, weeks 52  52  24  52 
Number of patients, n 105 205 40 165
Number of withdrawal, n (%) 20 (19) 53 (26) 2 (5) 47 (28)
Age, years 56.2  51.3  55.6  54.7 
Female, % 65  74  80  76 
RF positive, % 95  69  75  66 
Disease duration, months 2.9  13.3  60 21.6
Duration of SSZ use, prior to - - 19 6
combination, months
Doses MTX, mg/week 7.5-15 7.5-15 7.5-15 7.5-15
Doses SSZ, g/day 2-3 2-3 2 2-2.5
Co-medication NSAIDs NSAIDs NSAIDs NSAIDs
Folic acid use On occasion:  None On occasion: 5 mg/week
 deficiency  toxicity 
Efficacy of combination vs  DAS and ACR DAS responses DAS significantly  DAS significantly 
single treatment responses tended tended  better better and ACR
 to be better to be better  responses tended
    to be better
Toxicity of combination vs  Significantly more Significantly more Comparable Comparable
single treatment nausea  nausea  
Parallel trials
From the two parallel trials (6, 8), the first RCT showed not only a trend to increased efficacy, but 
also more toxicity (nausea) of the MTX–SSZ combination compared with the single-drug arms. The 
second study showed comparable efficacy in all three treatment groups with a small trend in favour 
of the combination group, and more adverse events (nausea) in the combination group (Table 1). 
Add-on trials
The two add-on trials (5, 7) showed that the addition of MTX to SSZ in patients who had failed 
to the latter drug was clinically significantly superior to a switch to MTX alone, without increased 
toxicity. The study by Capell et al. (5) also demonstrated that the addition of MTX to SSZ was clinically 
significantly more effective than continuing SSZ monotherapy (Table 1). 
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Comparing parallel with add-on trials
The mean changes in the DAS for the parallel trials and add-on trials are shown in Table 2 and 
Figure 2. Two RCTs with DMARD-naïve patients show mean changes in the DAS for the MTX–SSZ 
combination of 1.3 and 1.9, respectively, which points to a sub-additive effect of the combination 
therapy (Figure 2A). On the other hand, one RCT in patients with a suboptimal response to SSZ 
who received MTX in an add-on fashion showed an actual mean change in the DAS of 1.1, which is 
close to additivity (Figure 2B). Unfortunately, the second add-on trial did not include a SSZ single 
treatment arm.
Table 2. Mean changes in Disease Activity Score (DAS), including the baseline and end values, and 
American College of Rheumatology (ACR) 20, 50 and 70 responses 
 Haagsma Dougados  Haagsma Capell  
 et al. (8)  et al. (6)  et al. (7) et al. (5)
Combi baseline DASa 5.0 4.2 5.3 3.6
MTX baseline DAS 4.7 4.1 5.0 3.7
SSZ baseline DAS 4.6 4.2 - 3.7
Combi end DAS 3.1 2.9 2.7 2.5
MTX end DAS 3.0 3.2 4.0 3.1
SSZ end DAS 3.0 3.0 - 3.1
Combi absolute changeb  - 1.9  -1.3 -2.6  -1.1
MTX absolute change - 1.7 -0.9 -1.0 -0.6
SSZ absolute change - 1.6 -1.2 - -0.6
Combi relative change,% 38  31  49  31
MTX relative change,% 36  22 20 16
SSZ relative change,% 35  29 - 16
    
Combi ACR 20 responsec,% 80 - - 29
MTX ACR 20 response,% 74 - - 15
SSZ ACR 20 response,% 74 - - 18
Combi ACR 50 responsec,% 33 - - 11
MTX ACR 50 respons,% 21 - - 7
SSZ ACR 50 response,% 35 - - 6
Combi ACR 70 responsec,% 3 - - 4
MTX ACR 70 response,% 6 - - 2
SSZ ACR 70 response,% 12 - - 2
    
Effect sizesd    
Combi vs MTX 0.2 (-0.3, 0.7) 0.3 (0.1, 0.8) 1.8 (1.0, 2.5) 0.5 (0.1, 0.9)
Combi vs SSZ 0.3 (-0.2, 0.8) 0.1 (-0.2, 0.4) - 0.5 (0.1, 0.9)
Combi: combination therapy of methotrexate (MTX) with sulfasalazine (SSZ). aDisease Activity Score (DAS): data 
are mean values. bChange: end value minus baseline value. A negative value indicates a decrease in the variable 
over the follow-up. cProportion of patients achieving an American College of Rheumatology (ACR) 20, 50 or 70 
response. dCalculated effect sizes (95% CI) for MTX-SSZ combination vs monotherapy (MTX or SSZ) for change 
of DAS based on Cohen’s D formulation.
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Figure 2. Mean absolute changes in disease activity score (DAS) in (A) naïve patients and (B) sulfasalazine (SSZ) 
failures, clustered by treatment group.
Figure 3. Proportions of patients achieving ACR 20, 50 and 70 responses in (A) DMARD-naïve patients and (B) 
SSZ failures, clustered by treatment group. 
As is shown in Table 2, there was a large effect size (1.8) for MTX–SSZ combination vs MTX 
monotherapy in SSZ failures in the study of Haagsma et al.7 In the other study of SSZ failures, a 
smaller effect size (0.5) was found between combination therapy and monotherapy. However, the 
effect sizes in DMARD-naïve patients were even lower since they varied between 0.1 and 0.3. 
From two trials, ACR responses were available and the analysis of the latter yielded similar results 
to the analysis of the mean changes in the DAS (Figure 3). In the parallel trial with DMARD-naïve 
patients (Figure 3A), ACR 20, 50 and 70 responses were achieved by 80, 33 and 3% of the patients 
receiving MTX–SSZ combination therapy. These effects point to sub-additivity of the combination. 
In the add-on trial performed in SSZ failures (Figure 3B), MTX–SSZ combination therapy resulted in 
ACR 20, 50 and 70 responses of 29, 11 and 4%, respectively, pointing to additivity. 
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Discussion
In this review of RCTs on MTX–SSZ combination therapy, it appeared that in MTX–SSZ-naïve 
patients the effect of this combination was sub-additive, whereas in patients with an insufficient 
response to SSZ the effect of the combination was additive. 
These contrasting effects may be due to differential interactions of MTX and SSZ at the 
pharmacodynamic or pharmacokinetic level. There are two major known pharmacodynamic 
interactions between these agents. First, both DMARDs have anti-inflammatory effects mediated by 
increased intracellular adenosine concentrations and adenosine release (14–16). Second, both MTX 
and SSZ use the same cell transporter (reduced folate carrier; a folate pathway enzyme) for their 
intracellular uptake (17). Further, metabolites of both SSZ and MTX are partially eliminated by renal 
tubular secretion (18). However, in the study of Haagsma et al., it was shown that administration 
of SSZ did not influence the pharmacokinetics of MTX (7, 19) and pharmacokinetic interactions 
between MTX and SSZ are, therefore, unlikely (7). 
We propose that the difference in effect of the MTX–SSZ combination in naïve patients and 
SSZ failures might be explained by pharmacodynamic interactions between both drugs. A 
hypothetical reason for sub-additive treatment effects may be competition of the DMARDs at the 
level of intracellular uptake. Both MTX and SSZ act on the reduced folate carrier but at different 
binding sites. Binding of SSZ to this cell transporter diminishes cellular uptake of MTX and, thus, 
decreased anti-inflammatory effects of MTX (17). This could lead to sub-additive effects as was 
found in DMARD-naïve patients. In SSZ failures, on the other hand, the cell transporter might have 
a diminished susceptibility for SSZ and subsequently the intracellular uptake of MTX and its efficacy 
will not be limited. Also, ‘resistance’ to SSZ may develop by an increased drug efflux as a mechanism 
of cellular resistance (20) leading to reduced anti-inflammatory effects of SSZ. However, this seems 
not to influence the efficacy of MTX (20). 
Since several polymorphisms in genes of the folate pathway may be implicated in the clinical 
response to MTX (21, 22) or to the combination of MTX and SSZ (23), genetic factors may also play 
a part in the efficacy of MTX–SSZ combination therapy. In addition, the study of Wessels et al. (24) 
proposed a pharmacogenetic model for predicting the clinical response of MTX treatment in RA 
patients. This model included gene coding for the folate pathway enzymes, which are also involved 
in the anti-inflammatory action of SSZ (23, 25). 
In this review, the effects found in four RCTs were indirectly compared; therefore, our results 
might be confounded by differences in trial design or baseline characteristics. However, all RCTs 
analysed had similar duration and dosage schedules for MTX and SSZ, did not allow concomitant 
glucocorticoids, three had similar withdrawal percentages (5, 6, 8) and compliance was similar 
when assessed (7, 8). The add-on study of Haagsma et al. (7) was different from the other three 
trials in two ways: it was performed single blind and the rate of retention was high (95%). Intention 
to treat analysis with last observation carried forward was used in all trials, but may have led to an 
underestimation of the treatment effect in the other three trials with lower retention rates. Further, 
this add-on trial did not include a SSZ single treatment arm. However, if this trial had included a SSZ 
arm, it is unlikely that the efficacy of SSZ in SSZ failures would have been larger than the efficacy of a 
switch to MTX, and additivity was, therefore, assumed in this trial. Not surprisingly, the baseline DAS 
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was higher in the two RCTs performed in DMARD-naïve patients, which could have increased the 
chance of pronounced DAS changes and to achieve synergy, but this was not the case. As expected, 
patients in the add-on trials had longer disease duration than those in the parallel trials. Other 
baseline characteristics, such as age, gender and RF were similar among the four trials. 
The primary outcome measure in this study was the mean change in DAS. The ACR responses 
were also used as outcome measures and showed similar results as the DAS: in SSZ failures, the 
MTX–SSZ combination pointed to additivity and in DMARD-naïve patients sub-additivity of the 
combination was shown. However, there was a ceiling effect for the ACR 20 response in DMARD-
naïve patients. As can be expected, the mean DAS changes and ACR response percentages were 
lower in SSZ failures than in DMARD-naïve patients. This is in accordance with current evidence 
that treatment should be initiated in the early stages of RA in order to reduce disease activity most 
effectively: to achieve and sustain clinical remission (26–29). 
The results of the two trials with naïve patients show only minor advantage of the combination 
above the single components. This differs from the results of the step-down COBRA trial which 
showed that, in DMARD-naïve patients, the combination of MTX with SSZ and prednisone was clearly 
superior to SSZ monotherapy, and this superiority faded when tapering the combination towards 
SSZ monotherapy (30). The trials analysed in our study did not allow concomitant prednisone use; 
the differences might at least partly be explained by the high-dose prednisone in the COBRA trial. 
The findings in the two trials with SSZ failures are different from those from the BeSt study, which 
demonstrated that in MTX failures the combination of MTX and SSZ had no additive therapeutic 
effect compared to a switch to SSZ (31, 32). However, the design of the BeSt study was different than 
the studies included in our study and patients started with MTX instead of SSZ. In both strategies 
from the BeSt, treatment was optimized based on disease activity, which may have contributed 
to comparable treatment outcomes. Interestingly, based on the BeSt study and the four studies 
reviewed, the treatment effect of MTX–SSZ combination seems to depend on whether patients failed 
to MTX or to SSZ. The anti-inflammatory effect of MTX is a result of several intracellular pathways 
and some of them are also shared by SSZ (23, 25, 33). It is, therefore, conceivable that blockade of 
MTX pathways may result in diminished anti-inflammatory effects of SSZ as well. 
Our results are consistent with previous studies using triple therapy with MTX, SSZ and 
hydroxychloroquine (HCQ) compared with MTX and SSZ or MTX and HCQ (12, 13). In early RA 
patients naïve to the study drugs, triple combination showed more efficacy, though analysis of 
the ACR responses again approached a sub-additive effect (13). In patients with established RA, 
the triple combination was also superior to MTX alone or the combination of SSZ and HCQ and 
appeared to be additive (12). 
Taken together, our review indicates that in RA the combination of MTX and SSZ has sub-
additive effects in patients naïve to both drugs, but has additive effects in previous SSZ failures. 
Common pathways of MTX and SSZ may cause these different effects. Given the available evidence, 
addition of MTX to SSZ is a therapeutic option in SSZ failures, whereas combination of MTX and 
SSZ in DMARD-naïve patients may not be a preferred treatment choice unless it is a COBRA scheme 
including high doses of glucocorticosteroids. 
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Abstract
Objectives. MTX, either alone or in combination with SSZ, is effective in the treatment of RA. 
Trials have shown that, after SSZ failure, the addition of MTX to SSZ is more effective than a switch 
to MTX. Whether this is also the case in daily practice has not been analysed yet. In this study, we 
compared the efficacy of a switch to MTX monotherapy with that of the addition of MTX to SSZ 
in the daily clinical practice of RA patients who had failed SSZ monotherapy in the Nijmegen RA 
Inception Cohort. 
Methods. For this study, 230 patients who failed to SSZ monotherapy were followed for up 
to 52 weeks. A total of 124 underwent a switch to MTX alone, whereas 106 patients received the 
combination of MTX and SSZ. The primary outcome measure was the mean change in the disease 
activity score (DAS28) after 24 weeks. 
Results. Both treatment groups showed a significant decrease in DAS28 after 24 weeks, which 
was similar in both groups. Drug survival analysis showed that the chance to stop with a DMARD 
within 52 weeks was higher in the MTX–SSZ group (P <0.01). 
Conclusions. In RA patients who failed to SSZ the clinical efficacy of a switch to MTX monotherapy 
was similar to that of the addition of MTX, suggesting that in daily clinical practice a switch to MTX 
is a good option for patients with an inadequate response to SSZ. 
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Introduction
In the treatment of rheumatoid arthritis (RA), methotrexate (MTX) and sulfasalazine (SSZ), either 
alone or in combination, are disease modifying anti-rheumatic drugs (DMARDs) of first choice in 
clinical practice (1–3). Both agents are relatively inexpensive, have proven their efficacy in clinical 
trials and daily practice, and have a low toxicity profile (3–12). 
MTX monotherapy, SSZ monotherapy and MTX–SSZ combination have comparable efficacy in 
randomized controlled trials (RCTs) in patients naïve to those agents (13–15). Add-on trials have 
shown that the addition of MTX is better than a switch to MTX monotherapy after SSZ failure (16, 17). 
For daily clinical practice, the combination of MTX and SSZ might be adequate after a suboptimal 
response to SSZ. Though the BehandelStrategieën voor Reumatoide Artritis (BeSt) trial suggests that 
this might not be the case after an inadequate response to MTX (18, 19), in that study, the addition of 
SSZ in case of MTX failure was not superior to a switch to SSZ monotherapy. This, however, may cast 
some doubt on the benefit of the combination of SSZ and MTX if one of the drugs previously failed. 
Daily practice data may be of complementary value to data from RCTs. We therefore analysed the 
data from a large Dutch observational cohort to study whether the addition of MTX in SSZ failures is 
beneficial compared with a switch to MTX monotherapy in daily clinical practice. 
 
Methods
Design
Non-randomized observational comparison was performed among RA patients who failed to 
treatment with SSZ, who switched to MTX monotherapy and those who received MTX in addition 
to SSZ, in a large, well-defined, early RA inception Cohort (20). The propensity score method and 
confounder correction was used in order to correct for confounding by indication at baseline. 
Data collection
The Nijmegen RA Inception Cohort encompasses patients visiting the outpatient clinic of the 
rheumatology departments of the Radboud University Nijmegen and the Sint Maartenskliniek in 
Nijmegen. Patients are included when they have RA according to the 1987 revised American College 
of Rheumatology (ACR) criteria for RA (21), are ≥18 years of age, have a disease duration of <1 year 
and had no prior use of DMARDs. Enrolment started in July 1986 and all patients are regularly 
assessed in 3-month visits, but treatment decisions can be made at any time. The patients are treated 
according to the discretion of the treating physician. Data on patient characteristics, medication 
use and clinical and laboratory measures are prospectively stored in an electronic database. The 
local medical ethics committee (Commissie Mensgebonden Onderzoek (CMO), Region Arnhem—
Nijmegen, The Netherlands) approved the study. 
Patients
For this study, we screened the data from 903 patients from the Nijmegen Inception Cohort 
who were included between July 1986 and September 2007. We focused on patients who started 
treatment with SSZ as first or second DMARD followed by either (i) a switch to MTX or (ii) the 
4
58
Chapter 4
addition of MTX to SSZ. Analogous to a clinical trial, the moment of switch to MTX or addition of 
MTX to SSZ was regarded as baseline in our study. Patients who used concomitant DMARD therapy 
other than MTX or SSZ at baseline were excluded. Assessments of disease activity scores-28 (DAS28) 
within 2 weeks from baseline and a minimal follow-up of 3 weeks were required. Selection details 
are summarized in Figure 1. 
Figure 1. Flow chart of patient selection from the Nijmegen Inception Cohort.
Treatment strategy
Included patients were analysed according to two treatment strategies: switching to MTX 
monotherapy or the addition of MTX to their ongoing SSZ therapy. Prior to ‘switching’ or ‘adding’, 
patients had been treated with SSZ in doses of 750–3000 mg/day. Oral MTX was started at a 
weekly dose of 7.5 mg, which could be increased to a maximum of 30 mg. The daily dose of SSZ 
at study entry ranged from 750 to 3000 mg. Dose adjustments of MTX and SSZ, concomitant non-
steroidal anti-inflammatory drugs (NSAIDs) in usual doses and/or glucocorticoids were used in both 
treatment strategies based on the opinion of the individual rheumatologist. Patients received folic 
or folinic acid during treatment with MTX. Before 2004, the folic or folinic acid dose used was 1 mg/
day and after 2004, this was 5 mg/week with an increase to 10 mg/week in case of an MTX dose of 
≥15 mg/week. 
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Clinical assessments
The following baseline patient characteristics were retrieved from the database: age, sex, 
duration of RA, rheumatoid factor (RF) positivity, DAS28 and concomitant glucocorticoids. From 
previous DMARD therapies, in particular SSZ, information concerning dosage, dosing schedule and 
treatment duration were collected. Clinical efficacy and response to therapy were assessed using the 
3 monthly DAS28 (22) and the European League Against Rheumatism (EULAR) response criteria (23) 
at 6 and 12 months, respectively. Specially trained research nurses assessed the variables needed for 
the DAS28. The DAS28 includes the 28-joint counts for swelling and tenderness, general health (on a 
visual analogue scale of 100 mm) and the value for Elevated Sedimentation Rate (ESR) measured by 
the Westergren method (22–24). Changes in DMARD therapy and co-medication and the reason for 
change, including occurrence of adverse events, were recorded during follow-up. 
The primary outcome measure of this study was the mean change in the DAS28 from baseline 
to 6 months. Secondary outcome measures included the mean change in the DAS28 from baseline 
to 12 months, the EULAR response criteria at 6 and 12 months, the course over time of the DAS28, 
and cumulative drug survival at 12 months of MTX monotherapy or MTX–SSZ combination therapy. 
Sample size determination
It was assumed that the ‘addition’ group would show more efficacy than the ‘switch’ group. For 
this study, each treatment group consisted of at least 100 patients. Then, with an α of 0.05 and a 
1β (‘power’) of 0.80 and a total sample size of 200 patients, a difference between the groups of 0.4 
DAS28 points could be detected. This difference is smaller than the difference that was detected in 
both clinical trials (16, 17). 
Statistical analyses
Mean changes in the DAS28 were compared between the two treatment strategies using linear 
regression including treatment, baseline DAS28, a propensity score and other confounders as 
covariates. To test whether there was a difference in EULAR response rates the chi-square test was 
assessed. The course over time of the DAS28 was analysed using longitudinal linear regression (mixed 
models), correcting for repeated measurements using an autoregressive covariance structure. 
Differences in continuation were determined using a Kaplan–Meier curve with a log rank test. 
A Cox proportional hazards model was used to calculate the hazard for discontinuation within 1 
year. Discontinuation was defined as stopping with either MTX or SSZ within 1-year treatment, 
including starting with other concomitant DMARD therapy or anti-tumour necrosis factor (anti-
TNF)-α treatment. 
A propensity score was added to the regression models in order to account for confounding by 
indication, and additional confounders were added using 10% change in main effect as selection 
criterion. The propensity score was defined as the conditional probability of receiving MTX or 
MTX plus SSZ given the individual’s covariates (25). Logistic regression with a backward selection 
procedure (P < 0.20 as selection criterion) was used to determine as to which baseline variables 
were imbalanced between the two groups and were included in the propensity score. Patients were 
stratified based on quintiles of the propensity score. After stratification, balance of each baseline 
4
60
Chapter 4
variable between the two treatment strategies was assessed by using two-way analyses of variance 
(parametric) or van Elteren’s test (non-parametric) for continuous variables and logistic regression 
for dichotomous variables. Furthermore, the fit of the propensity score model was assessed by the 
Hosmer–Lemeshow test. 
In the clinical efficacy analyses, each patient remained in the treatment group to which they had 
been assigned, regardless of whether they completed or received that treatment (intention-to-treat). 
In case of treatment discontinuation (i.e. the use of concomitant therapy other than MTX or SSZ), the 
last available data were carried forward. In a sensitivity analysis, these results were compared with 
the results from the analysis in which only patients who actually received the intended treatment 
(‘completers’) were used. 
For the clinical efficacy analyses, the level of significance was set at P < 0.05. The analyses were 
carried out using SPSS 14.0 statistical software package. 
 
Results
Patients
As shown in Figure 1, we analysed 230 patients who had failed to SSZ. Out of those, 124 (54%) 
switched to MTX monotherapy and 106 (46%) patients received MTX in combination with SSZ. 
Reasons for SSZ discontinuation in patients who switched to MTX monotherapy were adverse 
events (n = 53, 43%) and lack of efficacy (n = 57, 46%). Lack of effect of SSZ (n = 88, 83%) was 
the most common reason for adding MTX to the ongoing SSZ therapy, besides toxicity (n = 11, 
10%). During follow-up, 81.5% of the MTX group and 69.8% of the MTX–SSZ combination group 
had a drug survival of at least 6 months. The 1-year drug survival was 66.1 and 50.0% of the MTX 
monotherapy group and the MTX–SSZ combination group, respectively (Figure 1). 
The main demographic and disease characteristics of the patients at baseline are summarized 
in Table 1. Patients had active disease at baseline as was demonstrated by a mean DAS28 of ~ 5.0. 
For 86% of the patients, SSZ was their first DMARD after onset of RA. The duration of previous SSZ 
use was significantly longer in the combination group than in the MTX group (median of 47 vs 14 
weeks). Prior to SSZ treatment, there was no significant difference in disease duration. The use of 
previous DMARDs, other than SSZ, was almost similar between the two treatment groups (15 vs 
13%). 
Since the inclusion time frame was >15 years and changes in treatment strategies during that time 
are expected, we investigated whether year of treatment start did differ between both strategies. 
Both treatment groups (‘switch’ or ‘add’) were equally employed during the cohort time frame and 
there was no significant difference in the starting year of SSZ between both groups. Furthermore, 
four sub-cohorts (1986–91, 1992–97, 1998–2003 and 2004–07) were defined within the total cohort 
based on the date of starting with SSZ. Patient profiles within each sub-cohort were investigated 
as well and no differences were found between both treatment groups in age, disease duration, RF 
positivity and disease activity prior to starting SSZ (data not shown). 
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Propensity score
Table 1 shows the balance of baseline variables between both treatment strategies, before and 
after stratification based on the propensity score quintiles. Before stratification, four variables (RF 
positivity, length of previous SSZ use, DAS28 at baseline and hospital) were found significantly 
different between the two groups and were included in the propensity score. After adjustment for 
propensity score quintile, all variables were balanced between the two treatment groups. However, 
the P-values for age and DAS28 moved in an opposite direction Therefore, these variables were 
regarded as potential confounders. The Hosmer–Lemeshow test was 3.9 (df = 8, P = 0.87), which 
indicated good fit of the propensity score model. 
Table 1. Demographic and baseline disease characteristics of patients
 MTX MTX+SSZ Before After 
 n = 124 n = 106 correction  correction*  
   P-value P-value
Age, mean ± s.d., years 63.8 ± 14.6 61.8  ± 14.5 0.286 0.065
Women, n (%) 87 (70) 78 (74) 0.565 0.587
Rheumatoid factor positive, n (%) 90 (73) 86 (81) 0.127** 0.662
Disease activity score-28, mean ± s.d.  5.1 ± 1.3 4.9 ± 1.3   0.225** 0.101
Disease duration, median (IQR), weeksa 14 (5.3,67.3)  47(20.2,109.0)  0.000** 1.000
SSZ dose prior to two treatments, 1494 ± 658 1486 ± 671 0.931 1.000
  mean ± s.d., mg/day 
Disease duration prior to SSZ, median (IQR), weeks 0 (0,13.8) 0 (0,14.8) 0.512 1.000
Concomitant glucocorticoids use, n (%) 10 (8) 10 (9) 0.713 0.821
Previous DMARDs, n (%)b 19 (15) 14 (13) 0.648 0.438
Hospital treatment, n (%) 74 (60) 52 (49) 0.107** 0.354
MTX: methotrexate, SSZ: sulfasalazine, DMARDs: disease-modifying anti-rheumatic drugs, IQR: interquartile 
range, s.d.: standard deviation. aAt baseline, includes duration of SSZ treatment as well. bOther than SSZ. 
*Comparison of variables between the two groups after adjusting for propensity score quintile. Two-way 
analyses of variance (parametric) or van Elteren’s test (non-parametric) was performed for continuous variables 
and logistic regression for dichotomous variables. **Significant in propensity score model based on logistic 
regression with a backward selection procedure with P < 0.2 as selection criterion.  
Clinical efficacy
Mean change in DAS28
After 6 months of treatment, there was a statistically significant decline in the mean DAS28 over 
time in both the therapy groups (P <0.0001). The mean changes (S.D.) in DAS28 over 6 months were 
–0.9 (1.3) in the MTX group and –0.8 (1.3) in the combination group and this was not statistically 
significant after adjustment for baseline DAS28 and propensity score (P = 0.737; Table 2). 
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Table 2. Difference in DAS28 between both treatment strategies
 Difference between mean changes in DAS28 ± S.E.a  P-value
0-6 months  0.05 ± 0.16 0.737
0-12 months 0.05 ± 0.15 0.756
6-12 months 0.11 ± 0.09 0.245
aThe difference between mean changes in disease activity score-28 (DAS28) between the two groups (MTX 
monotherapy or MTX-SSZ therapy) using analysis of covariance with the change in DAS28 as dependent 
variable, the treatment group as main effect, baseline DAS28 and the propensity score as covariates. The value 
in the table is the coefficient of the indicator variable (treatment group). 
After 1 year, a significant (P <0.0001) decrease in DAS28 was observed in both groups (mean 
(S.D.) of –1.1 (1.3) and –0.9 (1.2) for the MTX group and combination group, respectively). This was 
not significantly different between both therapy groups (P = 0.756), after analysis of covariance 
adjusted for DAS28 at baseline, the propensity score and age (Table 2). 
Since there were several reasons to start either MTX monotherapy or MTX–SSZ combination 
therapy after using SSZ monotherapy (inefficacy of SSZ, adverse events by SSZ or reasons unknown), 
aforementioned analyses were adjusted for these reasons as well. Applying this adjustment did not 
alter the main effect of the two treatment groups and no difference in clinical efficacy was observed 
between the two groups: a difference of 0.036 in DAS28 decrease between both groups (P = 0.849). 
Moreover, reasons to ‘switch’ or to ‘add’ were not effect modifiers: the difference between both 
treatment groups was equal in all the subgroups formed by stratification for reason. Additionally, 
when the reason was ‘lack of efficacy’, a decrease in DAS28 of –1.1 and –0.9 in the ‘switch’ and ‘addition’ 
group, respectively, was shown. These responses were not found to be significantly different (P = 
0.217). Since ‘adverse events’ were actually only a reason to ‘switch’, the change of DAS28 in this 
group was –1.0 and was comparable with the overall response rate in the ‘addition’ group (P = 0.693). 
Course over time of the DAS28
Although patients in the MTX group started from a somewhat higher level (5.1 vs 4.9), the 
changes in DAS28 were very similar with both groups. Patients from both treatment strategies 
reached a mean DAS28 of 4.0 after 1-year treatment (Figure 2). The mean difference between the 
two groups in the change of DAS28 at 6 and 12 months was not significantly different, after mixed 
models analyses adjusted for the propensity score and DAS28 at baseline (P = 0.153). 
EULAR response
The EULAR response for the two treatment groups is shown in Figure 3. Most patients achieved 
a moderate EULAR response. In both treatment strategies, most patients had a moderate level of 
disease activity after 6 and 12 months of treatment. After 12 months, 53% in the MTX group and 51% 
in the MTX–SSZ combination group achieved good/moderate response. None of the differences in 
EULAR responses between the two groups was found to be significant. 
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Figure 2. Mean change of DAS28 for both treatment strategies (patients using MTX or a combination of MTX 
with SSZ). Mixed models were used with time-averaged DAS28 as dependent variable, treatment group as 
factor, the propensity score and baseline DAS28 as covariates. Error bars indicate 95% CI.
Figure 3. (A) EULAR response after 6 and 12 months. Good: good response (DAS28 of <3.2 and an improvement 
from >1.2); moderate: moderate response (DAS28 of <5.1 and an improvement of 0.6–1.2); none: no response 
(DAS28 improvement of  ≤0.6). EULAR responses were compared by using chi-square test. (B) Disease activity 
at 6 and 12 months. High: high disease activity (DAS28 of >5.1); moderate: moderate disease activity (DAS28 of 
>3.2 and  ≤5.1); low: low disease activity (DAS28 of  ≤3.2); remission (DAS28 <2.6).
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DMARD and concomitant therapy
As is shown in Table 3, patients in both treatment strategies received similar doses of MTX 
during follow-up. In both strategies, the starting dose of MTX was 7.5 mg/week and the median 
number of MTX dose changes was two (range 1–3) and did not differ between both treatments 
(P = 0.70). Despite the fact that MTX dose was relatively low in both the groups (~13 mg/week), 
a large proportion of patients (41%) received ≥15 mg/week. In the group of patients who were 
treated with MTX monotherapy, 79% received concomitant folic acid and in the group of patients 
with combination therapy this proportion was 86% (P = 0.18). 
Table 3. Doses of DMARD used and concomitant glucocorticoid use
 MTX MTX+SSZ P-value*
 n = 124 n = 106 
Intervention DMARD use 
MTX dose, mean ± s.d., time-averaged, mg/week 13.4 (5.4) 13.3 (4.9) 0.825
SSZ dose, mean ± s.d., time-averaged, mg/day - 2000 (476) -
Concomitant glucocorticoids use   
Oral glucocorticoids use, n (%) 15 (12) 9 (8) 0.373
Glucocorticoids dose, median (IQR), time-averaged, mg/day 9.8 (7.9, 10.0) 9.6 (8.1, 16.4) 0.834
Intramuscular methylprednisolon, n (%) 35 (28) 18 (17) 0.044**
Frequency methylprednisolone, median (IQR) 1 (1, 2) 1 (1, 1) 0.310
MTX: methotrexate, SSZ: sulfasalazine, DMARDs: disease-modifying anti-rheumatic drugs, Time-averaged: 
mean dose within period of medication use, IQR: interquartile range, s.d.: standard deviation. *Comparison 
of variables between the two groups using independent t-test (parametric) or Mann-Whitney U test (non-
parametric) for continuous variables and chi-square test for dichotomous variables. **Significant after 
comparing the MTX group with the MTX + SSZ group by chi-square test. 
During intervention, a comparable number of patients used oral glucocorticoids in the MTX 
group (12%) and in the MTX–SSZ group (8%). Also, the median time-averaged doses of concomitant 
glucocorticoids did not differ between the two groups (P = 0.83; Table 3). With regard to the use of 
intramuscular methylprednisolone, significantly more patients in the MTX monotherapy received 
one or more intramuscular injections with methylprednisolone than the combination group (28 
vs 17%, respectively). The frequency of the intramuscular injections during treatment was in both 
groups similar (Table 3). Most patients received their injection at the beginning of the follow-up; 
within 4 months. Since the effect of intramuscular corticosteroids may influence the results in case 
of performing injections ≤4 weeks before evaluation of disease activity, the time points of the 
injections were assessed as well. However, there were only a few patients (three ‘switchers’ and two 
‘adders’) who received intramuscular corticosteroids 4 weeks prior to the evaluation of 6 months and 
four patients (two ‘switchers’ and two ‘adders’) prior to 12 months. Excluding this group of patients 
from efficacy analyses did not alter the main treatment effect between the ‘switch’ group and the 
‘add’ group (data not shown). 
Furthermore, the patients included were concurrently treated with NSAIDs. No difference in the 
number of prescribed NSAIDs was detected between the two groups: 96% in the MTX monotherapy 
group and 95% in the combination group (P = 0.80). 
65
To switch or to add after sulfasalazine failure
Sensitivity analyses
A sensitivity analysis was performed based on data from only patients who completed their 6 
months of treatment and showed us that the mean decrease in DAS28 (S.D.) was 1.1 (1.3) in the 
‘switch’ group and 0.9 (1.2) in the ‘addition’ group. There was no significant difference between both 
the groups (P = 0.866). Moreover, these results were comparable with those obtained from the main 
effect measured from data from all patients regardless of their treatment continuation. Furthermore, 
we performed a sub-analysis within the ‘addition’ group of those who discontinued SSZ early and 
those who completed their 1-year treatment of SSZ. The mean change of DAS28 after 1 year was 
1.0 and 0.7 in the ‘completers’ and SSZ discontinuation group, respectively. The difference was not 
found statistically significant (P = 0.158). 
Drug survival analyses
Cox proportional hazards models showed that the relative hazard to stop a DMARD within 1 year 
was 1.7 in the MTX–SSZ combination group, compared with the MTX monotherapy group (95% CI 
1.11, 2.46; P <0.01 by log rank test). Accordingly, the 1-year cumulative drug survival was lower in 
patients who received MTX in combination with SSZ (0.49 ± 0.04) than in those who switched to 
MTX monotherapy (0.64 ± 0.04; P < 0.05; Figure 4A). Drug survival of the combination was limited by 
the survival of SSZ. Drug survival of MTX was lower in the ‘switch’ group than in the ‘addition’ group 
(0.64 vs 0.77; P < 0.05; Figure 4B). 
Figure 4. (A) Cumulative drug survival of switching to MTX and addition of MTX to SSZ at 1 year, in patients 
who failed to SSZ. Drug survival has been corrected for the propensity score, including the duration of SSZ use 
prior to switching or adding. *P < 0.01. (B) Cumulative drug survival of MTX therapy in the ‘switch’ group and in 
the ‘addition’ group at 1 year, in patients who failed to SSZ. Drug survival has been corrected for the propensity 
score, including the duration of SSZ use prior to switching or adding. *P < 0.01.
Reasons for discontinuation
The rate of discontinuation was significantly lower in the MTX group compared with the 
combination group after 12 months of treatment (42 vs 53 patients; P = 0.013). This difference was 
mainly determined in the first 6 months (Table 4). 
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Table 4. Discontinuation of therapy within 6 or 12 months of treatment
 Reason to stop therapy within  Reason to stop therapy from 6 to 
 6 months of treatment, n = 56a 12 months of treatment, n = 39
 Combination therapyb  Combination therapyb
 MTX,  MTX, SSZ,  MTX,  MTX, SSZ, 
 n = 23 n = 11  n = 22 n = 19  n = 4  n = 16
Side effects, n (%) 18 (14.5) 7 (6.6) 2 (0.02) 5 (18.5)c 1 (7.5)c 2 (0.04)
Lack of effect, n (%) 0 (0) 1 (0.01) 12 (11.3) 5 (4.0) 0 (0.01) 5 (16.0)
Lost to follow-up, n (%) 0 (0) 0 (0) 1 (0.01) 1 (0.01) 0 (0) 0 (0.01)
Other reasons, n (%) 3 (0.02) 2 (0.02) 4 (0.04) 2 (4.0) 1 (0.03) 3 (6.6)
Unknown, n (%) 2 (0.02) 1 (0.01) 3 (0.03) 6 (6.5) 2 (0.03) 6 (8.5)
aSignificant difference in rate of discontinuation between both treatment strategies after 6 months using 
chi-square test. bCombination therapy consisted of methotrexaat (MTX) and sulfasalazine (SSZ). cSignificant 
difference in rate of discontinuation between both treatment strategies after 12 months using chi-square test.
The most frequent reason to discontinue MTX therapy was toxicity (78 vs 64% after 6 months 
and 26 vs 25% after 12 months, respectively; Table 4). In the MTX group, MTX was significantly more 
frequently discontinued for adverse events after 12 months (18.5%) than the MTX–SSZ combination 
group (7.5%). Whereas, as expected, SSZ discontinuation was mainly due to lack of response (after 6 
and 12 months, 55 and 31%, respectively). 
 
Discussion 
There are only a few clinical trials available that investigated the clinical efficacy of MTX–SSZ 
combination therapy after failure to one of these agents. The results of the latter are not consistent 
and seem to differ depending on the fact whether the initial failure was to SSZ or to MTX. Herein, we 
chose to compare the clinical outcome of a ‘switch’ to MTX monotherapy with the ‘addition’ of MTX 
to SSZ, in a cohort (20) of RA patients who failed to previous SSZ monotherapy and were treated 
according to usual care. 
Our results show that switching to MTX monotherapy and combination of MTX and SSZ resulted 
in a significant, and similar, decline in the mean DAS28 and EULAR responses after 1 year. Switching 
to MTX monotherapy yielded a better 1-year drug survival than the addition of MTX to SSZ. Adverse 
events of MTX occurred more frequently in the ‘switch’ group. Since a great proportion of this group 
started MTX after experiencing toxicity of SSZ and both DMARDs share common pathways, this may 
be a reason for toxicity of MTX as well. In patients who received MTX–SSZ combination therapy, the 
SSZ survival was lower than the survival of MTX. Lack of efficacy was mostly the reason to stop SSZ, 
when combined with MTX. From these results, therefore, we may conclude that MTX monotherapy 
has similar efficacy compared with MTX–SSZ combination therapy after SSZ failure in daily clinical 
practice. 
In this observational study, the magnitude of the treatment effects was of the same magnitude 
than those found in earlier clinical trials (16, 17). The finding of no difference in effect is, however, 
67
To switch or to add after sulfasalazine failure
in contrast with the results from two add-on trials, which demonstrated that the addition of MTX 
is more effective than a switch to MTX alone in patients with an inadequate response to SSZ (16, 
17). On the other hand, the results from this study are comparable with the findings in patients 
who had an inadequate response to MTX, as was investigated in the BeSt study. This strategic study 
demonstrated that in MTX failures, the addition of SSZ was not more effective than a switch to SSZ 
(18). 
A cause for the discrepancy between trial results and results from daily clinical practice might 
have been differences in the included patients and their disease characteristics. Especially, the DAS 
at baseline and the use of previous DMARDs are characteristics that may differ between patient 
groups in RCTs and cohort studies. After comparison of these characteristics between the clinical 
trials and clinical practice, however, we observed no difference in DAS at baseline or previous use 
of DMARDs. Furthermore, the patients included had comparable age, disease duration, duration 
of SSZ use prior to the switch or addition of MTX, there were similar percentages of women and 
RF-positive patients and no time trend towards ‘switch’ or ‘addition’ has been observed. Besides, in 
both study designs, outcomes were evaluated as an intention-to-treat analysis and a continuous 
outcome measure (DAS in trials and DAS28 in this study) had been used. 
Concomitant medication and treatment intervention itself may be another cause for the 
inconsistency between the clinical trials and clinical practice. With regard to DMARD intervention, 
MTX and SSZ dosage schedules were comparable with those applied in the RCTs. In the MTX group, 
more patients received concomitant intramuscular injections with methylprednisolone; mostly 
within 4 weeks after starting with MTX. Only a few patients received their injections 4 weeks prior 
to evaluation of 6 or 12 months and excluding these patients from analyses did not alter the main 
treatment effect. However, the fact that the MTX monotherapy group received more intramuscular 
corticosteroids may be indirectly related to a delay of action of MTX or the occurrence of more 
disease flares in comparison with the MTX–SSZ combination group. 
Overall, the different results from clinical trials and clinical practice cannot be explained by 
either differences in the included patients, treatment dosage schedules, disease characteristics 
at baseline or the number of patients who discontinued their treatment. In the study of intended 
effects, randomized controlled studies are conceptually superior to observational studies. The most 
important difference between RCT and observational study design, the lack of control over treatment 
allocation, may lead to biased estimates of treatment effects. In order to reduce this confounding 
by indication bias, the propensity score was used to balance the baseline characteristics between 
the two treatment groups. It was evaluated whether the propensity score model did fit the data 
by comparing the baseline variables before and after adjustment for the propensity score and 
by performing the Hosmer–Lemeshow test. Balance was achieved between the two treatment 
groups and the propensity score model fitted the data well. Although it is assumed that use of the 
propensity score contributed to estimate the true treatment effects, bias in patient selection could 
not definitely be ruled out by means of the propensity score because of unmeasured confounders. 
Therefore, the difference found in results between the present study and the clinical trials might still 
be due to confounding by indication bias. 
Loss to follow-up and missing data (e.g. information bias) could also be an important potential 
cause of bias in cohort data. To overcome this bias, the clinical efficacy was evaluated according to 
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an intention to treat analysis using last observation carried forward. The change in DAS at 3 and 6 
months did not differ between those patients who stopped combination therapy and continued 
with monotherapy (MTX or SSZ) and those who continued their MTX–SSZ combination. Moreover, 
a sensitivity analysis based on data from only patients who completed their 1-year treatment was 
performed and did not change the results that were obtained from data from all patients regardless 
of their treatment continuation. Therefore, it is not likely that this type of bias influenced the results. 
Although MTX and SSZ are currently regarded as the DMARDs of first choice in clinical practice, 
available evidence to support the use of MTX–SSZ combination is limited and only based on the 
results from a few clinical trials. A switch to MTX after inadequate SSZ response may be the preferred 
treatment choice in clinical practice. After MTX monotherapy, the addition of SSZ to MTX seems 
to be less effective (18). Starting with MTX–SSZ combination therapy is not more effective than 
monotherapy and may, therefore, not be the first choice in early, DMARD-naïve RA patients (13, 14). 
In conclusion, the results of this observational study suggest that there is no difference in clinical 
efficacy between MTX and SSZ combination therapy and MTX monotherapy in patients who failed 
to SSZ monotherapy, which is in contradiction to results of clinical trials. Both addition of MTX and 
switch to MTX lead to >50% responders, suggesting that in daily clinical practice an immediate 
switch to MTX monotherapy and addition of MTX are equivalent therapeutic options for patients 
with an inadequate response to SSZ. 
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Abstract
Objectives. To perform a modelling study on the cost-effectiveness of three outcome directed 
strategies in early Rheumatoid Arthritis (RA) patients: 1) starting methotrexate monotherapy (MTX), 
followed by addition of leflunomide (LEF), followed by MTX with addition of anti-TNF; 2) start with 
MTX and LEF combination followed by MTX with anti-TNF; 3) immediate start with MTX and anti-TNF. 
Methods. A validated Markov model was used to evaluate the cost-effectiveness of the three 
strategies. Effectiveness was determined using daily clinical practice data. Percentage of patients in 
remission with a disease activity score <2.6 was defined as final outcome of clinical efficacy. Using 
Monte Carlo simulation, expected costs and effects were calculated following both a health care 
and a societal perspective, measured as the incremental cost per quality adjusted life-year (QALY) 
gained and a five-year time horizon. 
Results. The percentage of patients in remission and number of QALYs were comparable 
between the three strategies. Starting with a combination (MTX plus LEF or anti-TNF) was more 
costly than starting with MTX alone. This resulted in an unfavourable incremental cost effectiveness 
ratio for starting on anti-TNF versus initially MTX: health care perspective of €138,028 and from a 
societal perspective of €136,150 per QALY gained over five years. 
Conclusions. Starting with MTX or anti-TNF has comparable effectiveness. However, initially 
anti-TNF was far more expensive than starting with MTX monotherapy. Therefore, based on this 
study a treatment strategy starting with MTX monotherapy is favoured over a strategy with MTX and 
anti-TNF right away in early RA patients. 
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Introduction 
Rheumatoid arthritis (RA) is a common idiopathic autoimmune disease characterized by 
symmetrical synovitis and associated with morbidity and impaired quality of life (1). The primary 
goal in early RA is to suppress inflammation as early and completely as possible and ultimately 
to prevent joint damage that leads to pain and functional disability (2-4). Since RA imposes a 
substantial economic burden on both the patient and society, it is expected that treatments that 
decrease functional disability of RA patients would have an effect on the long-term costs of RA as 
well (5). Treatment should, therefore, be initiated in the early stages of RA in order to reduce disease 
activity most effectively: to achieve and sustain clinical remission (1-5). Moreover, patients should be 
periodically assessed (three-monthly) for evaluation of activity of the disease and treatment should 
be adjusted subsequently (4).
The traditional treatment of early RA involves the start with disease-modifying anti-rheumatic 
drugs (DMARDs) (6, 7). Current treatment has shifted towards more intensified treatment- for 
instance the use of anti-tumour necrosis factor (anti-TNF) agents -  in order to achieve remission. 
In early RA, randomized controlled trials (RCTs) showed that anti-TNF agents in combination with 
methotrexate (MTX) are more effective than MTX monotherapy (8, 9). However, anti-TNF agents are 
more expensive than DMARDs (10). Another therapeutic option - the use of combined DMARDs as 
MTX and leflunomide (LEF) - also resulted in rapidly achieved and sustained low disease activity 
(11-13). Although combinations are more efficacious, such intensive approach is potentially also 
more toxic and expensive (5). Moreover, combination therapy might not be necessary for all newly 
diagnosed RA patients since 30 to 40% of the patients will experience a good response to MTX alone 
(13-15).   
In daily practice, a treatment option that is frequently used for early RA patients is to start with 
MTX, then add a second DMARD if MTX fails, and if that fails add an anti-TNF agent. In that case, 
the relative expensive anti-TNF treatment is only given to patients having demonstrated failure to 
DMARDs. However, effective anti-TNF treatment is then delayed. For this reason, it is mandatory to 
compare both the benefits and the costs of early treatment with anti-TNF agents with strategies that 
delay use of anti-TNF.
The most robust way to obtain insight in cost and effectiveness of treatment strategies is a RCT. 
However, with the exception of the BeSt study (16),Neither effectiveness nor cost-effectiveness 
data are available from head-to-head comparisons of these strategies, but there is substantial data 
available from daily practice registries. Moreover, RCT data do not always reflect clinical practice 
and observational data could therefore have additional value (17, 18). Since a modelling study is a 
good approach to combine several data sources that contain effectiveness and/or costs data (19), 
modelling was used in order to analyse cost-effectiveness of the proposed strategies (19). 
The aim of this study was to compare three different strategies for the treatment of patients 
with early RA using a cost-effectiveness modelling approach: 1) Starting treatment with MTX 
monotherapy followed by addition of LEF then followed by MTX plus anti-TNF when patients have 
inadequate response to treatment; 2) Start with MTX and LEF followed by MTX and anti-TNF; 3) Start 
with MTX plus an anti-TNF agent. 
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Methods
Treatment strategies
In more detail, the three treatment strategies that were compared were: 
1. start with MTX monotherapy, addition of LEF in case of failure, addition of a first anti-TNF to 
MTX followed by a second anti-TNF in case of failure, and treatment with rituximab in case 
of failure; 
2. start with the combination of MTX and LEF, followed by MTX and anti-TNF in case of failure, 
and subsequently a second anti-TNF in case of failure and rituximab thereafter; 
3. start with the combination of MTX and anti-TNF as first therapeutic option, followed by a 
second anti-TNF and rituximab in case of failure. 
MTX was chosen because it is the most commonly used DMARD, alone or in combination (20;21). 
A frequently used other treatment approach is to add sulphasalazine (SASP) to MTX is case of MTX 
failure, but it is shown that this approach is not effective (22). Furthermore MTX and SASP share the 
same pathway, which minimize the changes of good clinical effect of SASP when MTX has already 
failed (23). LEF has targets in a different pathway (24) and is has shown to be effective in MTX 
failures (11;12;25) and it was therefore selected as a good alternative for patients who failed MTX. 
Adalimumab and etanercept were chosen as effective anti-TNF agents since these are the most 
frequently prescribed anti-TNF agents in The Netherlands. In case of failure on all treatments in the 
strategy, we have assumed that usual care was provided by a combination of DMARDs. The structure 
of the model and the treatment strategies are shown in Figure 1.
Description of the model 
The model builds on a validated Markov model (26). The patients were initially distributed across 
several disease states (Markov states) defined by remission, low, moderate and high disease activity 
according to the disease activity score (DAS28). It was chosen to define states by DAS28 because 
low disease activity defined by the DAS28 is the most important target for treatment and therefore 
a DAS28 based model is a close reflection of daily clinical practice. After the first cycle patients may 
be either in remission (initial responders: DAS28<2.6) and remained on their initial treatment for 
the next three-months, or not in remission (non-responders: DAS28>2.6) and switched to the next 
treatment in the strategy. Patients were assumed to sustain in remission after being in remission 
for two cycles, based on study results of early RA patients who were able to sustain their remission 
(more than 90%) after remission of two consecutive visits, without therapy adjustment (27).  
Effectiveness of treatment was represented by transition probabilities that enable to move to 
more or less favourable disease states after one cycle (19). In this model, the cycle length was three 
months and the time horizon was five years. The analyses were done using TreeAge Pro Software, 
Williamstown, MA (2008).
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Figure 1. Decision tree for the strategy 1; starting with methotrexate (MTX). Cycle length=three months. The 
box and circles represent the decision node and chance nodes, respectively. The triangles reflect the four cut off 
points at disease activity.DAS=disease activity score 28 joint count; High DAS=DAS28 > 5.1; Mod DAS=DAS28 
of > 3.2 and ≤5.1; Low DAS=DAS28 ≤3.2 and > 2.6; Remission=DAS28<2.6. LEF=leflunomide; TNF1=first 
anti-TNF-α agent (adalimumab or etanercept); TNF2=second anti-TNF-α agent (adalimumab or etanercept); 
RTX=Rituximab; Usual=usual care. 
Strategy 2: Initially every patient in MTX+LEF and subsequently similar sequence as strategy 1. After RTX, 
patients spent two cycles in MTX and followed by usual care. 
Strategy 3: Initially every patient in TNF1 and subsequently similar sequence as strategy 1. After RTX, patients 
spent 2 cycles in MTX+LEF, 2 cycles in MTX and followed by usual care. 
Transition probabilities
For calculation of transitions probabilities, data from the Nijmegen RA inception cohort and 
Dutch Rheumatoid Arthritis Monitoring (DREAM) registry were used (28;29). In both cohorts, patients 
(18 years or older) are included when they have RA according to the 1987 revised American College 
of Rheumatology (ACR) criteria for RA (30). The inception cohort includes patients who have disease 
duration less than one year and have no prior DMARDs use. The DREAM cohort includes patients 
who start with their first anti-TNF agent. Patients are regularly assessed at three-month intervals by 
an independent trained nurse. Treatment decisions can be made at any time point according to the 
attending rheumatologist. The local ethical committee approved the study protocols.  
Data about MTX and/or LEF treatment were obtained from early RA patients as included in the 
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Nijmegen inception cohort and data about treatment of anti-TNF agents and rituximab were derived 
from the DREAM cohort. Efficacy of MTX was assessed in MTX-naive patients who had a dosage of at 
least 15 mg a week. For efficacy of LEF, anti-TNF and rituximab standard dosage schedules were used 
as given in the Dutch medication registration (appendix) (31). Assuming that response to a second 
anti-TNF agent is less effective than the response to a first anti-TNF agent (13;32), efficacy data were 
based on using a first and a second anti-TNF agent, respectively. According to daily practice, patients 
received at least two different DMARDs prior to anti-TNF. For the usual care data, patients received 
a combination of DMARDs that encompassed MTX and another DMARD. In all available datasets, 
patients were treated with corticosteroids at the discretion of the treating physicians; percentage 
of patients on corticosteroids was approximately 30% and the same in the used datasets. It was 
therefore not necessary to control for the use of corticosteroid in the analyses.
To compare the three strategies on effectiveness we selected patients who were treated 
according to those strategies which might have led to differences in baseline characteristics between 
these three groups of patients. If these baseline characteristics are prognostic for the effectiveness 
of therapy it can cause confounding. The DAS28 at baseline is known to be a strong and consistent 
predictor for treatment response (33). Therefore, patients that started with MTX, MTX plus LEF or 
anti-TNF agents were matched using their DAS28 at baseline. This was done by category matching 
in which patients available in de datasets were categorized into one of 10 categories according to 
their baseline DAS28. Random samples of patients were drawn from each category using a ratio 
based on the initial sample sizes in the available datasets of 1 MTX patient: 1 LEF patient: 3 anti-
TNF patients. Differences in baseline characteristics (after matching) were tested by using one-way 
analyses of variance and chi-square tests where appropriate.
Cost and Utilities 
All utility values and cost that were related to the Markov States were measured in a previous 
48-week multicentre trial of MTX treatment in RA patients (34). In this trial, costs were measured 
using a questionnaire and a patient diary and utility values were collected from the EuroQol-5D 
questionnaire, valued using the British Tariff. Two different perspectives were applied. First, the 
health care perspective, including medical costs: consultations general practitioner, outpatient 
visits to the rheumatologist and other medical specialists, surgery, hospitalization and other co-
medication. Second, the societal perspective, including nonmedical costs: absence from paid labour 
valued according the friction cost method, travel expenses and out-of-pocket costs (alternative 
treatment, home help and expensed related to RA) (34). Utility and costs were related to the four 
states of disease activity in the model of this study. The relationship between these states and utility 
and costs had been previously validated in the Markov model of Welsing et al. (26) In addition, the 
mean costs and utility were calculated for patients in each Markov state, as defined by their mean 
disease activity over the last three months (costs) or at week 48 (utility)). 
Costs prices for each drug treatment were added separately and derived from the Dutch National 
tariff list using standard dosage schedules according to the Dutch registration (appendix) (31). In 
case of sustained treatment of rituximab (> six months) mean cost of €1817 per cycle were used; 
assuming a mean time between treatments of nine months (35).
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Cost-effectiveness analysis
Cost-effectiveness analysis (CEA) was analysed using second order Monte Carlo simulation 
incorporating the influence of parameter uncertainty on the expected outcomes: probabilistic 
sensitivity analysis (19). During simulation, individual hypothetical patients were sampled based 
on the distributions of transition probabilities. This was simulated for a 1,000 patients. All input 
parameters used in the Markov model, including costs, utility and transition probabilities, were 
entered as distributions (36). Dirichlet distributions (groups of beta distributions for integer forms) 
were representing transition probabilities. Beta distributions (real number form) and gamma 
distributions were used for utility values and costs, respectively. 
Outcome measures
The model was evaluated from a health care and a societal perspective (19). Effects and costs 
were discounted at 4% per year resulting in 1% per cycle (19). The primary outcome measure was the 
incremental cost-effectiveness ratio (ICER) (37). The ICER was always compared to the first strategy 
as reference strategy. Acceptability curves were derived illustrating, in a Bayesian fashion with an 
uninformative prior, the probability of being cost-effective given a certain threshold (‘willingness 
to pay’ (WTP)) for a QALY (19). Percentages of remission at end of simulation were reported as a 
secondary outcome.
Scenario analysis 
The base-case analysis calculated cost and effectiveness using the transition probabilities with 
remission (DAS28<2.6) as outcome of response. In order to investigate the impact of a less strict 
outcome of response, we performed a scenario analysis concerning low disease activity score 
(DAS28≤3.2) as cut off point to hold the same treatment or to move to another. For this purpose, 
transition probabilities were again calculated from the Nijmegen inception and DREAM cohorts 
defined as the probability to achieve low disease activity and accordingly, Monte Carlo simulation 
was repeated. 
For this model, we used data from patients who previously used two DMARDs to model the 
effectiveness anti-TNF agents. We assumed that this effectiveness was the same for patients started 
the strategy with anti-TNF agents. This could have led to an underestimation of the real effectiveness. 
To get insight of the effect of this underestimation, we performed a second scenario analysis. In 
this analysis, remission results of anti-TNF treatment as shown in the Comet trial in DMARD-naive 
patients with early RA were used (3).
Results 
Baseline characteristics
After matching on disease activity, there were no significant differences in baseline DAS28 
between the treatment strategies (Table 1). On the other hand, a difference in disease duration 
and age remained between the treatment strategies. As expected from treatment in daily practice, 
patients received two or more DMARDs prior to their anti-TNF. 
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Table 1. Demographic and baseline disease characteristics of patients
 MTX (n = 112) MTX+LEF (n = 47) Anti-TNF (n =332) P-value
Age, mean ± s.d., years 64 ± 14 60 ± 14 57 ± 13 0.388
Women, % 70% 62% 70% 0.231
Rheumatoid factor positive, % 77% 82% 76% 0.776
Disease duration, median (IQR), weeks 1.0 (0.4, 4.6) 2.0 (1.2, 8.6) 7.1 (2.7, 13.2) 0.000
Disease activity score-28, mean ± s.d.  4.9 ± 1.2 4.7± 1.1 5.1 ± 1.3 0.309
Dossagea, median (IQR) 15 (15, 20) 20  40 / 50 -
Previous DMARDs, % 58%  62%  100%   0.019
No. of DMARDs used, median (IQR) 1 (1, 2) 2 (1, 2) 2 (2, 3) 0.000
MTX: methotrexate, LEF: leflunomide, anti-TNF: anti-tumour necrosis factor, DMARDs: disease-modifying anti-
rheumatic drugs, IQR: interquartile range. Data are obtained from the Nijmegen RA inception cohort and Dutch 
RhEumatoid Arthritis Monitoring (DREAM) registry. aDosage MTX mg/week,  LEF mg/day and anti-TNF was split 
into: adalimumab with a  dosage schedule of 40 mg every other week and etanercept with a dosage schedule 
of 50 mg every week.
Cost-effectiveness analysis
ICER
The estimated mean costs and effectiveness for each treatment strategy after five years, 
according to the health care or societal perspective, are shown in Table 2. This table shows that 
the number of QALYs in all strategies was comparable; however, starting with MTX and anti-TNF 
(€17,574) was more costly than MTX alone (€16,620). The additional cost for the anti-TNF strategy 
compared with the MTX strategy resulted in an ICER per patient of €138,028 according to the health 
care perspective and €136,150 according to the societal perspective per QALY gained over five years. 
Also, the strategy that started with MTX and LEF was more costly than the strategy that started 
with MTX alone, without any extra effect. Since the MTX-LEF strategy costs more than the anti-TNF 
strategy and results in less effectiveness, the MTX-LEF strategy was excluded from ICER calculation 
based on extended dominance.  
Figure 2A shows the probability that an intervention is cost-effective at different thresholds for 
Willingness To Pay (WTP) for a QALY. The point where the decision changes from strategy one to 
three as the preferred strategy equals the above-mentioned ICER of €138,028 according to a health 
care perspective. The uncertainty in the decision is small as can be seen by the steep acceptability 
curve. The societal perspective showed a comparable acceptability curve as that of the health care 
perspective. 
First scenario analysis
The first scenario analysis showed that changing the response rate to low disease activity 
resulted in an ICER of €512,292 (from the health care perspective ) and €512,076 (from the societal 
perspective) per QALY per patient over five years for strategy three versus strategy one (Table 2). 
The strategy of starting with MTX-LEF combination remained dominated in this analysis since the 
incremental cost for strategy two versus one was €742,271 (from the health care perspective) and 
€742,675 (from the societal perspective) per QALY per patient gained over five years. 
81
Cost-effectiveness in early rheumatoid arthritis
Second scenario analysis
The second scenario analysis was based on a 10% higher percentage of achieved remission 
of anti-TNF agents in DMARD-naive patients: 30% achieved remission after three months as was 
demonstrated in the Comet trial (3). The effectiveness in terms of the expected number of QALYs 
per patient over five years was 3.08 in the MTX-strategy and 3.12 in the anti-TNF strategy (Table 
2). After five years, costs (health care perspective) were €16,619 and €20,508 for the MTX-strategy 
and anti-TNF strategy, respectively. According to the societal perspective, these were €17,581 
and €21,412, respectively. This scenario analysis resulted in a more favourable ICER of the anti-
TNF agents’ treatment strategy: €116,598 from the health care perspective and €114,982 from the 
societal perspective (Table 2).
The acceptability curve according to the health care perspective of the second scenario analysis 
in Figure 2B illustrates the more favourable ICER of starting with anti-TNF (WTP of €116,598). 
However, this ICER is still considered high and starting with MTX remained, therefore, the most cost-
effective option over strategy three. Furthermore, the strategy that started with MTX and LEF was 
more costly and lay far above the €100,000 with a WTP of €437,960 per QALY.  
Table 2. Costs, number of QALYs, CERs, and ICERs per patient over five years for each treatment 
strategy using remission and low disease activity as response rate 
Outcome MTX monotherapy MTX + LEF combination MTX + Anti-TNF
Base case analyses: Remission  
Health care perspective ∞   
Total Costs, € 16,620 (16,607-16,633) 18,313 (18,301-18,327) 17,574 (17,574-17,588)
Total no. of QALYs 3.086 (3.079-3.092) 3.089 (3.083-3.096) 3.093 (3.086-3.099)
ICER, €/QALY†  438,056 (434.536-441.697) 138,056 (137,007-139,123)
Societal perspective ∞   
Total Costs, € 17,580 (17,558-17,601) 19,269 (19,247-19,290) 18,521 (18,499-18,542)
Total no. of QALYs 3.086 (3.079-3.092) 3.089 (3.083-3.096) 3.093 (3.086-3.099)
ICER, €/QALY†  437,014 (433.137-441,153) 136,207 (135,022-137,363)
Scenario analyses: Low Disease Activity  
Health care perspective ∞   
Total Costs, € 21,780 (21,766-21,792) 26,022 (26,009-26,035) 28,346 (28,333-28,359)
Total no. of QALYs 3.187 (3.179-3.196) 3.193 (3.185-3.202) 3.200 (3.192-3.209)
ICER, €/QALY†  742,508 (736,295-748,616) 512,355 (508,210-516,401)
Societal perspective∞   
Total Costs, € 23,000 (22,964-23,041) 27,243 (27,205-27,284) 29,560 (29,523-29,602)
Total no. of QALYs 3.187 (3.179-3.196) 3.193 (3.184-3.202) 3.200 (3.192-3.209)
ICER, €/QALY†  742,981 (735,942-749,816) 512,180 (507,565-516,682)
Scenario analyses: More effectiveness of anti-TNF  
Health care perspective ∞   
Total Costs, € 16,618 (16,606-16,632) 18,312 (18,300-18,326) 20,507 (20,496-20,520)
Total no. of QALYs 3.086 (3.080-3.092) 3.089 (3.084-3.096) 3.119 (3.113-3.126)
ICER, €/QALY†  437,785 (434,272-441,619) 116,598 (115,556-117,619)
Societal perspective∞   
Total Costs, € 17,580 (17,558-17,603) 19,269 (19,246-19,292) 21,412 (21,389-21,433)
Total no. of QALYs 3.086 (3.080-3.092) 3.089 (3.084-3.096) 3.119 (3.113-3.126)
ICER, €/QALY†  436,965 (432,724-441,049) 114,982 (113,768-116,076)
MTX: methotrexate, LEF: leflunomide, anti-TNF=anti-tumour necrosis factor, QALYs: quality-adjusted life years, 
CER=cost-effectiveness ratio, ICER: incremental cost-effectiveness ratio, Remission: disease activity score-28 
(DAS28) <2.6, Low disease activity: disease activity score-28 (DAS28) ≤3.2.
 Data presented as median (2.5-97.5 percentile) of the cost (€) and QALYs from all 1,000 simulations in the 
probabilistic sensitivity analysis. Costs and utilities were discounted 4% per year.
∞ According to the health care perspective, medical costs consisted of consultations physician, surgery, etc and 
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drug treatment. According to the societal perspective, total costs were composed of medical and nonmedical 
(absence from paid labour, travel expenses, etc) costs.
† An ICER is the additional costs of a treatment as compared with an alternative (MTX monotherapy) divided 
by the additional effect of a treatment compared with that of the alternative treatment (MTX monotherapy).   
 
Figure 2. Cost-effectiveness acceptability curve of  starting with methotrexate (MTX) monotherapy, starting 
with MTX and leflunomide (LEF) therapy and starting with anti-TNF agents therapy resulting from the base 
case analysis (A) and the 2nd scenario analysis with a assumed higher effectiveness of anti-TNF in DMARD-
naive patients (B) both according to the health care perspective. Different levels of ‘Willingness to pay’ (WTP) 
thresholds for a quality-adjusted life year (QALY) (horizontal axis) are shown related to the probability of cost-
effectiveness (vertical axis) falling below these different thresholds.
Remission
The percentages of patients spent in the remission states after treatment of all strategies are 
shown in Table 3. Patients who started with the combination of MTX and anti-TNF, a relatively high 
number of patients attained remission after this first treatment (15%). In the MTX-strategy, a lower 
percentage of patients achieved remission (7%) after their first treatment of MTX. After ten cycles 
(2.5 years), in each treatment strategy equilibrium was reached, meaning that there were no more 
transitions between Markov states. Moreover, there was no difference in the total number of patients 
who were in remission between the three strategies; 38% of patients had sustained remission. The 
latter finding is also in agreement with the fact that effectiveness in terms of QALYs gained was 
similar between the three strategies (as already shown in Table 2).
Table 3. Percentage of patients in remission states (DAS28<2.6) of each treatment strategy as  a 
result of the five- year base case Markov simulation  
 MTX Sequencea MTX+LEF  Sequencea MTX+anti-TNF  Sequencea
MTX monotherapy 6.52 1 4.32 5 4.32 4
MTX+LEF 7.23 2 7.74 1 5.55 5
First Anti-TNF 13.34 3 14.27 2 15.46 1
Second Anti-TNF 5.32 4 5.69 3 6.16 2
Rituximab 5.76 5 6.16 4 6.68 3
MTX: methotrexate, LEF: leflunomide, anti-TNF: anti-tumour necrosis factor, DAS28: disease activity score-28. 
aSequence number of DMARDs or anti-TNF given within each treatment strategy.
A B
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Costs
Table 2 shows that there is no relevant difference in efficacy in terms of QALYs gained between all 
three strategies. Therefore, the unfavourable ICERs obtained for strategy three versus one can largely 
be attributed to the cost of both strategies. This is also demonstrated in Figure 3A, which depicts the 
medical cost histograms of the three strategies, according to the health care perspective. It is shown 
that there is a large overlap in medical cost between the anti-TNF strategy and the MTX strategy. 
The difference in expected medical cost between these two strategies after five years is actually very 
small (€954). Using the societal perspective instead of the health care perspective, the MTX strategy 
was still the least expensive strategy despite the overlap of the anti-TNF strategy (data not shown). 
The analysis including low disease activity as clinical outcome, gave similar results compared 
to that of using remission as is shown in Figure 3B: the MTX strategy remained the least expensive 
option. However, starting with anti-TNF agents was far more costly than that of starting with MTX 
monotherapy and even than that of MTX plus LEF. This resulted in a large difference in medical cost, 
according to the health care perspective, between strategy one and three over five years (€6,566). 
Figure 3. Histograms according to a health care perspective of starting with methotrexate (MTX) monotherapy 
(=strategy 1) versus starting with MTX and leflunomide (LEF) therapy (=strategy 2) and starting with an anti-
TNF agent therapy (adalimumab or etanercept) (=strategy 3) using remission as response criteria (A) or low 
disease activity as response criteria (B). Histograms are generated from 1000 simulations in the probabilistic 
sensitivity analysis with a time-horizon of five years. Horizontal axis depicts total medical costs per after five 
years, Vertical axis depicts number of patients simulated. 
Discussion 
According to the results of this study, starting with the combination of MTX and anti-TNF agents 
was less cost-effective than starting with MTX monotherapy in early RA. This was explained by the 
relatively comparable effectiveness between both strategies and lower costs when starting with 
MTX monotherapy. Additionally, in the model, reaching remission (DAS28<2.6) was used as response 
criterion, a rather strict criterion. Accordingly, most patients starting with MTX monotherapy failed 
to this therapy and were already on anti-TNF after a few cycles. Moreover, all three strategies 
reached their equilibrium after ten cycles. On the other hand, a number of patients was successfully 
treated with MTX alone and did not need to be treated with anti-TNF, resulting in lower costs of the 
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MTX starting strategy. Taken together, the small difference in QALYs gained compared to higher 
costs, resulted in a large ICER for starting with the combination of MTX and anti-TNF versus starting 
with MTX alone: €138,028 according to the health care perspective and €136,150 according to the 
societal perspective. These ICERs indicate that €138,028 or €136,150 is needed to invest in a gain of 
one QALY over five years with the anti- TNF strategy, which generally are considered as unfavourable 
ICERs (38). 
In case of changing the response criterion to low disease activity (DAS28≤3.2), a less strict 
criterion, more patients were effectively treated with MTX monotherapy against lower costs of this 
strategy. Subsequently, initially MTX became an even more preferable option over initially MTX and 
anti-TNF. Assuming that anti-TNF is more effective in early RA patients than in established RA, greater 
effectiveness of starting with anti-TNF and thus a higher number of QALYs gained was obtained. This 
resulted into a more favourable ICER of MTX and anti-TNF against MTX. However, this ICER was still 
considered high (€116,598). 
When taking costs into consideration and based on this CEA, there seems to be no extra benefit 
of starting with the combination of MTX and anti-TNF agents. These results are in accordance with 
results of the CEA from the BeSt study. This study concluded that initial treatment with infliximab 
and MTX gained significantly more QALYs, but was more costly compared to that of initial MTX and 
was, therefore, considered not to be cost-effective using a societal cost perspective according to the 
friction cost method. However, if productivity was valued according to the human capital method 
then starting with infliximab was more cost-effective than starting with DMARDs (16). Though, the 
friction costs method allows a more realistic estimate of productivity costs by incorporating the 
possibility of replacement of absenteeism, which strengthens our choice for this method (39). We 
were not able to repeat our CEA according to the human capital method as cost data were used from 
a previous publication in which they were already valued according to the friction cost method. 
Altogether it can be concluded from the cost-effectiveness analysis of the BEST study that both 
a MTX step-up strategy or MTX combination with high dose prednisone (the COBRA scheme) are 
preferred over an initial treatment with infliximab in newly diagnosed RA patients. Furthermore, a 
systematic review of CEAs of anti-TNF agents concluded that anti-TNF agents are most cost-effective 
when used as last therapy, i.e. after failure of DMARDs (40). Our data also confirms a recent cost-
effectiveness modeling study by Finckh et al. who concludes that the additional costs of very early 
intervention with biologics may not be justified  and that strategies involving early conventional 
DMARDs is preferred (41).
The real challenge for the future is ‘how we can influence the ICER of the use of anti-TNF 
compared to DMARD strategies?’. Two important issues are involved with this challenge. First, the 
costs of drugs, key drivers of medical costs in case of anti-TNF therapy, might be changed when 
drug-free remission becomes a realistic option. There is evidence to suggest that drug-free remission 
especially in recent onset RA is realistic or anti-TNF-free remission after initial early use of anti-TNF 
(27;42). Second, the cost-effectiveness ratio might be influenced by taking other outcomes into 
account, like joint damage or functional capacity, that determine labour participation and surgery 
in particular. Additionally, there is evidence that in patients with early RA, anti-TNF results in less 
radiographic progression than MTX monotherapy, which may decrease long-term cost as well and 
may lead to more favourable cost-effect ratios of anti-TNF (3;15;43). However, long-term outcomes 
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of the positive effects of anti-TNF in terms of preventing joint damage has not yet been established 
(44). Therefore, in this study we focused on clinical efficacy (DAS28) only and consequently, long-
term outcome in terms of joint damage remains a matter of further research. From another point of 
view, this study showed low remission rates after MTX, which might actually become higher in case 
of optimal dosage schemes. Accordingly, ICERs that are even more favourable could be obtained 
with a strategy of starting with MTX alone.
Though this study examined the (common) strategy of starting with MTX and/or LEF, there 
remain, however, additional strategies for further research, i.e. starting with ‘triple’ therapy would 
be very interesting to assess as well. In addition, the recent TEAR study (45) showed us that initial 
‘triple’ therapy, a less costly DMARD combination of MTX, sulphasalazine and plaquenil, is more 
effective than starting MTX alone and may (hypothetically) result in a even more favourable ICER of 
strategy 1 (DMARDs started) versus strategy 3 (anti-TNF started). The COBRA strategy (combination 
of MTX, sulphasalazine and high dose prednisone (stepped down)) has shown long term effects on 
progression of joint damage and mortality and could therefore be a good alternative for initial TNF 
treatment (46).
Recently, Markov models have been used extensively in RA. The structures of these models 
differ on the measure used to define the Markov states. A frequently used measure is the Health 
Assessment Questionnaire (HAQ) (47-51) opposed to the DAS28 as used in our model. The HAQ 
as well as the DAS28 comprise an absolute measure of clinical importance in RA, but achieving 
low DAS28 is the most important target for treatment in RA. Furthermore, the HAQ is defined 
by psychosocial factors (52;53) and the HAQ is largely influenced by age and the presence of co-
morbidities (54). Therefore the relation of the HAQ with costs and utility might not be the same in 
different phases of the disease and in different populations. A clinically relevant division in the HAQ 
to define Markov states is less clear, which is also apparent from the different definitions within the 
Markov models using the HAQ. For the DAS clear cut-off values for remission, low disease activity, 
moderate disease activity and high disease activity are present (55).
A reference case for economic evaluations is RA was proposed by the Economic Working 
Group of OMERACT (Outcome Measures in Rheumatology) (56). Our study is in accordance with all 
recommendations except the one considering mortality as an outcome measure, which was not 
accounted for in this study. However a difference in mortality between the treatment strategies is 
not to be expected within the time horizon of five years as in our analyses.
A modelling study has its limitations. The model in this study used efficacy data from the Nijmegen 
inception cohort and DREAM registry, both large registries of RA patients in The Netherlands. 
However, by using observational data, the strategies in this CEA were indirectly compared with 
possible differences in baseline characteristics between the groups. In order to have comparable 
groups at baseline we matched for disease activity at baseline, the most important prognostic factor 
for clinical efficacy (33), and showed that these were comparable after matching. Though disease 
duration was different between the strategies, this would not have change the results since disease 
duration is not a prognostic factor for clinical efficacy according to a recent systematic review of 18 
studies on predictors for achieving remission in RA (33). We note that absolute comparability among 
different treatments is only expected through randomization (57). However, no more than the BeSt 
study performed a direct comparison of four treatment strategies (15). The ideal CEA would be using 
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data from a large, long-term RCT without selecting patients examining both efficacy and costs of 
different treatment strategies in early RA patients. Such head-to-head comparisons of treatment 
strategies are scarce, being costly and sometimes not feasible. Subsequently, a modelling study has 
an important contribution to select relevant treatment strategies and can be seen as a pilot of the 
ideal head-to-head study. 
Several assumptions were applied in the Markov model. Firstly, a cycle length of three months 
was assumed and accordingly treatment responders (remission) were identified after one cycle. It 
could be argued that a three-monthly cycle length may be too short and remission as treatment 
outcome may be very strict. However, three-monthly assessments are in accordance with clinical 
practice and aiming at remission is currently regarded as treatment goal (4;58;59). Secondly, we 
assumed that clinical responses of anti-TNF agents in DMARD-naive RA patients were comparable 
with those who failed to DMARDs. This assumption was applied for practical reasons; efficacy data of 
anti-TNF were only available from patients who failed to at least two DMARDs. This may have led to 
lower treatment responses since clinical trials with early RA patients showed higher responses than 
trials with established RA patients (8;60;61). Therefore, we carried out a second scenario analysis in 
case of a greater effectiveness of anti-TNF in DMARD-naive patients (3). 
In conclusion, this study showed comparable effectiveness in terms of clinical activity of starting 
with MTX or anti-TNF. However, initially anti-TNF was far more expensive than starting with MTX 
monotherapy. Therefore, based on this study a treatment strategy starting with MTX monotherapy 
is favoured over a strategy with MTX and anti-TNF or MTX and LEF right away in early RA.
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Appendix
Markov Model* High DAS28 Mod DAS28 Low DAS28 Remission
Transitionsa, point estimate (n/r)    
MTX monotherapy C1 0.20 (112/22) 0.63 (112/70) 0.06 (112/7) 0.12 (112/13)
MTX monotherapy C2 0.06 (16/1) 0.25 (16/4) 0.13 (16/2) 0.56 (16/9)
MTX + LEF C1 0.26 (47/12) 0.47 (47/22) 0.11 (47/5) 0.17 (47/8)
MTX + LEF C2 0.09 (11/1) 0.27 (11/3) 0.18 (11/2) 0.45 (11/5)
First Anti-TNF C1 0.09 (332/30) 0.53 (332/176) 0.17 (332/56) 0.21 (332/70)
First Anti-TNF C2 0.02 (60/1) 0.07 (60/4) 0.18 (60/11) 0.73 (60/44)
Second Anti-TNF C1 0.19 (96/18) 0.50 (96/48) 0.15 (96/14) 0.17 (96/16)
Second Anti-TNF C2 0.06 (16/1) 0.38 (16/6) 0.13 (16/2) 0.44 (16/7)
Rituximab C1 0.16 (88/14) 0.52 (88/46) 0.15 (88/13) 0.17 (88/15)
Rituximab C2 0.14 (14/2) 0.21 (14/3) 0.14 (14/2) 0.50 (14/7)
Usual care 0.24 (109/26) 0.55 (109/60) 0.14 (109/15) 0.07 (109/8)
Costsb, point estimate 92.3 68.5 45.3 23.5
Alpha (α) 6391,378 6579,704 19709,018 4730,988
Lambda (λ) 69,283 96,054 435,558 201,319
Costsc, point estimate 279.5 100.5 93.3 45.8
Alpha (α) 10262,281 11402,346 2891,751 4399,289
Lambda (λ) 36,717 113,456 31,011 96,159
Utilityd, point estimate 0.141 0.176 0.160 0.187
a 194215,347 536951,038 502672,827 177974,671
b 1183198,460 2824244,817 2349371,581 773761,537
*MTX: methotrexate, LEF: leflunomide, anti-TNF: anti-tumour necrosis factor (adalimumab or etanercept). 
DAS28: disease activity score-28, High DAS28: DAS28 of >5.1, Mod DAS28: DAS28 of >3.2 and ≤5.1, Low DAS28: 
DAS28 of ≤3.2, Remission: DAS28 <2.6. Cost-effectiveness analysis of the Markov model was performed by 
probabilistic sensitivity analysis with 1,000 simulations and 5-year time horizon. Effectiveness of treatment 
was represented by transition probabilities that enable to move to more or less favourable Markov states. All 
Markov states were accompanied with costs and utilities. Costs and utilities were discounted 4% per year.
aTransitions: the probability to achieve a state of High DAS28, Moderate DAS28, Low DAS28 or remission, after 
3-montly treatment (Cycle 1, C1) or 6-monthly treatment (Cycle 2, C2). Data are obtained from the Nijmegen 
RA inception cohort and Dutch RhEumatoid Arthritis Monitoring (DREAM) registry. Data are presented as 
Dirichlet distributions (groups of beta distributions for integer forms) with point estimates calculated from 
total population size (=n) and occurrence of DAS28 Markov state (=r) (point estimate=r/n).  
bCosts according to the health care perspective, including medical costs: consultations physician, surgery, etc 
and drug treatment. More details about the collections of costs (collected from patient diaries) can be found 
in the original paper (Welsing et al., 2004). Data are presented as gamma distributions (point estimate=α/λ).
cCosts according to the societal perspective, including total costs: medical and nonmedical (absence from paid 
labour valued according the friction cost method, travel expenses, etc) costs. More details about the collections 
of costs (collected from patient diaries) can be found in the original paper (Welsing et al., 2004). Data are 
presented as gamma distributions (point estimate=α/λ).
dUtility values (per cycle) were collected from the EuroQol-5D questionnaire; valued using the British Tariff. 
More details about the collections of utilities (collected from patient diaries) can be found in the original paper 
(Welsing et al., 2004). Data are presented as beta distributions (real number form) (point estimate=a/(a+b)).
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Drug treatment* Dosage schedule Drug treatment costs per cycle €
MTX monotherapy Minimal 15 mg a week 13
MTX + LEF 20 – 40 mg a day 181
Adalimumab 40 mg every other week 3067a
Etanercept 50 mg a week 3067a
Rituximab 2 x 1,000 mg 5420 + 1817b
Usual carec - 50
*MTX: methotrexate, LEF: leflunomide, anti- TNF: anti- tumour necrosis factor (adalimumab or etanercept). 
Dosage schedules were valued according to the Dutch medication registration (30). Costs prices for each 
treatment were derived from the Dutch National tariff list (30).
aCosts of anti-TNF per cycle were an average from adalimumab and etanercept. 
bStarting with rituximab led to initial costs (€5450) and in case of sustained treatment (> six months) mean costs 
of €1817 per cycle were used; assuming a mean time between treatments of nine months (33). 
cAccording to usual care patients received a combination of DMARDs including at least MTX and another 
DMARD. Since several combinations were reasonable, we accounted for type of DMARD combination and 
dosages.
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Abstract
Objectives. Tight control studies including regular assessments of disease activity have shown 
that this approach has beneficial effects on disease activity, disability and joint damage in treating 
rheumatoid arthritis (RA) patients. Some of these studies included tight control with protocolised 
treatment, while others applied tight control without protocolised treatment. The aim of this study 
was to compare the effects of tight control with usual care and to compare the effects of tight control 
studies with and without protocolised treatment adjustments. 
Methods. A systematic literature search was performed to identify clinical trials in RA that 
evaluated tight control strategies in comparison with usual care. Two types of study were compared: 
(i) those using disease activity monitoring with protocolised treatment adjustments, and (ii) those 
using disease activity monitoring without protocolised treatment adjustments. The databases 
PubMed and Cochrane were searched from 1995 up to 2009. Primary outcome measure was the 
mean change in the 28-joint DAS (DAS28), which was used in a random-effects meta-analysis. 
Results. Six controlled trials regarding tight control in RA patients were included in the meta-
analysis. In all trials, patients treated in the tight control arms had significantly higher DAS-28 
responses than patients treated according to usual care [weighted mean difference (WMD) = 
0.59, P < 0.001]. Moreover, tight control was significantly more effective (P < 0.001) by means of 
protocolised treatment adjustments (WMD = 0.97) compared with non-protocolised monitoring of 
disease activity (WMD = 0.25). 
Conclusion. Tight control in RA resulted in significantly better clinical outcomes than usual care. 
It is suggested but not proved that tight control with protocolised treatment adjustments is more 
beneficial than if no such protocol is used. 
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Introduction
 
The primary treatment goal in Rheumatoid Arthritis (RA) is to achieve and sustain clinical 
remission as early as possible and to prevent joint damage and excess functional disability (1). 
Starting treatment early in the disease course and tight control of disease activity are essential 
to achieve this goal (2, 3). Several tight control studies in RA, and notably the tight control for RA 
(TICORA) study, have shown that the tight control approach has beneficial effects on disease activity, 
disability and joint damage (3-6).
Tight control may be understood as the frequent assessment of inflammation with the aim 
to keep inflammation at an agreed low level, or ultimately in remission (7). In most tight control 
studies, the disease activity score (DAS) or or 28-joint DAS (DAS28) is used for assessment of 
inflammation. In some studies, such as the TICORA study, protocolised treatment adjustments are 
made. In other studies, such as the TRAC study, only an advice is provided to rheumatologists that 
“treatment changes should be made as long as the target of low inflammation is not reached” or, in 
other words, non-protocolised treatment adjustments are made (Figure 1) (3, 8). Whether there is 
an additional value of protocolised tight control in suppressing disease activity compared to that of 
non-protocolised tight control is not yet clear. This is an important question to be answered as strict 
protocol-driven therapy alone has shown positive effects on the treatment outcome of patients 
with RA compared to that of usual care (3).
The objective of this meta-analysis was to study the effects of tight control in RA by (i) comparing 
the effects of tight control with usual care; and (ii) comparing the effects of tight control studies with 
and without protocolised treatment adjustments.  
Figure 1. Overview of studies comparing tight control with usual care.
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Methods 
Literature search 
A search of the electronic database PubMed (Issue 2, 2007, between January 1995 and August 
2009) and The Cochrane Library was performed to find trials comparing tight control with usual 
care in RA. Tight control was defined as the frequent assessment of inflammation that guided 
treatment changes with the aim to keep inflammation at an agreed low level. Usual care was 
defined as treatment decisions left to the discretion of the rheumatologist and patients reflecting 
daily clinical practice. The following MeSH headings (including all subheadings) were used: ‘arthritis, 
rheumatoid’; ‘antirheumatic agents’; ‘drug monitoring OR drug therapy’ and ‘effec* OR effic* OR 
treatment outcome’. These four subsets were combined by the AND operator. The search was 
limited to randomized controlled trials (RCTs) or clinical trials as study type and English-written 
publications. Selected articles were used to identify additional references via hand search and to 
identify articles by using the tool ‘related articles’ (based on the main topic of the articles selected) 
as given by PubMed. Based on empirical evidence and theoretical considerations, concealment of 
treatment allocation, blinding of outcome assessment, and handling of patients attrition in the 
analysis should generally be assessed in selecting articles for a meta-analysis. Since all trials included 
for this study fulfilled these quality measures, no other attempts were made for quality assessment 
of RCTs selected for this meta-analysis. Moreover, sensitivity analysis was performed to assess the 
influence of randomisation; randomised versus non-randomised clinical trials.   
Study selection 
Study selection was performed by two reviewers (L.T.C.vH. and L.G.S.) who screened titles and 
abstracts of all identified references. Eligible articles were reviewed in full text, applying the following 
inclusion criteria: (i) the study had to compare tight control versus usual care defined as mentioned 
above; (ii) included patients had RA according to the American College of Rheumatology (ACR) 
1987 revised criteria (9); (iii) the prescribed treatment had to consist of at least disease modifying 
antirheumatic drugs (DMARDs), anti- tumour necrosis factor- (anti-TNF-) agents or glucocorticoids; 
(iv) the study had to measure clinical efficacy and (v) the primary or secondary outcome measure 
had to be the disease activity score (DAS or DAS28 or all separate components of the DAS(28)) (10). 
Studies that described safety issues only, did not use a usual care control group or observational 
studies were excluded. In case of disagreement, consensus was achieved by discussion. 
Study descriptives
Data extracted from the articles included study design characteristics (study design, study 
duration, number of patients and percentage of attrition) and baseline patient characteristics (age, 
proportion rheumatoid factor (RF) positive, gender, duration of RA and baseline DAS28). Information 
on tight control elements was collected as well: the instrument of monitoring (e.g. DAS28) including 
the treatment target; the frequency of assessment; treatment options and concomitant therapy. 
Further, data on relevant effect parameters such as mean change in DAS28 or DAS, percentage 
of patients in remission, changes in DMARDs treatment, joint damage, mean increase in physical 
function according to the Health Assessment Questionnaire (HAQ) and toxicity were extracted from 
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the articles selected. If necessary, individual authors, i.e. from the Computer Assisted Management 
in Early RA (CAMERA) study, were contacted to provide additional information about mean change 
in DAS28.
Meta-analysis  
The mean change of DAS28 (from baseline to one year) was used as primary outcome measure; 
we extracted or calculated the mean change of DAS28 for all studies included. The DAS28 includes 
the 28-joint counts for swelling and tenderness, general health (on a visual analogue scale of 100 
mm), and the value for erythrocyte sedimentation rate (ESR) measured by the Westergren method 
(10-12). When the original DAS (11) was reported, a transformation formula was used to calculate 
change in DAS28 (13). 
For each trial, the mean difference (MD) in efficacy between tight control group and the usual 
care group was calculated using the mean change in DAS28 between baseline and end of trial of the 
tight control group and the usual care group. The difference between these two groups was tested 
using a Z-statistic and a border of statistical significance of P = 0.05 (14). Then, the MDs of all trials 
were pooled using the weighted MD (WMD) with a 95% confidence interval (95% CI) (15). 
Sensitivity analysis was used to assess the influence of randomization. Trials were stratified 
according to whether or not patients had been randomized into the treatment arms and the WMD 
of both tight control and usual care strata of randomised and non-randomised trials was compared. 
The WMD reflected again the WMD in DAS28 between tight control and usual care. The Z-statistic 
was used to test whether the difference between the two types of trial was significant in comparing 
tight control with usual care. 
Next, the analysis was stratified according to trials in which monitoring was applied with 
protocolised treatment adjustments and trials that monitored without protocolised treatment 
changes. For both strata, a WMD with 95% CI was calculated and the significance of the difference 
between the two strata was tested by using the Z-statistic. 
A fixed effect model using the inverse method was used for analysis under ignorance of between-
study variation, or in other words heterogeneity (14). In case of considerable heterogeneity between 
studies a random-effects model using the DerSimonian and Laird method (15) was used in this meta-
analysis. The between-study variation, or heterogeneity, was assessed by calculating the Cochran’s 
Q-statistic and I2 (16, 17). A lower Cochran’s Q corresponds with a low degree of heterogeneity. The 
quantity I2 describes the percentage of total variation across studies that is due to heterogeneity 
rather than chance (ranging from 0% to 100%); a value of more than 30% was used to indicate 
considerable heterogeneity (16, 17).  
 
Results
Study selection 
The search strategy yielded a total of 396 articles. Of this total, 382 articles were excluded after 
screening titles and abstracts because they did not fulfil the inclusion criteria, i.e. no comparison 
of tight control with usual care; patients included did not fulfil the ACR criteria for RA; no DMARDs 
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treatment or no measurement for clinical efficacy in terms of DAS was performed (Figure 2). There 
were 14 articles retrieved for detailed review. Eight studies that compared tight control with usual 
care were not included in the final selection because they compared inpatient team care with day 
patient team care (19, 20), the reported results of direct access to hospital review in comparison with 
regular review care (21, 22), the control group of usual care given by a rheumatologist was lacking, 
usual care used a medication protocol and did use clinical outcome measures other than DAS28 
(23, 24), compared multidisciplinary team care with routine outpatient care (25) or evaluated the 
influence of rheumatologists’ adherence to a methotrexate guideline in RA patients (26). Finally, six 
studies were included in the meta-analysis (3, 8, 18, 27, 28, 29). 
Figure 2. Flow of study selection process. RA: Rheumatoid Arthritis; DMARD: disease-modifying antirheumatic 
drug.
Study and patient descriptives
Design
The characteristics of the six studies included are listed in Table 1. Four studies were randomised 
clinical trials (RCTs) (3, 8, 18, 28). Two studies were controlled clinical trials (CCTs) (27, 29). In addition, 
one study compared tight control with usual care by means of two different cohorts: patients from 
the Behandel-Strategieën (BeSt) study (tight control) and patients derived from Early Arthritis Clinics 
(usual care) (29). The other non-randomised study applied a cross-over design (27). Study duration 
varied from 12 to 24 months. Three studies (8, 27, 28) had a tight control arm of frequent disease 
activity assessment and supplying the DAS before patient visits in order to change treatment by 
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the individual rheumatologist (without using protocolised treatment adjustments). The three other 
studies (3, 18, 29) had a tight control arm including frequent disease activity assessments including 
protocolised treatment adjustments. Two (18, 19) of the three studies including protocolised 
treatment adjustments were in early DMARD-naïve RA, while all three studies (8, 27, 28) using non-
protocolised treatment adjustments were in patients with both early and established RA. Five trials 
(3, 8, 27-29) used the DAS or the DAS28 for assessment of RA inflammation. The sixth study (18) 
provided additional data from which changes in DAS28 could be calculated.
Study population
The patient characteristics at baseline of the six trials included are summarised in Table 1. The 
number of patients ranged from 110 to 435 per study, with an attrition proportion of 4– 39%. Of the 
patients, 60–70% comprised females and 42–80% were RF positive. Average disease duration of the 
included patients ranged from 0.4 to 11 years. At baseline, the mean DAS28 varied from moderate 
(DAS28 > 3.2 and  ≤ 5.1) to high (DAS28 > 5.1). 
Treatment adjustments
Tight control as applied with protocolised treatment adjustments consisted of sequential 
or step-up strategies of the conventional DMARDs, methotrexate (MTX), sulfasalazine (SSZ) and 
hydroxychloroquine (HCQ) (Table 2). The dose schedules of MTX (up to 30 mg a week), SSZ and HCQ 
were generally comparable. 
Tight control studies without using protocolised treatment adjustments applied treatment 
based on current guidelines at rheumatologists’ discretion, which includes in most patients starting 
with MTX and adding or switching to a second DMARD. 
Five studies used treatment of DMARDs therapy without using biologicals and one study 
prescribed biologicals in a small part of patients only (29). In all studies, patients were allowed to 
take intra-articular or intra-muscular prednisone. Studies that applied non-protocolised treatment 
adjustments allowed oral prednisone as well. Most patients were concurrently treated with NSAIDs 
in stable doses. 
Reported clinical efficacy 
Table 2 shows the efficacy of tight control intervention and usual care in each study. In five 
studies, tight control in naive and established RA patients was significantly superior to usual care in 
improving signs and symptoms (DAS28) and effecting clinical remission (DAS28 < 2.6) after one year 
of therapy. In one of those studies patients with low disease activity had also been included, but the 
effect was only visible in the subgroup with a DAS28 > 3.2 at baseline (8). The study of van Hulst et 
al. (28) was the only study for which no difference in effect between tight control and usual care was 
reported, and the number of medication changes was equal in both groups. Generally, medication 
changes occurred more frequently in tight control than in usual care. Besides the clinical benefit, 
tight control improved physical function, reduced the progression of joint damage and was well 
tolerated and safe in patients with RA, and did not result in more toxicity compared to usual care. 
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Meta-analysis
Tight control intervention versus usual care
The mean decrease in DAS28 from baseline to one year for the two intervention groups, tight 
control and usual care, is shown in Table 3, together with the MD per trial. From one study, only the 
MD had been reported since mean decreases in DAS28 of both groups were lacking (27). In all trials, 
patients treated according to tight control had higher DAS28 responses after one year than patients 
treated according to usual care, though not always significant. 
According to the Q-statistic (Q = 25) and the I2 quantity (80%) there was heterogeneity between 
the studies analysed. For the overall analysis of tight control versus usual care, there was not much 
difference in WMD between fixed and random models: 0.61 (95% CI 0.46, 0.76) versus 0.59 (95% CI 
0.22, 0.97), respectively. Both models were significant, the P-value of the fixed effects model (P < 
0.0001) was smaller than that of the random model (P < 0.001). According to both analyses, tight 
control was significantly more effective than usual care in reducing the DAS28; the mean decrease 
was 0.6 points more in tight control. 
Sensitivity analysis of tight control versus usual care
Four trials were randomised trials and two trials were non-randomised. According to the fixed-
effects model, the WMD for tight control versus usual care was 0.64 (95% CI 0.41, 0.87) and 0.59 (95% 
CI 0.40, 0.78) in randomised and non-randomised trials, respectively. The random-effects model 
showed a WMD of 0.65 (95% CI 0.10, 1.21) in randomised trials and 0.80 (95% CI 0.38, 1.21) in non-
randomised trials. For the analysis of tight control versus usual care in randomized trials only, both 
fixed- effects and random-effects models were significant, with P-values of P < 0.0001 and P < 0.010, 
respectively. 
Tight control with protocolised treatment adjustments versus non-protocolised tight 
control 
Overall, the DAS28 responses for tight control were higher in the three studies using tight control 
including protocolised treatment adjustments, than in the three studies using non-protocolised 
treatment adjustments (Table 3). Heterogeneity was assessed of both types of tight control and 
was found to be different. Additionally, the trials, using patients who were not treated according 
to a protocolised treatment, showed no degree of heterogeneity (Q = 0.17; I2 = 0%). For the trials 
performing protocolised treatment adjustments, the heterogeneity was much higher (Q = 5.15; I2 
= 61%). This was mainly due to the large efficacy and relatively low number of patients included as 
shown in the TICORA study (3).
According to the fixed model, tight control was more effective in case of protocolised treatment 
adjustments (WMD 0.91, 95% CI 0.72, 1.11; P < 0.0000) than without protocolised treatment 
adjustments (WMD 0.25, 95% CI 0.03, 0.46; P < 0.002) (Table 3). This difference (0.66) was found 
statistically significant (P < 0.0000) (Figure 3). In other words protocolised tight control resulted in a 
0.66 point more decrease in DAS28 compared to non-protocolised tight control. Though there was 
a difference (0.25) between the latter type of tight control and usual care, this may be regarded as a 
small difference and even as a not clinical relevant difference.
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The random-effects model showed comparable results: a WMD of 0.97 (95% CI 0.64, 1.30; P < 
0.0000) in the protocol-driven group and a WMD of 0.25 (95% CI 0.03, 0.46; P < 0.002) in the non-
protocolised treatment group (Table 3). Thus, a larger difference in efficacy was found between 
protocolised tight control and usual care compared to that of non-protocolised tight control and 
usual care. This comparison of protocol-driven with no protocol-driven therapy led again to a 
statistically difference (WMD 0.72, P < 0.0002) (Figure 3). 
Figure 3. Mean difference in change of DAS28 between usual care and tight control, according to a fixed effect 
model (A) or a random effect model (B). For each trial, data are presented as mean difference (MD) in change 
of DAS28 between usual care and tight control. Overall effect is presented as a weighted mean differences 
(WMDs) in change of DAS28 between usual care and tight control.
Sensitivity analyses of protocolised versus non-protocolised tight control 
Table 3. Mean decrease in DAS28 for tight control and usual care after one year
UC: usual care; TC: tight control; No: number of patients; DAS28: disease activity score based on 28 joints; SD: 
standard deviation; MD: mean difference; SE: standard error of the mean; DL: DerSimonian & Laird method. *: 
significant; WMD: weighted mean difference; CI:confidence interval; Z:Z statistic; NM: not mentioned.
By leaving out the two non-randomised studies, the DAS28 responses for tight control were again 
larger using tight control including protocolised treatment adjustments than using non-protocolised 
treatment adjustments. According to the fixed model, protocolised treatment adjustments were 
Comparison 
Title Patient No  
UC 
Patient No  
TC 
Mean  
decrease (SD) of 
DAS28 UC 
Mean decrease (SD) 
of DAS28 TC 
MD (SE) Fixed Model 
(Inverse method) 
Random Model 
(DL  
method) 
Protocolised tight 
control 
vs 
Usual care 
Grigor et al., 
2004 
(3) 
50 53 2.61 (1.40) 4.25 (1.10) 1.43 (0.25)* 
WMD=0.91 
95%CI=0.72-1.11 
Z=9.03 
P<0.0000 
WMD=0.97  
95%CI=0.64-1.30 
Z=5.69 
P<0.0000 
Goekoop et 
al., 2009  
(27) 
201 234 1.90 (1.50) 2.70 (1.50) 0.80 (0.14)* 
Verstappen 
et al., 2007 
(28) 
148 151 2.10 (1.47) 2.93 (1.52) 0.83 (0.17)* 
         
Non-protocolised 
tight control 
vs 
Usual care 
Van Hulst et 
al., 2009 (29) 
 
104 144 0.32 (1.42) 0.51 (1.42) 0.19 (0.18) 
WMD=0.25  
95%CI=0.03-0.46 
Z=2.22  
P<0.02 
WMD=0.25  
95%CI=0.03-0.46 
Z=2.22  
P<0.02 
Fransen et 
al., 2003 (26) 
 
190 190 NM NM 0.30 (0.21) 
Fransen et 
al., 2005 (8)  81 61 0.14 (1.20) 0.40 (1.00) 0.26 (0.18) 
Overall effect of tight control with protocolised treatment adjustments 
versus non-protocolised tight control 
 
Difference=0.66 
Z=4.46  
P<0.0000 
Difference=0.72 
Z=3.57  
P<0.0002 
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more effective with a difference in WMD of 0.81 (P < 0.0001). The random-effects model showed 
comparable results: a difference in WMD of 0.88 (P < 0.003) in favour of protocol-driven tight control. 
Discussion
In this meta-analysis of randomised and controlled clinical trials, a comparison was made between 
the effects of tight control versus usual care. Moreover, the effect of tight control studies including 
protocolised treatment adjustments was compared with the effect of tight control studies in which 
the treatment adjustments were not protocolised. The results show that tight control resulted in 
more changes in DMARD treatment and resulted in significantly better clinical outcomes - disease 
activity, functionality and joint damage - than usual care. Furthermore, the results of this meta-
analysis suggest that the combination of systematic monitoring of disease activity and protocolised 
treatment adjustments was significantly more beneficial than systematic monitoring without such 
protocolised treatment adjustments.
 However, all studies investigating protocolised treatment adjustments were performed in early 
RA patients and studies with non-protocolised treatment adjustmens were all in established RA. 
Therefore, the large advantage of tight control over usual care in early RA does not automatically 
generalise to established RA. Moreover, the small difference between tight control and usual care 
in established RA may be caused by the lack of protocolised treatment adjustments, but also by 
treatment responses being lower in established RA  (30, 31). However, as treatment response is 
more difficult to reach this rather underlines the importance of the use of protocolised treatment 
adjustments in established RA. Therefore, the question remains how effective tight control with 
protocolised treatment adjustments is in long-standing RA. 
In established RA, there may be several reasons for the small difference between tight control 
without protocolised treatment adjustments and usual care. In tight control studies without 
protocolised treatment adjustments medication changes are left to the discretion of the treating 
rheumatologist. Dependent on the actual local circumstances, medication decisions could be 
influenced by organisational context (lack of time), professional or patient context, i.e. knowledge 
(lack of familiarity), attitudes (lack of outcome expectancy or patient’s wishes, fear for side effects), 
and social context (standard of usual routine in practice) (32, 33). Accordingly, the amount of DMARD 
changes was much higher if a tight control strategy with protocolised treatment adjustments 
were made compared to non-protocolised tight control. Apparently, just as in a medication study, 
reasons not to change DMARDs were more often ‘over ruled’ when medication changes were forced 
by a protocol.
It therefore seems justified to state that the combination of monitoring and protocolised 
treatment adjustments has a significant value in controlling disease activity effectively. In the three 
tight control studies in this meta-analysis, DAS < 2.4 was used as treatment target in two studies (3, 
29), while in the other study the percentage improvement in disease activity from previous visits 
was used (18). Though, the first two tight control studies applied a similar treatment target, they 
performed different in treatment strategies. Notably, the treatment effect of tight control in the 
TICORA study was very large (4.3 change in DAS) compared with the study of Goekoop-Ruiterman 
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et al. (29) (2.7 change in DAS). This may be explained by the applied treatment strategy. In addition, 
the TICORA study used conventional DMARDs such as MTX, SSZ and ciclosporin and allowed intra-
articular injections of steroids. In the study of Goekoop-Ruiterman et al. (29) patients received 
besides MTX and SSZ, also antimalarials, leflunomide and a small proportion of the patients received 
infliximab. After comparing both treatment strategies, the monthly injections of intra-articular 
steroids applied in the TICORA study seem to be responsible for the large treatment effect found in 
this study (3).
There are some limitations to this meta-analysis related to the quality of the studies and data 
available. The total number of studies was actually low, in presence of heterogeneity. Random-effects 
models were used to deal with heterogeneity, and there was no difference in results between fixed- 
and random-effects models. Heterogeneity existed between the protocolised tight control studies 
and was most likely caused by the relatively large effects in the TICORA study. Four of the six trials 
were randomised and sensitivity analysis showed that the results did not alter after analysing the 
randomised trials only. Notably, only two of the six studies were performed outside the Netherlands 
(Switzerland and Scotland) (3, 27). In total, 14 tight control studies were identified, but eight studies 
were not included (figure 2); basically, since they did not include a usual care intervention. 
Furthermore, it is remarkable that all studies applying protocolised treatment adjustments used 
patients with early RA, with low disease duration, no prior DMARDs use and high disease activity 
at baseline. This is in contrast with studies applying non-protocolised treatment adjustments: they 
used a mixed RA population with generally longer disease duration, more previous DMARDs and 
lower disease activity at baseline. Despite differences in baseline characteristics between the studies, 
there were no differences within the studies. In other words, baseline characteristics between tight 
control and usual care within each study were comparable. This had also been confirmed in the 
study of van Hulst et al. (28). Though reduction in disease activity was larger and medication changes 
were more frequently in early RA patients, there was no difference between tight control and usual 
care stratifying for early and established RA patients (28). Besides that, the study of Fransen et al. (8) 
showed there was a significant difference not only in DAS reduction between tight control and usual 
care, but also in medication changes. This indicates that applying DMARD changes according to the 
level of disease activity leads to better results in patients with established RA also.
Finally, it is not yet clear which treatment protocol should be applied in early RA patients in 
clinical practice. In the treatment of early RA, recommendations are already given based on several 
clinical trials. These include the early introduction of DMARDs (MTX) in combination with prednisone 
and rapid introduction of anti-TNF in case of failure (1, 6, 34). However, several treatment strategies 
have shown to be effective. Therefore, comparative studies are needed to investigate the efficacy 
of one treatment protocol versus another protocol in order to optimise the strategy of the effective 
DMARDs/biologics. Since initial anti-TNF, as investigated in the BeSt study, apparently is not feasible 
for most patients and payers, comparison of intensive strategies including conventional DMARDs is 
needed.
The idea that tight control including protocolised treatment changes aiming at remission is 
more effective than usual care has already been pointed out by other reviews (34, 35). However, no 
formal meta-analysis had been performed. In the current meta-analysis, we showed the beneficial 
effects of tight control versus usual care, and showed that in tight control protocolised treatment 
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adjustments are needed to reduce disease activity more effectively in RA. Therefore, we suppose 
that the definition of tight control should comprise protocolised treatment adjustment. The latter is 
also in agreement with a recent consensus statement: ‘Tight control of inflammation in RA improves 
outcome and is understood as frequent assessments of disease activity combined with an objective 
structured protocol to make treatment changes that maintain low disease activity or remission at 
an agreed target’ (7). 
In conclusion, efforts should be made for the implementation of tight control strategies in 
the treatment of RA. Furthermore, consensus about optimal protocolised treatment needs to be 
achieved in the future as well. In tight control, a strategy should be adopted in which systematic 
disease activity monitoring is combined with protocolised treatment adjustments, because at least 
in early RA, protocolised treatment adjustments are more effective than systematic monitoring 
alone.
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Abstract 
Objective. There is strong evidence from several clinical trials that the application of a tight 
control treatment strategy is very effective in reaching remission in Rheumatoid Arthritis (RA). 
However, the question is whether these results indeed can be translated into daily clinical practice. 
The aim of this study was to investigate whether in early RA a tight control treatment strategy aiming 
at DAS28<2.6 is more effective than usual care treatment in reaching remission after 1 year. 
Methods. Two early RA inception cohorts from two different regions including patients who 
fulfilled the ACR criteria for RA were compared. Patients in the tight control cohort (n=126) were 
treated according to a DAS28-driven step-up treatment strategy starting with MTX, and addition of 
SSZ and exchange of SSZ by anti-TNF in case of failure. Patients in the usual care cohort (n=126) were 
treated with MTX or SSZ, without DAS28 guided treatment decisions. Primary outcome was the 
percentage remission (DAS28<2.6) at 1 year. Secondary outcome measure was the mean change in 
DAS28 from baseline to 1 year. 
Results. After 1 year, 55% of tight control patients had a DAS28<2.6 versus 30% of usual care 
patients (OR 3.1; 95%CI 1.8-5.2). The median time to first remission was 25 weeks for tight control 
and 52 weeks for usual care (p<0.0001). The DAS28 decreased with -2.5 in tight control and -1.5 in 
usual care (p<0.0001). 
Conclusion. In early RA, a tight control treatment strategy aiming for remission leads to more 
rapid DAS28 remission and higher percentages of remission after 1 year than usual care treatment. 
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Introduction 
The ultimate goal in Rheumatoid Arthritis (RA) is to achieve and sustain clinical remission as 
early as possible in order to prevent joint damage and functional disability (1-3). Current treatment 
approaches include early and intensive treatment, which are believed to be essential to achieve 
early remission and to provide a better clinical outcome of RA (4-11). 
Several clinical trials have demonstrated that applying a tight control strategy is effective in 
reducing disease activity, disability and progression of joint damage (7;12-14). Tight control in RA 
is defined as optimising treatment by measurement of disease activity in order to make treatment 
adjustments to reach a  predefined target, notably low disease activity or clinical remission (15-17). 
It is suggested that disease activity measurement in combination with a treatment protocol is more 
effective than tight control without protocol-driven treatment changes (18). However, the question 
is whether these results of clinical trials of tight control indeed can be translated into daily clinical 
practice.
Therefore, two inception cohorts from two different regions were used to study the effect of tight 
control versus ‘usual care’ in early RA: one tight control cohort with remission as treatment goal, and 
one usual care cohort. Cohort data from daily clinical practice are of value to investigate the effects 
of interventions in daily practice, including the effects of tight control (19;20). The patients included 
in a clinical cohort are supposed to be representative of the RA population and they are treated 
under daily practice circumstances. 
The aim of this study was to investigate in early RA whether a tight control treatment strategy is 
more effective than treatment according to usual care in reaching remission after one year, in daily 
clinical practice cohorts.
 
Methods
Study design 
For the aim of this quasi-experimental study, patients were selected from two distinct early 
RA inception cohorts from out-patient clinics in two different regions in The Netherlands. In The 
Netherlands, all patients with RA are treated by clinic based rheumatologists. In the ‘tight control’ 
cohort, regular evaluation of disease activity was applied in combination with protocolised treatment 
adjustments aiming for remission (21). In the ‘usual care’ cohort, patients were treated according to 
daily clinical practice with regular evaluation of disease activity but without protocolised treatment 
adjustments (22). Each patient gave informed consent before inclusion in the inception cohorts, and 
the responsible local medical ethics committee had approved the study protocols of both cohorts. 
Inclusion and data collection are still ongoing. 
Data selection  
In both cohorts, patients with early RA were included according to the following inclusion criteria: 
meeting the 1987 revised American College of Rheumatology (ACR) classification criteria for RA (23), 
age ≥18 years, symptom duration ≤one year and no previous treatment with disease modifying 
antirheumatic drugs (DMARDs) or prednisolone. Patients were included at the moment of diagnosis. 
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For the current study, all included patients had complete assessments of disease activity at baseline, 
had a minimal follow-up time of 48 weeks, and were not in remission at baseline.
Tight control
Since January 2006, consecutive patients with early RA were enrolled in the Dutch Rheumatoid 
Arthritis Monitoring (DREAM) remission induction cohort study. The rheumatology clinics of three 
hospitals participated in this study: Medisch Spectrum Twente, Enschede; Ziekenhuisgroep Twente, 
Almelo/Hengelo; and Isala Klinieken, Zwolle, The Netherlands.  
Patients visited the clinic at week 0, 8, 12, 20, 24, 36 and 52 and every three months thereafter. 
Therapy adjustments were standardised and protocolised, aiming at remission using the Disease 
Activity Score based on 28 joint counts (DAS28) with DAS28<2.6 as cut point. Patients started 
treatment upon diagnosis with methotrexate (MTX) 15 mg/week. In case of inefficacy, the 
consecutive intensification steps with DMARD medication were: at week 8, increase in MTX dose to 
25 mg/week; week 12, addition of sulphasalazine (SSZ) 2000 mg/day; week 20, increase in SSZ dose 
to 3000 mg. In accordance with the Dutch guidelines, anti-tumour necrosis factor (anti-TNF) therapy 
was prescribed for patients whose DAS28 remained ≥3.2. These subsequent steps included: at week 
24, adalimumab 40 mg every two weeks; week 36, frequency increase of adalimumab to every week; 
week 52, exchange of adalimumab for etanercept 50 mg per week; one year plus three months, 
infliximab 3 mg/kg bodyweight every eight weeks; one year plus six months, frequency increase of 
infliximab to every four weeks (all in addition to MTX 25 mg/week). 
If the remission target of DAS28<2.6 was met, medication was not changed. In case of sustained 
remission (≥ 6 months) the most recently added drug was tapered, e.g. first anti-TNF was tapered 
followed by the DMARD. In case of a disease flare (DAS28 ≥2.6), the most recently effective medication 
or medication dosage was restarted, and treatment could subsequently be intensified.
Nonsteroidal anti-inflammatory drugs (NSAIDs), prednisolone at ≤10 mg/day and corticosteroid 
injections were allowed at the discretion of the attending rheumatologist.
Usual care
In the usual care cohort, patients were visiting (between March 2005 and 2008) the outpatient 
clinic of the rheumatology departments of the Radboud University Nijmegen or the Sint 
Maartenskliniek in Nijmegen, The Netherlands. 
In this cohort, all patients were regularly assessed in three-monthly visits, but treatment decisions 
could be made at any time according to the discretion of the treating rheumatologist. Patients were 
treated with conventional DMARDs and/or biologicals following the guidelines for RA (24;25). A 
common strategy applied was starting with MTX monotherapy, subsequently switching to SSZ or 
adding SSZ in case of MTX failure, and adding an anti-TNF agent after two or more DMARDs failed, 
in accordance with the Dutch guidelines. Also, NSAIDs and prednisolone (oral or injections) could be 
used at the discretion of the attending rheumatologist.
Clinical assessments
The following variables were collected at baseline: age, sex, disease duration, symptom duration 
and rheumatoid factor positivity. Clinical assessments included the disease activity score (DAS28) 
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every three months and the Dutch version of the disability index of the Health Assessment 
Questionnaire (D-HAQ) every six months (26;27). Specially trained research nurses assessed the 
variables needed for the DAS28 (26). Other clinical variables assessed were: patient rating for pain 
on a 100 mm Visual Analogue Scale (VAS) and C-reactive protein (CRP; mg/L). Changes in DMARD 
and/or biological therapy and concomitant therapies with prednisolone (oral / intra-muscular) and/
or NSAIDs were standardly registered during follow-up.
Outcome measures
The primary outcome of this study was the percentage remission (DAS28 <2.6) at one year after 
baseline. Secondary outcome measures were: time to achieve remission, the mean change in DAS28 
from baseline to one year, the course over time of the DAS28, the mean change in the individual 
core set variables from baseline to one year, and the European League Against Rheumatism (EULAR) 
response criteria at one year (28).
Sample size estimation
Sample size was estimated for the primary outcome measure, percentage remission (DAS28<2.6) 
at one year. It was aimed to detect a clinically relevant difference in remission of 20% between both 
groups; assuming that tight control would show more effectiveness than usual care. Applying an 
α of 0.05 (conventionally two-sided) and a 1-β (‘power’) of 0.90, the necessary sample size was 
estimated to be at least 2 x 125 = 250 patients. Consequently, 126 patients were included from the 
tight control cohort and 126 from the usual care cohort. 
Statistical analyses
Baseline differences between both cohorts were analysed using the 2-sample t test, the 2-sampel 
Wilcoxon, or the Chi-square test, as appropriate.
Logistic regression analysis was performed to test whether there was a between group difference 
in the percentages of patients in remission according to a DAS28<2.6 (primary outcome). Confounder 
correction was applied using a stepwise forward procedure by adding additional covariates (age, 
gender, rheumatoid factor positivity, baseline HAQ score, baseline DAS28 or its single components) 
to the logistic regression model using 10% change in the main effect as selection criterion. 
Kaplan-Meier survival curves and Cox proportional hazards regression model including 
confounder correction was used to analyse a between-group difference in time to achieve remission. 
Linear regression was used to compare the DAS28 changes between the two treatment groups. For 
both analyses, the same confounder correction procedure was followed as described above for the 
primary outcome. Using the multivariate regression models, an adjusted hazard ratio (HR) and an 
adjusted odds ratio (OR) for the between-group difference were estimated. The course over time 
of the DAS28 in both groups was analyzed using longitudinal linear regression (mixed models), 
correcting for repeated measurements using an autoregressive covariance. To test differences in 
changes in core set variables between both groups, the 2-sample t test or the 2-sample Wilcoxon 
test were used, as appropriate. Between group differences in EULAR response rates were analysed 
using the chi-square test. Treatment with DMARDs, anti-TNF and prednisolone was described at 
baseline and at one-year of follow-up in both groups. 
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The level of significance was set at a two-sided p-value less than 0.05. The statistical analyses 
were carried out using the Statistical Package for the Social Sciences (SPSS, version 16.0, statistical 
software package, Chicago, IL, USA). 
 
Results 
Baseline characteristics 
Table 1 shows demographic and clinical variables of both treatment groups at baseline. Both 
groups were similar at baseline regarding age and gender, as well as for disease duration (0 weeks) 
by design. The mean DAS28 at baseline was similar for both groups and nearly half of the patients 
had high disease activity (DAS28 >5.1). The only significant differences (P < 0.05) were for HAQ, 
patient’s rating of pain and patient’s global assessment of disease activity, which were higher in the 
tight control group. 
Table 1. Demographic and baseline disease characteristics 
 Tight control  Usual care
 n = 126 n = 126
Age, mean ± s.d., years 56 ± 13 57 ± 14
Women, n (%) 78 (62) 77 (61)
Rheumatoid factor positive, n (%) 79 (63) 93 (74)
Disease activity score-28, mean ± s.d.  5.0 ± 1.2 4.8 ± 1.1
HAQ score, median (IQR) 1.1 (0.8,1.5) 0.9 (0.5,1.3)*
Swollen joint count, median (IQR) 8 (5,12) 8 (5,12)
Tender joint count, median (IQR) 5 (2,10) 4 (2,9)
ESR, median (IQR), mm/h 28 (14,44) 29 (18,44)
CRP, median (IQR), mg/L 11 (5,34) 9 (0,31) 
VAS pain (0-100), mean (SD), mm 53 ± 23 45 ± 22*
VAS GH (0-100), mean (SD), mm  53 ± 24 44 ± 22*
HAQ: Health Assessment Questionnaire; ESR: Erythrocyte Sedimentation Rate; CRP: C-Reactive Protein; 
VAS: Visual Analogue Scale; GH: General Health. IQR : interquartile range (P25-P75); s.d.: standard deviation. 
*Significant difference after comparison of clinical variables between the two groups using independent 
t-test (parametric) or Mann-Whitney U test (non-parametric) for continuous variables and chi-square test for 
dichotomous variables.
Remission 
After one year, 55% of tight control patients were in DAS28 remission compared to 30% of usual 
care patients in remission (P < 0.0001), (Figure 1A). The OR (95%CI) was 3.1 (1.8-5.2) and adjusted for 
baseline DAS28, there were no other variables that operated as confounders. Accordingly, patients 
treated according to tight control had about a three times higher odds to have a DAS28 <2.6 one 
year after baseline, compared to those patients who were treated according to usual care.
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Figure 1. Remission (A) and European League Against Rheumatism (EULAR) (B) response at twelve months of 
both tight control and usual care group.  
Time to achieve remission
Time-to-remission (DAS28 <2.6) was significantly shorter in the tight control group than in the 
usual care group, with a median of 25 weeks versus a median over 52 weeks (P < 0.0001), (Figure 2). 
Already after eight weeks, the survival curve of the tight control group appeared to diverge from the 
curve of the usual care group. After 20 weeks, the difference between both groups was at its largest 
and it remained stable until 52 weeks.
Figure 2. Probability to achieve remission (DAS28 <2.6) of tight control and usual care at one year in early RA 
patients. 
A B
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EULAR response
The EULAR response at year one for the two treatment groups is shown in Figure 1B. Overall, the 
response rates were significantly better in the tight control group (P < 0.0001). In the tight control 
group 67% showed a good response, 24% a moderate response, and 9% no response. In the usual 
care group, 33% of patients had a good response, 39% had a moderate response, and 28% had no 
response.
Mean change in DAS28  
At one year, the DAS28 was significantly decreased compared to baseline in both groups. The 
DAS28 decrease in the tight control group was -2.5 (1.3) versus -1.5 (1.4) for the usual care group. 
The between-group difference adjusted for baseline DAS28 as the only confounder was 0.9 (95% CI 
0.6-1.1, P < 0.0001) in favour of tight control.
Course over time of the DAS28  
Figure 3 depicts the course over time of the DAS28 in both groups. It can be seen that the 
decrease in DAS28 was similar for both groups in the first 12 weeks of treatment, but after 12 weeks 
the decrease continued in the tight control group. Also according to the mixed models analysis, the 
course over time of DAS28 was significantly different between both groups (P < 0.0001).
Figure 3. Mean change of Disease Activity Score based on 28 joint counts (DAS28) for both treatment strategies 
(tight control and usual care). Mixed models were used with time-averaged DAS28 as dependent variable, 
treatment group and baseline DAS28 as covariates. 
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Decrease in core-set variables   
Table 2 shows the average changes from baseline to one year of individual core-set variables 
and the DAS28. In all core-set variables, except for the acute phase response (ESR and CRP), the 
improvements were significantly larger in the tight control group. The baseline values can be found 
in Table 1. 
Table 2 shows the average changes from baseline of core-set variables after one year. In all 
core-set variables, except for the acute phase response (ESR and CRP), the improvements were 
significantly larger in the tight control group.  
Table 2. Mean change from baseline for core-set variables after one year  
 Tight control  Usual care  P-value*
 n = 126 n = 126 
Disease activity score-28, mean ± s.d.  -2.5 ± 1.3 -1.5± 1.4 0.000
HAQ score, median (IQR) -0.5 (-1,-0.2)  -0.3 (-0.8,0) 0.003
Swollen joint count, median (IQR) -7 (-10,-3)  -3 (-8,0) 0.000
Tender joint count, median (IQR) -4 (-8,-1)  -2 (-6,0) 0.000
ESR, median (IQR), mm/h -11 (-28,-2)  -12 (-25,-1) 0.542
CRP, median (IQR), mg/L -5 (-28,0)  -3 (-21,0) 0.397
VAS pain (0-100), mean (SD), mm -30 ± 27  -16 ± 28 0.000
VAS GH (0-100), mean (SD), mm  -32 ± 28  -16 ± 27 0.000
HAQ: Health Assessment Questionnaire; ESR: Erythrocyte Sedimentation Rate; CRP: C-Reactive Protein; VAS: 
Visual Analogue Scale; GH: General Health. IQR: interquartile range (P25-P75); s.d. : standard deviation. Negative 
values indicate improvement from baseline. *After comparison of core-set variables between the two groups 
tight control and usual care using independent t-test (parametric) or Mann-Whitney U test (non-parametric).
Medication use  
All patients in the tight control group started with MTX in a dose of 15 mg a week that could 
be increased to 25 mg a week. After one year, 50% of the patients were still on MTX monotherapy 
and 30% received a combination of DMARDs, nearly always MTX and SSZ. After one year 12% of the 
patients in the tight control group received anti-TNF (Table 1). Oral prednisolone and intra-muscular 
injections of methylprednisolone were given to 15% and 25% of the patients, respectively. 
Patients treated according to usual care, started with MTX or SSZ mono therapy, or occasionally 
another DMARD. After one-year of follow-up, most patients were still on DMARD monotherapy, 
about 13% had switched to another DMARD and 10% of the patients received a second DMARD in 
addition. After one year, anti-TNF therapy was given for 14% of the patients. Oral prednisolone was 
given to 20% of the patients and 54% of the patients received at least an intra-muscular injection of 
methylprednisolone. 
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Table 3. Medication use at baseline and after 1 year follow-up in tight control and usual care
 Tight control  Usual care
 n = 126 n = 126
DMARDs at baseline  
MTX, n (%) 118 (94) 71 (56)
SSZ, n (%) 0 (0) 44 (35)
Other DMARDs, n (%) 0 (0) 11 (9)
Prednisolone monotherapy, n (%) 3 (2) -
No medication, n (%) 5 (4) -
  
DMARDs strategy after one year  
Monotherapy, n (%) 63 (50) 79 (63)
DMARD Sequential: switch, n (%) 4 (3) 16 (13)
DMARD Combination: add-on, n (%) 37 (29) 13 (10)
Anti-TNF, n (%) 15 (12) 18 (14) 
No medication, n (%) 7 (6) -
DMARDs: disease-modifying antirheumatic drugs; MTX: methotrexate; SSZ: sulfasalazine; anti-TNF: anti-tumour 
necrosis factor. 
 
Discussion
According to the results of this study, a tight control treatment strategy aiming for remission 
leads to more patients being in remission more rapidly than treatment according to usual care, 
in early RA. Concordantly, the tight control strategy resulted in a larger decrease of DAS28, more 
EULAR good responders, and larger improvements in functional ability and patient assessments of 
pain and disease activity.
This quasi-experimental study was performed using daily practice data of two early RA cohorts. 
The results of this study are in accordance with those from ‘tight control’ randomized controlled 
trials (TICORA and CAMERA) (12;13). Also, the quasi-experimental study of Goekoop et al. compared 
tight control treatment with that of usual care and showed a better response after one year for tight 
control (14). The results from the current study are valuable as they contribute to the robustness of 
the finding that tight control is effective and feasible for the treatment of early RA in daily practice.
There are three important implications of the findings of this study. First, aiming for remission is 
feasible in daily clinical practice and the results therefore confirm that clinical remission can be our 
current treatment goal (3;29). Besides clinical remission as treatment aim, remission could also be 
defined as the absence of progression of joint damage. However, there still remains discussion about 
defining remission and whether it should be regarded as the absence of clinical disease activity or 
the absence of progression of joint damage (30). Presumably, the concept of clinical remission in 
RA should include both absence of clinical signs and symptoms and absence of progression of joint 
damage (29;31).  
Second, tight control with protocolised treatment adjustments contributes to a better disease 
outcome compared to non-protocolised treatment adjustments (15;17;32). Therefore, it may be 
recommended that in the application of tight control, a treatment protocol should be included to 
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promote quick and sufficient intensification of treatment. A multitude of treatment strategies have 
shown to be effective in RA and there is choice as to which could be used in a treatment protocol 
(1;8;11;16;33-35).
Third, a tight control add-on strategy starting with MTX monotherapy, as was applied, has shown 
to be very effective in daily practice. The DMARDs of the tight control treatment were MTX, SSZ, and 
anti-TNF, supplemented with prednisolone. In comparison with usual care, the tight control group 
received higher doses of MTX and more frequently an add-on combination of DMARDs. However, 
anti-TNF was prescribed equally in both groups. Based on the results of this study, it may therefore 
be suggested that a reasonable strategy for treatment of early RA in daily practice is initial MTX 
monotherapy with optimal dose of MTX and early addition of a next DMARD or anti-TNF in case of 
inadequate response.
This study has shown that tight control is feasible in daily practice, and that it is more effective 
than usual care. However, this study also has its limitations.
In this study, DAS28 was used to define remission in early RA. However, the remission definition 
of DAS28<2.6 is still a matter of discussion since patients with a DAS28 may have residual disease 
activity, notably swollen joints in simultaneous presence of a very low ESR. Also, synovitis may be 
present in joints not included in the 28 joint count, such as the feet (36). More stringent remission 
criteria using the DAS variables are being formulated but stringent criteria currently are infrequently 
met in RA patients (37). The advantages of using the DAS28 for daily practice are that it is relatively 
easy to obtain, that it is a continuous measure of disease activity state, and that DAS28<2.6 indicates 
clinical remission or very low disease activity for the majority of patients. Moreover, a DAS28<2.6 
can be reached in practice as we showed, which in itself supports the movement to more stringent 
remission criteria.
Another limitation of this study is the follow-up of one year. We regard that one year is reasonably 
informative but longer follow up is needed to get insight into long-term efficacy of tight control, also 
regarding progression of joint damage. It also is a limitation that data on joint damage progression 
are currently not available. Future research in these cohorts will focus on long term effects, joint 
damage progression and adverse events (19). In the last years and in both cohorts, patients are 
being included who do not (yet) fulfil the 1987 classification criteria for RA, but who were regarded 
to have RA and consequently were treated alike. In the future it can be seen how effective tight 
control is for those patients. It could be hypothesized that treatment could be tapered and probably 
stopped (medication free remission) if patients are treated sufficiently early in the disease process. 
In conclusion, it was shown that in early RA, a tight control approach including regular 
measurement of the DAS28 and protocolised treatment decisions is feasible in daily practice, and 
that it leads to more rapid DAS28 remission and higher percentages of DAS28 remission after 1 year 
than usual care treatment.
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Figure 1. Timeline of significant drug developments and trial publications.
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Introduction 
The ultimate treatment goal of rheumatoid arthritis (RA) is to control the inflammatory process 
without progression of joint damage in order to maintain or restore normal physical function 
and capacity to work (1). New developments have led to new treatment insights, including early 
start of treatment, use of combination therapies, specific intervention with biological response 
modifiers (BRMs) and response-driven treatment (2). These are important strategies that provide 
the opportunity to aim for clinical remission and ultimately prevention of joint damage (3). Here 
we review briefly historical developments of the treatment of RA, discuss the current treatment 
strategies, and whether we are able to find an answer to the question: step-up or step-down in early 
RA patients?
Historical
Treatment of RA has changed considerably over time. Until the mid-1980s, treatment of RA 
occurred according to the pyramid approach, involving the use of NSAIDs for years until joint 
damage was shown and disease-modifying anti-rheumatic drugs (DMARDs) were applied (4). In this 
approach, most patients experienced poor long-term outcomes, including joint damage, functional 
disability and work loss (5). Since we realize that RA is a serious chronic disease that requires early 
and intensive use of DMARDs, important therapeutic changes of RA occurred during the last two 
decades (6). These concern the increase in the number of (more effective) drugs. Additionally, 
early treatment, aiming for remission and performing tight control of disease activity has become 
essential in using intensive DMARDs strategies, including combination of DMARDs and BRMs (7-9). 
In other words, the traditional pyramid including the ‘go low, go slow’ approach in patients with RA 
has been replaced by a more early intensive treatment striving for remission.
How: aiming for early remission and tight control 
Realization of early diagnosis and early initiation of (DMARD) intervention are important changes 
within the management of RA and appear to be essential in optimizing treatment of early RA. Results 
from clinical trials affirmed the benefit of early treatment over delayed introduction of DMARDs in RA 
(10;11). Another important change is that therapy should control inflammation in terms of applying 
‘tight control’ (1;12). Tight control comprises regular assessments of disease activity, a treatment 
goal, and protocolised treatment adjustments in case this goal has not yet been reached (13;14). It is 
relevant to realize that remission, rather than low disease activity, should currently be the treatment 
goal and ultimately a state of sustained drug-free remission (15). 
What: to step-down or to step-up? 
It is clear that RA patient benefit from early start of DMARDs and applying tight control improves 
clinical outcomes in patients. However, the number of therapeutic options for the treatment of RA 
has increased considerably during the past decades and the question arises which DMARD should 
be applied first and what is the best therapeutic strategy? Since MTX has shown to reduce clinical 
symptoms and progression of joint damage, has relatively infrequent serious adverse events and 
has practical ease of use (16-18), MTX has been applied as first-choice DMARD in daily practice. 
However, the question remains which treatment strategy should be applied? Additionally, 
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should initially MTX be combined with other DMARDs and taper one of these DMARDs down in 
case of clinical response; the step-down approach? Or should MTX be given as initial monotherapy 
and in case of suboptimal treatment response, a second DMARD should be added etc.; the step-
up approach? Since both strategies have never been compared directly, it is difficult, or in fact 
impossible, to give preference for one strategy above the other. However, we could give several 
considerations in making a choice for step-down or step-up strategies.  
Step-down
It has been suggested that there is a ‘therapeutic window of opportunity’ in which early treatment 
may allow the modification of early inflammation and the prevention of development of (further) 
joint damage, in other words ‘the earlier, the better’ (19-22). This approach should include early and 
intensive use of DMARDs; starting DMARDs combination therapy as a step-down strategy in order 
to achieve optimal outcomes as remission, halting radiographic progression and maintain long-
term functionality (23;24). For instance, intensified glucocorticoid therapy in combination with MTX 
and SSZ, applied as a step-down strategy (the COBRA scheme), has shown to improve short-term 
clinical efficacy and may have long-term structural benefit in early RA patients compared to SSZ 
monotherapy (25;26). However, we have concerns whether this treatment approach should be the 
RA strategy of first choice. 
First, the COBRA study showed only a small further decrease in clinical efficacy after the 
withdrawal of glucocorticoids. Moreover, after one year, there was no difference in clinical efficacy 
between the COBRA scheme and SSZ monotherapy (25). In other words, it may be stated that the 
short-term efficacy was only temporary and mainly due to ‘bridge therapy’ of glucocorticoids. 
Second, despite comparable efficacies after one year, it was demonstrated that there was less 
radiographic progression in the COBRA group after five years of follow-up (26). However, no data 
were given about sick leave and working capacity and, therefore, the question still remains what is 
the clinical relevance of the detected difference in radiographic progression between combination 
and monotherapy? In other words, it is not clear how reduced joint damage will be translated in 
more long-term functionality or labour participation (27). This issue will be interesting to investigate 
further, incorporating the fact that long-term outcomes are difficult to study. 
Third, the existence of a ‘window of opportunity’ in early RA is hypothesised and is, therefore, 
accompanied with uncertainties. On one hand, it is conceivable that ‘hitting hard’ early in disease 
and thus suppressing disease activity aggressively may result in a better long-term outcome (19;20). 
On the other hand, ‘what is early disease?’ or actually what is the time-frame of the ‘window of 
opportunity’; is there a beginning, is there an end? 
Fourth, a step-down strategy involves that all RA patients should be treated early and intensively. 
However, in about 30 to 40% of the patients a sustained suppression of disease activity may be 
achieved with MTX monotherapy (28-30). Whether initial combination treatment is needed remains 
uncertain until tapering is followed by a flare of disease activity. Identifying clinical and serologic 
parameters as well as genetic variations may be appropriate to recognize patients who will benefit 
from a step-down strategy. Though prognostic factors are generally known (7), a validated prognostic 
model to identify these patients is not (yet) available. Therefore, we suppose that intensive treatment 
strategies will lead to overtreatment.
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Step-up 
The step-up strategy involves the addition of medication in case of a suboptimal treatment 
response until remission is achieved. In daily practice, this strategy has been applied in most patients 
with MTX as first-choice DMARD and in case of failure a second DMARD or a BRM combined with MTX 
is indicated. Several clinical trials demonstrated that a step-up strategy comprising tight control in 
early RA patients led to significantly better clinical and functional outcomes compared to usual care 
(31-33). Additionally, in the TICORA study, patients in the intensive treatment group had reduced 
radiologic progression compared to patients in the usual care group (32). Though there were also 
patients with joint damage, patients included in TICORA did not receive any anti-TNF treatment 
and, therefore, the results may be better by integration of anti-TNF into the treatment strategy. 
Furthermore, in daily practice, a response-driven treatment according to a step-up approach has 
shown to be feasible and has led to high remission rates and low radiographic progression (34;35).
Compared to step-down, one could state that applying a step-up strategy the ‘window of 
opportunity’ will be missed, which may result in less drug-free remission on the long-term. 
Unfortunately, no such data about the long-term effects of step-down versus step-up strategies and 
drug-free remission in particular, are yet available. Although, a few strategy studies have recently 
been published comparing initial combination therapy, like the step-down approach, with step-up 
combination therapy. 
Initial combination versus step-up combination 
Recent strategy studies applied tight control and compared immediate combination therapy 
with a short-term delay of combination of DMARDs/BRMs by means of step-up. Generally, the 
studies conclude that both strategies have comparable effectiveness.
The TEAR study shows us that initial ‘triple’ (methotrexate, sulfasalazine, hydroxychloroquine) 
therapy was completely comparable with a step-up ‘triple’ strategy (36). After one year, 60% in the 
initial triple therapy group and 41% in the step-up triple therapy group achieved an EULAR good 
response and 45% versus 33% achieved DAS28 remission (not significant). Radiological progression 
was similar in both groups.
In the GUEPARD trial initial adalimumab combined with MTX was compared with initial MTX 
monotherapy and addition of adalimumab after three months in case of DAS28>3.2. Though 
patients treated with initial combination therapy showed an earlier improvement in disease activity 
at three months, after one year, the proportion of patients with low disease activity was similar 
in both groups (65% reached low disease activity) and there were no differences in joint damage 
progression between the groups (37). 
In a second very recent TEAR study by O’dell et al., no clinical differences were detected after 
one year between immediate combination therapy (methotrexate plus etanercept or triple therapy) 
versus a step-up strategy (starting with methotrexate and addition of etanercept or triple therapy 
in case of no low disease activity was reached). Unfortunately, no data are yet given on (long-term) 
radiographic progression (38).  
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Conclusions
Based on previous concerns regarding immediate combination in a step-down strategy (i.e. 
overtreatment and uncertainties about long-term effects in terms of work disability) and the latest 
results from strategy studies we would like to recommend the following treatment strategy in patients 
with early RA. A step-up treatment strategy with an immediate start of MTX monotherapy, including 
initial corticosteroids to bridge until efficacy of MTX is optimal, followed by rapid introduction of 
BRMS (in combination with MTX) in case of insufficient response of DMARDs. Additionally, patients 
should be treated as early as possible – also in case of ‘likely’ RA – and followed intensively with respect 
to the effect of therapy (tight control) and in case the remission aim is not achieved, treatment must 
be changed until ultimately a state of sustained drug-free remission is reached. Last but not least, 
many different ways of prescribing DMARDs/BRMs, including combination therapies, are available 
but definite conclusions about the ‘perfect’ strategy could still not be drawn. Therefore, we would 
like to encourage more (cohort) data collection from daily clinical practice to enable documentation 
of efficacies of different treatment strategies specifically and long-term outcomes of RA generally.
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Figure 1. PERFECT treatment strategy in patients with early RA
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General Discussion
The aim of this thesis was to elucidate the most effective and efficient treatment strategy in 
patients with early rheumatoid arthritis (RA) in order to reach early and sustained remission. The 
main conclusions of this thesis are:
•	 Time to achieve first remission is the most important predictor for sustainability of remission; 
attaining remission sooner increases the probability of sustained remission. 
•	 In early RA, methotrexate (MTX) and sulfasalazine (SSZ) combination therapy is not more 
effective than starting with either MTX or SSZ alone.  
•	 In case of failure of SSZ, the addition of MTX to SSZ is effective; step-up strategy.
•	 In early RA, a treatment strategy starting with MTX monotherapy is more cost-effective than 
a strategy with initial MTX plus anti-tumour necrosis factor (anti-TNF). 
•	 In early RA, ‘tight control’ with protocolised treatment adjustments appears to be more 
beneficial in achieving remission than non-protocolised treatment adjustments. 
•	 A ‘tight-controlled’ step-up strategy aiming for remission is feasible in patients with early RA 
as treated in daily practice and leads to high remission rates.
There is general agreement that aiming for remission is the ultimate treatment goal in RA, even if 
it currently is not reached in a majority of patients. Early effective treatment is essential in achieving 
remission rapidly since there might be a ‘window of opportunity’ where early intensive treatment 
might alter the natural course of RA and improve the long term outcome. This is underlined by the 
fact that time to achieve first remission is predictive for sustainability of remission. RA treatment 
should start early and should be sufficiently intensive, which can be reached by applying a ‘tight 
control’ strategy. 
These statements and conclusions are in line with the recent published EULAR recommendations 
for the treatment of early RA (1). There are several key recommendations being made: ‘Treatment 
with disease modifying anti-rheumatic drugs (DMARDs) should be started as soon as the diagnosis 
of RA is made’ (recommendation 1). Treatment should be aimed at remission as soon as possible 
and as long as the remission target has not been reached, treatment should be adjusted by frequent 
(every 1-3 months) and strict monitoring; ‘tight control’ (recommendation 2). 
Based on the results of this thesis and in line with recent EULAR recommendations (1) a treatment 
strategy was devised for the early effective treatment of patients with RA; PERFECT: Pursuit of 
effective treatment of RA. The PERFECT strategy is shown in the following table: 
The PERFECT strategy includes the following treatment protocol in patients with early RA. 
1. Patients will start with subcutaneous MTX (20 mg/week) in combination with 
hydroxychloroquine (HCQ). Initial MTX-HCQ therapy will be immediately combined with 
intramuscular corticosteroids (120 mg). Doses of MTX are increased to MTX 25 mg/week 
and subsequently MTX 30 mg/week (with corticosteroids) if no remission is reached. 
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2. If the clinical response to the combined MTX-HCQ therapy is still insufficient (DAS28 >3.2), 
anti-TNF treatment is rapidly added to these DMARDs at week sixteen. Anti-TNF treatment 
includes either Etanercept (50 mg a week) or Adalimumab (40 mg every other week). This 
treatment is followed by increasing doses after 12 weeks of treatment and switching anti-
TNF treatment after 24 weeks if the DAS28 is still higher than 3.2. If the clinical response 
remains still inadequate anti-TNF treatment will be replaced by the combination of MTX 
with Rituximab (two infusions of 1 gram) or MTX with Abatacept (10 mg/kg/4weeks) (week 
52). 
3. If patients have sustained remission (DAS28 <2.6 for more than six months), anti-TNF 
treatment is first withdrawn, thereafter HCQ and in case of maintaining remission MTX will 
be tapered until ultimately a state of drug-free remission has been attained. In case of a 
flared disease activity (DAS28 >2.6) after lowering a anti-TNF or DMARD, the last effective 
dose of the last combined agent will be reintroduced again. 
Step 1: Starting treatment with MTX and HCQ in combination with corticosteroids 
Methotrexate (MTX) is the treatment of first choice in RA and thus also in this strategy chosen 
as first-line DMARD. MTX is highly effective, the experience of MTX is extensive, it has a favourable 
ratio of efficacy/safety and has also on the long term proven to be effective and safe (2-6). Current 
evidence supposes that MTX at higher weekly doses (20–30 mg/week) is more effective than MTX at 
lower weekly doses (7.5–15 mg/week) (7). In case 20 mg/week is not sufficient, fast escalation with 
5 mg/month to 30 mg/week is recommended. Starting with subcutaneous MTX is supposed to give 
less toxicity than MTX orally (7). Moreover, it is clear that MTX should be the ‘anchor’ DMARD since it 
has ability to increase the efficacy of other DMARDs or biologicals when used in combination (8-13). 
Besides MTX as the ‘anchor’ DMARD, it is combined with HCQ as second DMARD in the PERFECT 
treatment strategy. Reason is to enhance the clinical response of MTX in case it is combined with 
HCQ (9;14-16). There are suggestions that the combination of MTX and HCQ is more effective than 
the combination of MTX and SSZ. This may be due to pharmacologic interactions. First, HCQ may 
inhibit metabolism of MTX to its less active metabolite resulting in more efficacy of MTX (14-16). 
Second, the combination leads in less urinary excretion and elevated serum levels of MTX (14-16), 
thus more efficacy of MTX is expected. Third, it is suggested that HCQ interacts with MTX reducing 
the bioavailability of MTX resulting in a reduction of MTX-associated liver toxicity (14-16).
To the combination of MTX and HCQ, corticosteroids should be added until optimal effect is 
reached. Reason is that the addition of corticosteroids to DMARDs has shown to improve outcomes 
in early RA (12;13;17-19). Corticosteroids have disease-modifying effects since they are able to 
suppress both disease activity and radiographic progression, alone or in combination therapy (19-
21). In very early disease when DMARDs are started, a short course of intra-muscular corticosteroids 
may rapidly reduce disease activity (12;22), especially until full efficacy of DMARDs develops, and 
can even be advantageous in retarding radiographic progression (12;13;17). Corticosteroids provide 
benefit as initial short term treatment, but they should be tapered as rapidly, in case of remission, 
since they may show toxicity at the long term.  
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Step 2: Rapidly addition of anti-TNF in case of inadequate DMARDs response
In case of conventional DMARDs failure of MTX and HCQ, anti-TNF treatment should rapidly be 
followed since it is an effective and tolerable treatment after DMARD (MTX) failure (23-25). Though 
anti-TNF is given after DMARD failure, a minimal delay of anti-TNF should be advocated (week 16). 
This is also in according to current guidelines, which recommend anti-TNF after failure of at least 
two DMARDs (26). Moreover, anti-TNF after DMARDs failure is a more cost-effectiveness option than 
initial anti-TNF in DMARD naive patients (27). Based on current evidence all anti-TNF treatments 
are supposed to have comparable effects (28;29); Adalimumab and Etanercept are thus equal 
therapeutic options (30;31). Therefore, no recommendation of an anti-TNF agent could be given (32) 
and both anti-TNF can be prescribed in the PERFECT strategy at week 16. Anti-TNF should, however, 
always be combined with MTX treatment since this combination has shown to be more effective 
than anti-TNF monotherapy (31;33;34). 
After inadequate response of the first Adalimumab treatment in the PERFECT strategy, the 
frequency of administration of Adalimumab is increased in order to improve clinical responses. This is 
based on studies that have shown that an inadequate response of Adalimumab due to the formation 
of anti-Adalimumab antibodies can be improved by increasing frequency of administration (35;36). 
In case of starting with Etanercept and suboptimal responses, a switch to Adalimumab is proposed 
in the PERFECT strategy. Observational studies have demonstrated that a switch to a second anti-
TNF agent may be an useful therapeutic option (37;38). This might not be the case after failure of 
two anti-TNF agents and thus switching to a third anti-TNF treatment (39;40). Therefore, patients 
in the PERFECT strategy for whom a second anti-TNF has failed, should receive another biological 
(Rituximab or Abatacept) (41-45). Based on the current evidence, a preference for one biological 
over the other could not be given in patients who failed to anti-TNF therapy and both are preferred 
in PERFECT at week 52 (46;47).
Step 3: Tapering DMARDs or anti-TNF in case of sustained remission
After remission is reached and sustained (more than six months) in the PERFECT treatment 
strategy, first anti-TNF treatment is tapered and subsequently HCQ and MTX are tapered in case 
there is anti-TNF free remission. In case of a disease flare, the latter DMARD or anti-TNF tapered 
should be started again. The efficacy of DMARD or anti-TNF tapering remains still to be clarified 
since only a few trials have investigated this issue. In addition, in the BeSt study, initial anti-TNF 
therapy could be successfully tapered and a group of patients discontinued even all DMARDs and 
achieved thus drug-free remission (48;49). Although, remission seems to be more difficult to sustain 
after stopping all DMARDs (50-52). It is assumed that in patients who start with MTX monotherapy 
and receive ‘delayed’ anti-TNF treatment in case of DMARDs failure, are able to withdraw anti-
TNF treatment but this will lead to high flare rates (about 75%). Anti-TNF could thus less often be 
successfully discontinued than if given as initial treatment (53-55).
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Aims for future research 
By introducing this new treatment strategy, several questions remain for future research. 
There currently is no direct evidence that addition of HCQ to MTX is beneficial in the treatment of 
early RA. Therefore, the following questions remain to be clarified. First, is there indeed a beneficial 
effect of MTX combined with HCQ compared with MTX alone? Second, does the addition of HCQ 
follow the proposed pharmacodynamic way of action? A clinical trial that compares a strategy of 
MTX monotherapy with a strategy of MTX and HCQ in early RA patients can give an answer on 
these issues. Moreover, the efficacy results of the PERFECT strategy could be compared with other 
treatment strategies as applied in daily practice as well.
Most patients will respond well to initial MTX or initial MTX plus HCQ. However, if it could be 
predicted which patients will not respond favourably, those patients could start with anti-TNF 
right away. In addition, patients with poor prognostic factors (high risk of radiological progression) 
may benefit more from initial anti-TNF therapy than initial MTX monotherapy. By comparing these 
strategies in a clinical trial setting, predictors can be identified for patients who will respond to 
initial DMARDs or anti-TNF and can be described in a clinical prediction model. This model should 
be validated in more early RA cohorts to evaluate the quality of the model. 
Tapering of anti-TNF has been successful in studies with patients with early RA starting with 
anti-TNF (49;56). Tapering of anti-TNF in patients with established RA, starting on anti-TNF after 
DMARD failure, has been unsuccessful up to now (53-55). The question is whether in early escalating 
anti-TNF therapy (as the PEFECT strategy), anti-TNF can also be successfully be tapered. Further, 
could DMARDs as HCQ and MTX be withdrawn as well and ultimately leading to a state of drug-free 
remission? Thus, more research should focus on the maintained effect of tapering of anti-TNF or 
DMARDs in case of sustained remission. Further, there should be focussed on whether six months 
sustained remission is a beneficial time-frame after which successfully could be tapered and whether 
the dosing length during tapering is effective.
Starting with anti-TNF, taking the overtreatment for granted, can be cost-effective in comparison 
with ‘delayed’ but life-long anti-TNF treatment, on the premise that early anti-TNF is more effective 
and can be successfully tapered in a sufficient number of patients. Additionally, tapering in case 
of sustained remission decreases the costs and more favourable cost-effectiveness ratios could be 
obtained. However, there are no studies that did yet investigated this issue. Therefore, a modelling 
study in early RA patients is suggested to answer the question whether starting with anti-TNF is 
more cost-effective in case of tapering anti-TNF after sustained remission (accounting for anti-TNF-
free remission) compared with starting MTX and addition of anti-TNF after a suboptimal response to 
MTX without tapering anti-TNF. 
Tight control leads to more intensive treatment and favourable patient outcomes. Moreover, 
‘tight control’ has shown that it also translates in meaningful differences in joint damage. Although, 
more intensive treatment may also lead to more toxicity. Further, ‘tight control’ may lead to more 
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cost savings as more favourable outcomes are expected. However, the suggested beneficial effects 
of tight control at the long term remains still to be proven. Therefore, by applying ‘tight control’ 
treatment strategies in early RA patients in daily practice, i.e. an early RA cohort, the long term effects 
and cost-effectiveness of ‘tight control’ can be evaluated.  Further research should concentrate 
on the comparison of different treatment strategies in daily practice including the ‘tight control’ 
principles in searching the most optimal treatment strategy.
Remission may be defined as absence of clinical signs and symptoms of disease activity (hence: 
clinical remission), associated with no progression of joint damage and no excess disability. Strict 
remission criteria are best prognosticators for no joint damage and no excess disability, but 
currently are not frequently reached in practice. Though new ACR/EULAR definitions of remission in 
RA are being developed, remission is still ill-defined, including its prognostic value. Therefore, more 
research should focus on defining remission as applicable in daily practice.
Although anti-TNF has been effective in improving clinical outcomes and reducing structural 
damage, there is the concern of the increased risk of serious infections and malignancies. From the 
available literature, definite conclusions about the long-term safety could not be reached. However, 
there are a few cohort studies performed and these studies did not find yet an increased risk of 
infections and did not detect an increased risk for malignancies. More large-scale cohort studies are 
clearly needed to address the risks of anti-TNF and confirm these previous results. Further, there is 
currently no evidence to increase efficacy by escalating doses of anti-TNF. Increasing doses of anti-
TNF is even supposed to be not cost-effective. Cohort data can also be very valuable to evaluate 
cost-effectiveness of dose escalation of anti-TNF treatment.
Concluding remarks
In the treatment of early RA, remission early in the disease course is crucial in the further disease 
course and is, therefore, the treatment target in patients with early RA. Frequent assessments of 
disease activity in combination with a treatment protocol should be used to achieve remission as 
soon as possible and to sustain remission as long as possible. In conclusion, the currently optimal 
treatment strategy in early RA uses ‘tight control’ principles and starts with MTX and corticosteroids, 
probably MTX and HCQ and corticosteroids; followed by anti-TNF in case of failure and subsequently 
a second anti-TNF or biological in case the remission aim is not achieved. Tapering of treatment is 
advocated if sustained remission is reached. This strategy is supported by the findings in this thesis 
and is in line with the new EULAR guidelines. Adopting these kind of strategy will ultimately lead to 
more patients in sustained remission and preferably drug-free remission, less progression of joint 
damage and less functional disability. These expected beneficial long-term effects will attend with 
more medical and societal cost savings and most importantly a higher and longer quality of life of 
patients diagnosed with early RA. 
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Summary
Introduction
The current treatment aim of rheumatoid arthritis (RA) is to control disease activity as soon as 
possible, as completely as possible and that this control should be maintained for as long as possible. 
In addition, we are now aiming for remission. Since there is a concept of window of opportunity, 
in which early intensive treatment may positively alter further disease course, early diagnosis and 
accordingly an early start of treatment are essential. Moreover, an initial good response to treatment, 
ideally remission, is associated with sustainability of remission. To achieve remission, many efficacious 
options in the treatment of early RA are available and different treatment strategies could, therefore, 
be recommended. Additionally to these intensive treatment options, tailored treatment on the basis 
of disease activity (tight control) has shown to increase the ability to incuse remission in early RA. 
With tight control, treatment should be changed until the remission aim is achieved. Since there 
is a great diversity of traditional disease modifying anti-rheumatic drugs (DMARDs) and relatively 
new biologicals, and thus also treatment strategies, more insight in the optimal treatment strategy 
in patients with early RA will be important and could contribute to a better disease outcome in 
these patients. Therefore, the general objective of this thesis was to investigate the most effective 
treatment strategy in early RA in order to aim for early and sustained remission.
Chapter two
It is generally known that clinical remission should be the treatment target in patients with early 
RA. According to the window of opportunity, it is hypothesized that early remission is associated 
with a higher number of patients who sustain their remission. The aim of chapter two was to study 
the association between time to achieve first remission and sustainability of remission in early RA 
patients treated according to daily practice care during three years follow-up. Remission was defined 
according to the Disease Activity Score (DAS) <1.6 and the American Congress of Rheumatology 
(ACR) remission criteria. Remission of at least six months duration was regarded as sustained 
remission. Data were used from inception cohort.
The analyses of this chapter demonstrated that predictors to achieve more rapidly DAS remission 
were male gender, younger age and a low DAS or disability at baseline. Time to achieve early remission 
was the most important predictor for sustainability of remission. Over calendar time, reflecting more 
intensive treatment, the time-to-remission tended to shorten, the occurrence of sustained remission 
tended to increase, but the relation between time-to-remission and sustainability remained fairly 
constant. This indicates that the relation between time-to-remission and sustainability of remission 
does not heavily depend on the type or strategy of DMARDs given. Results obtained with the ACR 
remission criteria were similar.
Thus, attaining first remission sooner, chance of sustained remission is becoming significantly 
higher. Supporting that aiming for early remission should be the treatment goal. Besides, this is in 
line with the concept of window of opportunity; ‘the earlier, the better’. 
10
154
Chapter 10
Chapter three
Both methotrexate (MTX) and sulfasalazine (SSZ) are used as first-choice DMARDs. For 
pharmacological reasons, the effect of the combination of MTX and SSZ may be different in RA 
patients who are naïve to these drugs compared to patients with an insufficient response to one of 
them. Therefore, a comparison was made between the results of randomized controlled trials (RCTs) 
on the combination of MTX and SSZ in naïve patients and in patients with an insufficient response 
to SSZ. A systematic literature search was performed to identify RCTs that compared the MTX–SSZ 
combination to either drug alone. The efficacy of combination or monotherapy was assessed using 
the mean change in the DAS and the ACR criteria.
Four RCTs were identified to compare the efficacy of the combination MTX–SSZ to the efficacy 
of either drug alone. Two parallel trials were performed with patients naïve to both drugs and two 
add-on trials were performed in SSZ failures. In the trials with naïve patients, the mean DAS changes 
for the combination MTX and SSZ pointed to a sub-additive efficacy. In the trials with patients who 
previously failed to SSZ, the mean DAS changes for the combination MTX and SSZ indicated additive 
efficacy. These contrasting effects may be due to differential interactions of MTX and SSZ at the 
pharmacodynamic level; both DMARDs use the same cell transporter for their intracellular uptake 
(depending naive SSZ).
Given the available evidence, addition of MTX to SSZ is a therapeutic option in SSZ failures, 
whereas combination of MTX and SSZ in DMARD-naïve patients may not be a preferred treatment 
choice since the combination had no added value in early RA.
Chapter four
Since clinical trials have shown that the addition of MTX is better than a switch to MTX 
monotherapy after SSZ failure, the MTX-SSZ combination might be an adequate option after a 
suboptimal response to SSZ in daily clinical practice. Though this might not be the case after an 
inadequate response to MTX as another clinical study showed that the addition of SSZ was not 
superior to a switch to SSZ monotherapy in case of MTX failure. This may cast some doubt on the 
benefit of the combination of MTX and SSZ if one of the drugs previously failed. Therefore, data from 
a large Dutch inception cohort were analysed to compare the efficacy of the addition of MTX with a 
switch to MTX alone in SSZ failures in daily practice. 
For this study, 230 patients who failed to SSZ monotherapy were followed for up to 52 weeks. A 
total of 106 patients received the combination of MTX and SSZ, whereas 124 underwent a switch 
to MTX alone. Both treatment groups showed significant decreases in DAS28 and EULAR responses 
after 52 weeks, which was similar in both groups. Drug survival analysis showed that the chance to 
stop with a DMARD within 52 weeks was higher in the MTX–SSZ group (P <0.01). In this combination 
group, the SSZ survival was lower than the survival of MTX due to lack of efficacy of SSZ. In patients 
who switched to MTX monotherapy, the most frequent reason to stop with MTX was occurrence of 
adverse events.  
Both addition of MTX and switching to MTX lead to >50% responders, suggesting that in daily 
clinical practice an immediate switch to MTX monotherapy and the addition of MTX are equivalent 
therapeutic options for patients with an inadequate response to SSZ.
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Chapter five
In early RA, the relatively new and effective anti-TNF agents has been suggested as a more 
intensive therapy instead of starting conventional DMARDs and anti-TNF in case of DMARD 
failure. However, treatment with anti-TNF is relatively expensive with mean medication costs of 
approximately €1,000 per month. For this reason, it is mandatory to compare both the benefits and 
the costs of early treatment with anti-TNF agents with strategies that delay use of anti-TNF. Therefore, 
a modelling study was performed on the cost-effectiveness of three outcome directed strategies in 
early RA: 1) starting MTX monotherapy, followed by addition of leflunomide (LEF), followed by MTX 
with addition of anti-TNF; 2) start with MTX-LEF combination followed by MTX with anti-TNF; 3) 
immediate start with MTX and anti-TNF. 
A Markov model with Monte Carlo simulation was used to evaluate the cost-effectiveness. 
Effectiveness was determined using daily practice data. The percentage of patients in remission and 
number of QALYs were comparable between the three strategies. Starting with a combination (MTX 
plus LEF or anti-TNF) was more costly than starting with MTX alone. This resulted in an unfavourable 
incremental cost effectiveness ratio for starting on anti-TNF versus initially MTX: €136,150 according 
to the societal perspective  (incorporating job loses as well). This indicates that €136,150 is needed 
to invest in a gain of one QALY over five years with initially anti-TNF, which generally is considered 
too high.
Based on this cost-effectiveness study a treatment strategy starting with MTX monotherapy is 
favoured over a strategy with MTX and anti-TNF or MTX and LEF right away in early RA patients. 
These results are in line with other CEAs performed in early RA. 
Chapter six
In RA, treatment strategies can be improved by applying tight control of disease activity in order 
to change therapy if necessary. Tight control comprises regular assessments of disease activity (i.e. 
DAS28), a treatment goal (i.e. remission), and performs treatment adjustments based on disease 
activity. Accordingly, if remission is not achieved the therapeutic strategy must be intensified by 
employing other DMARDs until remission is reached. The adaptation of treatment can be based 
on protocolised treatment adjustments or can be left to the discretion of the rheumatologist (non-
protocolised). To compare the effects of tight control with and without protocolised treatment 
adjustments, a meta-analysis was performed. 
After a systematic literature search, six controlled trials applying tight control in RA were included 
in the meta-analysis. In all trials, patients treated in the tight control arms had significantly higher 
DAS28 responses than patients treated according to usual care (WMD=0.59, p<0.001). Confirming 
that tight control in general lead to clinically better responses than usual care. Moreover, tight 
control was significantly more effective on lowering disease activity by means of protocolised 
treatment adjustments (WMD=0.97) compared to non-protocolised monitoring of disease activity 
(WMD=0.25) (p<0.001).
Overall, frequent monitoring of a validated disease activity measure (DAS28), an agreed 
treatment target (remission) and an intensive escalation treatment protocol can improve the effects 
of RA compared with routine care. This may indicate that in future, a protocol for therapy changes in 
applying tight control should be essential.
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Chapter seven
There is strong evidence from several clinical trials that the application of a tight control 
treatment strategy is very effective in reaching remission in RA. However, the question remains 
how far tight control in daily practice indeed leads to a substantial larger proportion of RA patients 
in clinical remission than usual care. The last study investigated whether a protocol-driven tight 
control strategy aiming at DAS28 remission was more effective than treatment according to usual 
care in reaching remission after one year in early RA patients. 
Two strategies derived from two early RA inception cohorts from two different regions including 
patients who fulfilled the ACR criteria for RA with a disease duration less than one year were 
compared. Patients in the tight control cohort (n=126) were treated according to a DAS28-driven 
add-on strategy starting with MTX, addition of SSZ, exchange of SSZ by anti-TNF. Patients in the 
usual care cohort (n=126) were mainly treated with MTX or SSZ at rheumatologists’ discretion, 
without DAS28 guided treatment decisions. 
After 1 year, 55% of tight control patients had a DAS28<2.6 versus 30% of usual care patients 
(OR 3.1; 95%CI 1.8-5.2). The median time to first remission was 25 weeks for tight control and 52 
weeks for usual care (p<0.0001). The DAS28 decreased with -2.5 in tight control and -1.5 in usual 
care (p<0.0001). In both groups, an add-on strategy was most commonly applied and the number 
of anti-TNF users was comparable.
The results have shown that in early RA, a tight control treatment strategy aiming for remission 
leads to more rapid DAS28 remission, higher percentages of remission and larger improvements in 
functional ability after one year than treatment according to usual care. 
General conclusion
In conclusion in early RA, disease activity should be assessed frequently, as long as the remission 
aim is not achieved and based on disease activity, treatment should be adapted by means of 
protocolised treatment adjustments. A protocolised add-on strategy, thus starting with MTX 
monotherapy in combination with glucocorticoids and rapidly anti-TNF after suboptimal responses, 
has proven to be effective in management of tight control.
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Introductie
Reumatoïde artritis (RA) is een chronische ziekte die zich kenmerkt door ontsteking 
(inflammatie) en uiteindelijk beschadiging van meerdere gewrichten. Het is de meest voorkomende 
inflammatoire gewrichtsaandoening. De ziekte gaat gepaard met een forse ziektelast, inclusief 
arbeidsongeschiktheid, en een verminderde levensverwachting. Hoewel er vooralsnog geen 
therapie bestaat die tot genezing leidt, kan de ziekteactiviteit worden geremd en zelfs volledig 
worden onderdrukt; remissie. De afgelopen jaren zijn er nieuwe inzichten gekomen omtrent de 
diagnostische criteria voor RA, ontwikkeling van nieuwe anti-reumatica en omtrent het intensief 
monitoren van ziekteactiviteit. Deze inzichten hebben geleid tot een grote en succesvolle 
verandering in de aanpak van RA waarin vroege diagnostiek en het snel starten van behandeling 
als essentieel worden beschouwd. Een snel begin met anti-reumatica heeft namelijk een gunstig 
effect op het verdere ziektebeloop van RA: onderdrukking van de ziekteactiviteit, tegengaan van 
progressie van gewrichtsschade en behoud van functionaliteit. Voor de behandeling van RA zijn 
er verschillende conventionele disease-modifying antirheumatic drugs (DMARD’s) beschikbaar en 
ook de relatief nieuwe anti-tumour necrosis factor (anti-TNF) middelen die specifiek aangrijpen 
op de pathogenese van RA. Gezien de uitgebreide keus van DMARD’s en anti-TNF middelen is een 
optimale medicamenteuze strategie bij actieve RA van groot belang waarbij wordt gestreefd naar 
een snelle en forse vermindering van de ziekteactiviteit: remissie. Dit proefschrift had tot doel de 
meest optimale behandelstrategie in kaart te brengen voor patiënten met vroege RA met remissie 
als doel.
Hoofdstuk twee
Het streven naar klinisch remissie, en idealiter zelfs vasthouden hiervan, wordt als algemeen 
en huidig behandeldoel beschouwd, zeker in geval een patiënt onlangs is gediagnosticeerd met 
RA. Het belang van vroege diagnostiek én behandeling is hierbij essentieel. De gedachte hierbij 
strookt met het concept van de ‘window of oppurtunity’: hoe eerder met (intensieve) behandeling 
wordt gestart, hoe groter de kans op het slagen van de behandeling en dus ook het behalen van 
remissie. Meer inzicht in factoren die de kans op (aanhoudende) remissie vergroten, zijn belangrijk 
in het optimaliseren van de behandeling van RA en leiden tot betere uitkomsten van patiënten 
met RA. Het effect van snelle remissie op de uitkomst van vroege RA patiënten was het onderwerp 
van hoofdstuk twee. De resultaten van deze studie laten zien dat de tijd tot eerste remissie de 
belangrijkste voorspeller was voor het vasthouden van remissie bij vroege RA patiënten behandeld 
volgens dagelijkse praktijk. Met andere woorden: hoe eerder remissie wordt bereikt, hoe groter de 
kans op het vasthouden van remissie. Deze conclusie past dan ook geheel in het concept van de 
window of oppurtunity. De studie benadrukt dan ook dat klinische remissie vroeg in het ziekteproces 
belangrijk is in het verdere beloop van RA en bevestigd dat remissie het huidige behandeldoel moet 
zijn.
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Van de voorgeschreven DMARD’s worden voor vroege RA patiënten methotrexaat (MTX) en 
sulfasalazine (SSZ) gezien als eerste keus behandeling. Beide DMARD’s hebben bewezen effectief 
te zijn, zonder relatief veel bijwerkingen. Bovendien is het een goedkope behandeling en is er 
ruime ervaring met deze anti-reumatica. Er zijn echter verschillende behandelopties mogelijk met 
deze conventionele DMARD’s: beginnen met monotherapie van of MTX ofwel SSZ en vervolgens 
een tweede DMARD toevoegen bij onvoldoende effect (add-on strategie) of de eerste DMARD 
vervangen voor een tweede DMARD in geval van onvoldoende response (sequentiële strategie). 
Gezien het belang van een vroege en ook intensieve start wordt ook wel gesuggereerd met een 
combinatie van DMARD’s te beginnen met als doel snellere onderdrukking van de ziekteactiviteit. Er 
zijn een aantal klinische studies die hebben gekeken naar de effecten van combinatietherapie met 
MTX en SSZ versus monotherapie, in zowel vroege RA patiënten als patiënten met een onvoldoende 
response op MTX of SSZ. De vraag hierbij is of starten met combinatietherapie effectiever is dan 
monotherapie. Bovendien wat is het effect van combinatietherapie (add-on strategie) vergeleken 
met een switch naar MTX monotherapie (sequentiële strategie) na falen op SSZ?
Hoofdstuk drie
Het derde hoofdstuk had tot doel om in zowel vroege RA patiënten als patiënten met een 
suboptimale response op SSZ het effect van combinatietherapie (MTX en SSZ) te vergelijken met het 
effect van monotherapie (MTX of SSZ). Er is hiervoor gebruik gemaakt van resultaten uit klinische 
studies. De resultaten van deze analyse laten zien dat in patiënten die nog geen DMARD’s hebben 
gebruikt het effect van de combinatie met MTX en SSZ ‘sub-additief’ was en niet duidelijk effectiever 
was dan MTX of SSZ monotherapie. In tegenstelling tot het ‘additieve’ effect van combinatietherapie 
in patiënten die faalden op SSZ monotherapie, waarbij het toevoegen van MTX aan SSZ (add-on) 
significant beter was dan een switch naar MTX monotherapie (sequentieel). Een verklaring van deze 
verschillende effecten kan worden gevonden in het feit dat er gezamenlijke interacties zijn tussen 
MTX en SSZ op farmacodynamisch niveau welke afhankelijk zijn of een patiënt eerder is behandeld 
met SSZ of niet. Wat betreft de effecten van andere DMARD’s combinaties in vroege RA zijn deze niet 
overtuigend groter dan het effect van monotherapie. Een uitzondering hierop is de COBRA studie, 
waarin de combinatie MTX, SSZ en hoge dosering prednison wel duidelijk effectiever was dan SSZ 
monotherapie. Dit maakt dat we op basis van deze studieresultaten mogen concluderen dat het 
toevoegen van MTX aan SSZ een zinvolle therapeutische optie is in patiënten met onvoldoende 
effect op SSZ. Bij vroege RA patiënten, blijft monotherapie (MTX/SSZ) vooralsnog eerste keus, tenzij 
het wordt gecombineerd met hoge dosis prednison. 
Hoofdstuk vier
Hoewel aanbevelingen over het gebruik van MTX en SSZ kunnen worden verkregen op basis 
van resultaten uit klinische studies, zijn er maar weinig studies die naar het effect van deze frequent 
voorgeschreven DMARD’s hebben gekeken. Bovendien blijft het de vraag of deze effecten ook 
in de dagelijkse praktijk worden gezien. In dagelijkse praktijk wordt tot dusver niet gestart met 
combinatietherapie en vroege RA patiënten starten pas met combinatietherapie in geval van 
onvoldoende response op DMARD monotherapie. Met hulp van data uit een observationeel 
inceptie cohort hebben we in hoofdstuk vier gekeken bij patiënten met een onvoldoende 
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response op SSZ naar de effecten van het toevoegen van MTX aan SSZ (add-on) en het switchen 
naar MTX monotherapie (sequentieel) in de dagelijkse praktijk. Opvallend is dat de resultaten een 
vergelijkbaar effect aantonen in beide strategieën; zo’n 50% van de patiënten die faalden op SSZ 
lieten een goede response zien op zowel toevoegen als switchen. Hoewel dit resultaat niet goed 
overeenkomt met de bovengenoemde studieresultaten (add-on was effectiever dan sequentieel), 
blijft het vooralsnog moeilijk een verklaring hiervoor te geven. Wel kan er worden gedacht aan het 
effect van patiëntenselectie in geval er gebruik wordt gemaakt van observationele data. Ondanks 
dat suggereert deze studie dat in de dagelijkse praktijk bij patiënten met onvoldoende response op 
SSZ een directe switch naar MTX een gelijke therapeutische optie is als het toevoegen van MTX aan 
SSZ. 
In de dagelijkse praktijk zijn conventionele DMARD’s eerste keus behandeling en worden anti-TNF 
middelen pas ingezet na falen van minstens één DMARD (MTX). Naast de conventionele DMARD’s, 
wordt ook het inzetten van anti-TNF als eerste keus therapie geopperd. Anti-TNF heeft immers 
bewezen zeer effectief te zien, zowel klinisch als radiologisch. Bovendien wordt er verondersteld 
dat met het krachtig onderdrukken van ziekteactiviteit, zoals de directe start van anti-TNF, vroeg in 
het ziekteproces van RA het optreden van radiologische gewrichtsschade kan worden voorkomen 
later in het ziekteproces (window of opportunity). Hier tegenover staat dat anti-TNF middelen erg 
duur zijn in vegelijking met de conventionele DMARD’s als MTX. Bovendien is MTX ook erg effectief 
gebleken in de behandeling van vroege RA patiënten. Om deze redenen is het belangrijk om zowel 
de kosten als de effectiviteit te onderzoeken van behandelstrategieën die direct starten met anti-
TNF en strategieën die anti-TNF pas toestaan na falen van één of meer DMARD’s. 
Hoofdstuk vijf
In hoofdstuk vijf is er bij patiënten met vroege RA gekeken naar de kosten en de effectiviteit 
van een behandelstrategie waar anti-TNF werd ingezet na twee DMARD’s en een strategie met anti-
TNF als eerste behandeling waarbij er gebruik werd gemaakt van een kosteneffectiviteitmodel. De 
resultaten van de kosteneffectiviteitanalyse laten zien dat er vergelijkbare effectiviteit is tussen beide 
strategieën. De kosten waren alleen bij het starten met anti-TNF duidelijk hoger, wat resulteerde 
in hoge kosteneffectiviteitratio; meer kosten tegenover geringe verbetering van de effectiviteit 
(€136,150). Deze ratio lag zelfs hoger dan de Nederlandse aanbevolen grens van €80.000, voor 
het al dan niet de voorkeur geven aan een nieuwe therapie (starten met anti-TNF) boven een 
bestaande therapie (starten met MTX en anti-TNF in geval van ‘falen’). Op basis van deze resultaten, 
lijkt een strategie met MTX en vervolgens anti-TNF de voorkeur te hebben, gezien de gunstige 
kosteneffectiviteitratio. Deze resultaten komen overeen met eerdere kosteneffectiviteitanalyses bij 
vroege RA patiënten. 
Ondanks een ongunstige kosteneffectiviteitratio indien er wordt gestart met anti-TNF, kan deze 
ratio positief worden beïnvloed in geval van medicatievrije remissie. Dit laatste zou betekenen 
dat in geval van remissie, anti-TNF wordt afgebouwd wat resulteert in minder kosten en dus een 
gunstigere kosteneffectiviteitratio ten opzichte van starten met MTX. Hoewel er wel aanwijzingen 
zijn dat medicatievrije remissie mogelijk is, blijft onderzoek hiernaar zeer gewenst. Tot die tijd blijft 
MTX eerste keus en bij falen anti-TNF toegevoegd.
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Hoewel remissie wordt gezien als het ultieme behandeldoel, blijft het aantal patiënten in remissie 
in de dagelijkse praktijk aan de lage kant. De verwachting echter is dat dit aantal groter wordt door 
in de eerste plaats meer en effectievere behandelopties en in de tweede plaats door intensiever te 
behandelen in geval geen remissie is bereikt. Dit laatste betreft onder meer regelmatig evalueren 
van de ziekteactiviteit (zoals met bijvoorbeeld de DAS28) waarop vervolgens de behandeling wordt 
aanpast op basis van deze ziekteactiviteit, zolang remissie nog niet is bereikt: tight control. 
Hoofdstuk zes 
Het aanpassen van de behandeling naar aanleiding van ziekteactiviteit wordt meestal door 
de reumatoloog zelf bepaald, maar kan ook plaatsvinden op basis van een vooraf opgesteld 
behandelprotocol. In hoofdstuk zes hebben we deze twee vormen van tight control met elkaar 
vergeleken met hulp van resultaten uit klinische studies. Twee belangrijke conclusies kunnen worden 
getrokken uit deze meta-analyse. In de eerste plaats, zien we dat tight control in het algemeen tot 
een betere behandeluitkomst leidt dan behandeling volgens de ‘gewone’ dagelijkse praktijk. Het 
belang van tight control wordt hiermee bevestigd. In de tweede plaats was het toepassen van tight 
control in combinatie met geprotocoliseerde behandelopties duidelijk effectiever dan wanneer 
tight control zonder protocol werd toegepast en beperkt bleef met metingen van de ziekteactiviteit 
en de keuze werd overgelaten aan reumatoloog. Geconcludeerd kan worden dat het frequent 
meten van de ziekteactiviteit met behulp van bijvoorbeeld de DAS28, het streven naar remissie én 
een geprotocoliseerd behandelprotocol leidt tot een betere uitkomst van vroege RA patiënten. Dit 
zou betekenen dat een behandelprotocol bij de toepassing van tight control in de klinische praktijk 
noodzakelijk is. 
Hoofdstuk zeven 
De bovengenoemde resultaten zijn gebaseerd op klinische studies. In hoofdstuk zeven is het 
effect van geprotocoliseerde tight control welke streeft naar remisie bestudeerd bij patiënten met 
vroege RA in de dagelijkse praktijk. Dit effect is vergeleken met de ‘standaard’ behandeling van 
vroege RA patiënten zoals gegeven in de dagelijkse praktijk. De analyse toont aan dat in vroege 
RA, een tight control behandeling welke streeft naar remissie, leidt tot snellere remissie en ook 
meer patiënten bereiken remissie na één jaar en een beter functioneren dan de dagelijkse praktijk. 
Het viel op dat de behandelingsopties (MTX, SSZ, anti-TNF) en strategie (add-on) vrijwel gelijk 
waren in beide groepen. Bovendien was het aantal patiënten op anti-TNF klein en niet verschillend 
tussen beide groepen. Concluderend kan worden gezegd dat een add-on strategie, welke streeft 
naar remissie met behulp van tight control, in de dagelijkse praktijk toepasbaar is. Bovendien leidt 
zo’n tight control add-on strategie tot betere en snellere remissie leidt dan de standaard gegeven 
behandeling zonder tight control. Verder valt het op dat met tight control van ziekteactiviteit en 
aanpassen in geval van geen remissie, het behalen van remissie een realistisch doel is in dagelijkse 
praktijk.
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Lydia Schipper, de schrijfster van dit proefschrift, werd geboren op 24 maart 1979 te Maarn. Zij 
behaalde in 1997 haar VWO diploma aan de Katholieke scholengemeenschap De Breul, te Zeist. 
Na een High School programma in Johannesburg (Zuid-Afrika), begon zij in 1998 met de studie 
Biomedische Wetenschappen aan de Radboud Universiteit Nijmegen. Zij liep een korte stage, 
in het kader van het bijvak ‘Voeding bij Gezondheid en Ziekte’, op de afdeling Maag-, Darm- en 
Leverziekten van het UMC St. Radboud onder leiding van Dr. A.H.J. Naber. Voor haar tweede bijvak 
‘Geneesmiddelenonderzoek’, volgde zij een stage op de afdeling Medicinal Chemistry Oss van 
het farmaceutische bedrijf Organon bij Dr. C.P.A.M. Kloks. In het kader van haar afstudeerrichting 
Toxicologie liep zij een stage op de afdeling ‘Pathologie en Immunobiologie’ van het Rijksinstituut 
voor Volksgezondheid en Milieu onder leiding van Dr. E.A.E. van Tienhoven. In 2003 studeerde zij 
af in de richting Toxicologie en begon datzelfde jaar met de studie Geneeskunde aan de Radboud 
Universiteit Nijmegen. In 2005 heeft ze een co-schap gelopen op de afdeling Interne Geneeskunde 
in het Universitätsmedizin te Mannheim (Duitsland). Zij behaalde in 2007 het artsexamen en 
begon aansluitend als arts-onderzoeker aan haar promotieonderzoek ‘Treatment Strategies in Early 
Rheumatoid Arthritis’ op de afdeling Reumatische Ziekten in het UMC St Radboud. Dit onderzoek 
werd begeleid door prof. dr.  P.L.C.M. van Riel en dr. J. Fransen. De resultaten van dit onderzoek staan 
beschreven in dit proefschrift. In het laatste jaar van haar (promotie)onderzoek was zij werkzaam 
als arts-assistent op de afdeling Reumatologie van het UMC St. Radboud in Nijmegen. Hierna zal zij 
beginnen met de vooropleiding Interne Geneeskunde in het CWZ Ziekenhuis te Nijmegen (opleider 
dr. A.S.M. Dofferhoff) in het kader van de opleiding tot reumatoloog (opleider prof. dr. P.L.C.M. van 
Riel). 
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Dankwoord
Het afsluiten van een promotie geeft mij veel voldoening, maar het bezig zijn met die promotie 
kan soms nog veel meer voldoening geven. De uitdaging die je aangaat, de vragen die je probeert 
te beantwoorden, de antwoorden hierop die weer nieuwe vragen oproepen, het voortdurend 
zoeken naar het juiste te volgen pad, het heeft mij allemaal erg geboeid en erg gestimuleerd tot 
het succesvol afronden van mijn onderzoek. Maar de meeste stimulans is toch voortgekomen uit de 
fijne en vruchtbare samenwerking met mijn collega’s aan de ene kant en uit de onvoorwaardelijke 
steun van mijn dierbare naasten aan de andere kant. Daarvoor  ben ik veel dank verschuldigd!
 
Mijn dank gaat allereerst uit naar mijn promotor Piet van Riel en co-promotor Jaap Fransen. 
Beste Piet, voor het vertrouwen dat jij in mij gesteld hebt en voor de ondersteuning die ik van 
jou gekregen heb, ben ik je oprecht dankbaar. Je hebt mij niet alleen de mogelijkheid geboden het 
promotiepad te betreden, maar mij ook alle ruimte gegeven om me verder te ontwikkelen op het 
onderzoeksgebied en om voldoende ervaring op te doen op klinisch terrein. Dat ik ook voor al die 
kleine vragen en problemen bij jou terecht kon, heb ik altijd erg gewaardeerd. Het is bovendien een 
voorrecht te kunnen profiteren van jouw kennis van zaken en van het belangrijke onderzoek binnen 
reuma dat jij al verricht. Dank voor de leuke jaren en veel dank voor de begeleiding.
Beste Jaap, bij alle fases van het onderzoek kon ik rekenen op jouw hulp en inbreng, maar ook 
wist ik mij altijd verzekerd van jouw geduld. Positieve kanten werden door jou benadrukt, details 
werden serieus genomen en de grote lijn werd steeds in zicht gehouden. Ik heb veel van jou geleerd 
en jouw ideeënrijk enthousiasme heeft mij keer op keer aangemoedigd verder te gaan met mijn 
onderzoek. Daarnaast beperkte jouw interesse zich niet tot het onderzoek alleen, maar toonde je 
ook een persoonlijke betrokkenheid, waardoor ik onze samenwerking als buitengewoon prettig 
heb ervaren. Een betere begeleiding had ik mij echt niet kunnen wensen. Hartelijk dank voor alles.
Uiteraard wil ik ook de co-auteurs graag bedanken voor  hun meedenken, hun meeschrijven 
en voor hun kritische blik, gekoppeld aan een goed advies bij de verschillende artikelen in mijn 
proefschrift. 
Mijn bijzondere dank gaat uit naar een van mijn co-auteurs en directe collega Wietske Kievit. 
Jouw kennis van de kosteneffectiviteitanalyse heeft mij veel geholpen in mijn onderzoek. Niet 
alleen op het onderzoeksgebied heb je mij ondersteund, maar je was ook een collega die, letterlijk 
en figuurlijk, heel dichtbij was: ik kon altijd voor alles bij jou aankloppen. Met jouw nuchtere, 
pragmatische visie had je voor elk probleem een goede oplossing of een nuttig advies. Daarnaast 
heb jij altijd veel aandacht geschonken aan de sociale kant van onze samenwerking en mede 
daardoor heb ik me van het begin af aan thuis gevoeld op de afdeling.
De leden van de leescommissie, prof. dr. G.J. van der Wilt, prof. dr. P.C.M. van de Kerkhof en prof. 
dr. B.A.C. Dijkmans, wil ik bedanken voor hun bereidwilligheid het proefschrift te beoordelen. 
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Als onderzoekers kunnen wij gebruik maken van de geweldige database die al sinds 20 jaar op de 
afdeling reumatologie wordt bijgehouden. De verpleegkundige reumaconsulenten Ellis, Jacqueline, 
Carine en Joke verdienen veel waardering voor hun inzet bij het dag in dag uit verzamelen van 
patiëntengegevens. Ik wil graag jullie, maar zeker ook de collega’s van het datacentrum, Thea, Lia, 
Monique, Carine en Nicolette, hartelijk danken voor het verzamelen en ‘mangenen’ van de kostbare 
patiëntengegevens, die ik heb mogen gebruiken en die onontbeerlijk zijn geweest voor de analyses. 
Voor allerlei vragen kon ik bij jullie terecht. De praktische ondersteuning en de prettige omgang 
met jullie heb ik erg op prijs gesteld. Er was altijd ruimte voor de ‘human touch’ en dat doet goed. 
Bedankt voor de fijne samenwerking.
Een speciaal woord van dank geldt voor mijn enthousiaste en gedreven (ex) collega-onderzoekers 
van ‘boven’ en van ‘buiten’, Bea, Delia, Dewy, Elke, Jos, Kavish, Marlies, en Yvonne. Enerzijds voor de 
gezelligheid en de plezierige werksfeer en anderzijds voor de geboden steun en de vaak nuttige 
en inspirerende gesprekken, waarvan ik zoveel profijt heb gehad. Ik zal altijd met veel plezier 
terugdenken aan de congressen, lunches en aan alle uitjes buiten het werk. Bedankt voor jullie 
betrokkenheid en heel veel succes in jullie carrières.
 
Ik wil niet vergeten ook mijn collega Marloes Vermeer uit Enschede te bedanken voor de prettige 
en vruchtbare samenwerking in binnen- en buitenland. In het bijzonder voor de hulp en steun, voor 
het meedenken en meeschrijven bij ons eerste en mijn laatste artikel. Jouw aandacht voor details 
heeft me scherp gehouden. Bedankt daarvoor.
Verder bedank ik alle collega’s van de afdeling reumatologie voor de fijne sfeer op de werkvloer. 
Jullie hebben ervoor gezorgd, dat ik me hier meteen heb thuis gevoeld en dat heeft het werken 
aan mijn promotie heel wat gemakkelijker gemaakt. Het was niet alleen prettig maar ook leerzaam 
met jullie samen te werken. Bedankt ook voor de interesse die jullie hebben getoond tijdens de 
afrondingsfase van mijn proefschrift. 
Mijn paranimfen, Laura en Ruud, wil ik bedanken voor het feit dat zij op deze bijzondere dag 
naast mij willen staan, waardoor ik vol vertrouwen mijn promotie tegemoet kan zien. Op alle fronten 
hebben jullie mij hulp geboden, zowel wetenschappelijk als persoonlijk, en daarvoor ben ik blij en 
dankbaar.
Lieve Laura, in de eerste plaats dank ik je voor al je hulp, voor je scherpzinnige opmerkingen en 
voor de stimulerende discussies. Binnen het onderzoek hadden we altijd onze favoriete onderwerpen 
waar we niet uitgepraat over raakten... De bijzondere band die wij opgebouwd hebben, hoef ik denk 
ik niet uitvoerig voor je te beschrijven, maar je was meer dan een goede collega, je was een ‘friend’ 
met wie ik veel lief en leed gedeeld heb en dat zowel in het wetenschappelijk als in het persoonlijk 
vlak. Als ik ergens mee zat, voelde je dat altijd perfect aan en kon ik altijd met vragen bij je terecht. 
Dit heeft veel voor mij betekend. Dankjewel en succes met de laatste loodjes van jouw promotie. 12
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Chapter 12
Lieve Ruud, vanaf de eerste dag dat wij elkaar kennen tijdens de co-schappen, heeft het tussen 
ons geklikt. Hoewel onze onderzoeksterreinen weinig overeenkomst vertonen, delen wij des te 
meer de interesse in het onderzoeken zelf. Daarnaast delen wij onze eerste ervaringen in de kliniek. 
Ik waardeer je humor en je nuchtere kijk op alles. Bedankt dat ik altijd bij je terecht kan voor goede 
raad, maar vooral ook voor een gezellig gesprek; we raken niet snel uitgepraat! Veel succes met je 
eigen promotieonderzoek en het afronden daarvan. Je bent al heel goed op weg, dus dat gaat met 
een extra dagje erbij zeker goed komen.
Mijn ouders ben ik dankbaar dat zij mij altijd de kans hebben gegeven om te doen wat 
ik wilde doen en dat zij mij daarin steeds met volle overtuiging hebben gestimuleerd. Jullie 
onvoorwaardelijke steun en voortdurende belangstelling en bovenal jullie liefde is voor mij van 
grote betekenis geweest. Mijn lieve ‘zusje’, Eline, zegt wel eens dat ze trots is op haar ‘zus’. Maar ik ben 
er niet minder trots op zo’n fijne zus te hebben. Jouw betrokkenheid, je heldere oordeel en je morele 
steun hebben mij altijd erg geholpen.
Het laatste woord is voor mijn liefste Rutger. Dankjewel voor al je liefde, je geduld en je 
relativeringsvermogen. Jij staat altijd voor mij klaar en jij houdt mij in balans. Jouw steun had ik echt 
niet kunnen missen en ik kan niet zeggen hoe dankbaar ik je daarvoor ben. Ik denk wel eens ..., nee, 
ik geloof het zeker, dat wij een mooie tijd tegemoet gaan, waarin wij samen kunnen genieten van 
onze kleine trots, Alec. Lieve Alec, meer dan al het andere is het jouw lach die mij gelukkig maakt.
